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The work presented in this thesis aims to develop methods and apply them for the 
assessment of quality and safety of herbal medicines. Quality is the paramount issue 
which affects the efficacy and safety of herbal medicines. Analytical methods were 
developed to evaluate the quality of herbal medicines and related products, while ex 
vivo and in vivo methods to assess potential herb-drug interactions were explored. 
 
With regards to assessment of quality, an adulterant was detected in the extract of a 
premixed bulk powder for dietary supplement and structurally elucidated. It was 
determined to be an analogue of acetildenafil (hydroxyacetildenafil). Its structure was 
identified by nuclear magnetic resonance (NMR), fourier transform infrared (IR), 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) and high resolution 
mass spectrometry (HRESIMS). This is the first report of hydroxyacetildenafil found 
as an adulterant in a dietary supplement. Its structural information would be helpful 
for screening phosphodiesterase type 5 enzyme (PDE-5) inhibitors and their analogues 
to control the quality of dietary supplements and herbal products.  
 
Ligusticum chuanxiong is a Chinese herb that improves blood circulation and is 
selected as a model herb for the assessment of quality and safety (herb-drug 
interactions). High performance liquid chromatography (HPLC), LC-MS/MS and high 
resolution liquid chromatography-mass spectrometry (LC-MS) methods were 
 IX 
successfully developed for the chemical analysis of L. chuanxiong and its reported 
chemical markers (tetramethylpyrazine and ferulic acid). The concentrations of ferulic 
acid were found to be low in all the extracts whereas tetramethylpyrazine could not be 
detected by HPLC, and even LC-MS/MS at a low detection limit of 1.3×10-8 g. Hence, 
the results suggest that these two analytes could not be used as marker compounds to 
assess the quality of L. chuanxiong. A novel and efficient LC-ESI-MSn method was 
developed and successfully applied for the quality control of L. chuanxiong. A total of 
70 compounds (mainly different kinds of phthalides) were identified or tentatively 
characterized based on a combination of retention times, high resolution mass data 
and their multistage fragmentation behaviors.  
 
One of the important safety issues is herb-drug interaction. To assess the potential 
herb-drug interaction of L. chuanxiong, the effects of the ethanol extract of L. 
chuanxiong and its reported active components tetramethylpyrazine and ferulic acid 
on the most important drug-metabolizing enzymes, cytochrome P450 (CYP) 3A and 
2D activities were determined in Sprague-Dawley rat liver. 14-day pre-treatment with 
L. chuanxiong extract (10 g herb·kg-1·d-1) significantly increased CYP2D activity 
(p<0.05), but did not affect on CYP 3A activity in ex vivo experiments. The activities 
of CYP 3A and CYP 2D were not affected by separate treatments with low dosages (2 
g herb·kg-1·d-1) of the L. chuanxiong extract, ferulic acid or tetramethylpyrazine. For 
further confirmation of the induction effect of L. chuanxiong pre-treatment on CYP 
2D activity, the effect of L. chuanxiong extract on the pharmacokinetics of 
 X 
dextromethorphan (a CYP 2D substrate) was investigated in SD rats in vivo. 
Unfortunately, it was found that L. chuanxiong did not affect the pharmacokinetics of 
dextromethorphan and dextrorphan after a single intraperitoneal (i.p.) administration 
of 30 mg·kg -1 dextromethorphan to SD rats in vivo. The results suggest no obvious 
effects of L. chuanxiong pre-treatment on CYP 2D in SD rats in vivo, despite the 
enzyme induction effect seen ex vivo.  
 
In the present study, the potential pharmacokinetic and pharmacological interactions 
between L. chuanxiong and aspirin were also investigated in vivo in Sprague-Dawley 
rats. 14-day pre-treatment of L. chuanxiong extract did not affect the antiplatelet effect 
produced by a single intraperitoneal administration of aspirin in rats nor did it change 
the pharmacokinetics of aspirin after a single intravenous administration of aspirin. 
Most of the pharmacokinetic parameters of aspirin and salicylic acid after a single 
intraperitoneal administration of aspirin remained unchanged except for a reduction in 
the bioavailability (F) of aspirin in SD rats pre-treated with L. chuanxiong for 14 days 
when compared to the rats in the control group. The mean F value (i.p. administration) 
of aspirin was decreased by 54.6 % upon 14-day pre-treatment of L. chuanxiong 
extract in vivo, indicating a potential pharmacokinetic herb-drug interaction between 
aspirin and L. chuanxiong in SD rats.  
 
In conclusion, the analytical methods developed and used in this thesis provide useful 
information for screening PDE-5 inhibitors or their analogues and for rapidly profiling 
 XI 
the main components in L. chuanxiong extract. In addition, the combined 
pharmacodynamic and pharmacokinetic experimental models for the studies of 
herb-drug interactions, illustrated by aspirin and L. chuanxiong – a potential 
interaction pair, may form the basis for general screening to investigate herb-drug 
interactions in rat model. These data provide support and experimental platform for 
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Chapter 1   
Introduction  
 
The popularity of using herbal medicines to prevent and treat diseases lies largely in 
the belief that they are at least as efficacious as synthetic pharmaceutical drugs (Linde 
et al. 1996; Normile 2003) without the serious adverse effects usually associated with 
the latter. Herbal medicines are often used in the form of health food or dietary 
supplements. The global market for herbal medicines currently stands at over US $ 60 
billion annually and is growing steadily (World Health Organization 2004).  
 
An increasing number of published papers on herbal medicines undoubtedly illustrate 
the growing interests and concerns over the quality, safety and efficacy of herbal 
products. Large number of studies have been carried out to investigate the application 
of herbal medicines in disease prevention and treatment (Martin and Ernst 2003; 
Nahin and Straus 2001). Epidemiological studies have shown that herbal medicines 
are widely used as an alternative therapy for many chronic diseases, such as cancer 
(Kelly 2004; Hardy 2008), HIV (Ma et al. 2008), diabetes (Johnson et al. 2006), 
obesity (Shi et al. 2006), ischemic heart diseases (Lin et al. 2001), etc.  
 
Traditional herbal medicines are potential sources of useful drug leads. It was 
reported that derivatives from natural products including plants, animals and microbes 
accounted for 25-30% of modern medicine (Calixto 2005). Most studies on drug 
discovery focus on the active ingredients isolated from herbal medicines. However, it 
is also believed that treatments using active ingredients from herbal medicines might 
impair the original effectiveness and result in more serious adverse effects. In Asia, 
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based on the traditional theory and practice, most herbal medicines incorporating 
composite prescriptions (Fu-Fang) are believed to have synergistic effects or can 
eliminate the side effects of some harmful constituents in the formulation. The effects 
of traditional remedies may be due to the joint actions of up to 20 herbs. Traditional 
herbal remedies may express their effects through multi-components in herbal 
medicines and multi-targets for disease prevention (Chan 1995; Oka et al. 1995). 
Hence, studies of herbal medicines including reasonable and safe combination of 
remedies are important. Beneficial effects of intentional combined use will ascertain 
the advantages of proper integrative treatment of herbal medicines (Chan 1995). Some 
of the well-known Fu-Fang prescriptions have been manufactured into Chinese 
proprietary medicines (CPM, ‘Zhong Cheng Yao’) in the final dosage forms 
convenient for use.  
 
1.1. Quality issues 
Herbal medicines are often claimed to be safe because of their natural origin and 
long-term use as folk medicine. Despite globalization of their usage, herbal medicines 
are still not well studied in terms of their mechanisms of action, clinical effects and 
toxicities. Problems related to the toxicity and adverse effects of some herbal products 
have been repeatedly reported (Bent et al. 2003; Ernst 1998; Haller et al. 2007). It is 
recognized that the current status can no longer ensure the confidence of consumers 
and the progress of integrative treatment using herbal medicines. 
 
A successful utilization of herbal medicines integrated into modern medical practices 
depends on the good performance in the inter-related issues of quality, safety and 
efficacy. Quality is the paramount issue which affects the efficacy and/or safety of the 
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herbal medicines. Quality control is a fundamental aspect in the standardization of 
herbal medicines for pharmacological evaluation and therapeutic use.  
 
1.1.1. Factors affecting quality 
Herbal medicines are mixtures of various kinds of organic compounds, including 
flavonoids, alkaloids, glycosides, saponins, fatty acids and terpenes (Rotblatt and 
Ziment 2002). The levels of these constituents may vary substantially since plants are 
dynamic living organisms and the physical and chemical characters can vary due to 
genetic influence. For example, with regards to the concentration of hypericin in St. 
John’s Wort (Hypericum perforatum), it was found that populations with narrow 
leaves have higher concentration than the variety with broader leaves (Southwell and 
Campbell 1991). Most herbal materials also show organ-originating specificity. 
Chemical biosynthesis usually happens in the leaves and the phytochemicals are then 
transported through the stems to the roots for storage. A systematic study on the 
site-specific accumulations of the active compounds responsible for the 
immunostimulant effect of Echinacea species described this point well (Bauer and 
Wagner 1991; Bauer 1988). 
 
A single herb always contains many kinds of active components, each of which may 
contribute to the herb’s pharmacological effects and toxicities. In most cases, it is 
uncertain which or how many constituents in a particular herb are pharmacologically 
important in humans. Many of these active ingredients remained unidentified or 
misidentified. For example, hypericin in St. John’s Wort was thought to be primarily 
responsible for its antidepressant effect. But current research pointed to hyperforin, 
which is a more therapeutically active compound (Muller et al. 2001). 
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Many extrinsic factors also affect the quality of herbal medicines. Environmental 
factors, such as altitude, soil, light, water, temperature, atmospheric humidity, shade 
and supplied nutrients, can affect their phytochemical accumulation (McChesney 
1999; Singh and Saini 2008). The methods employed in plant collection, harvesting 
(Li et al. 2007), post-harvest processing (Klepser and Klepser 1999), shipping and 
storage also influence the physical appearance and chemical quality of the herbal 
materials.  
 
Excessive toxic heavy metals (Graham-Brown 1992), herbicides, pesticides or 
microbial contaminants may come from a contaminated environment during 
cultivation of these herbal materials (Chan 2003). Sometimes, insects, animals, animal 
parts and animal excreta also can be introduced at any stage of herbal materials 
production, leading to lower quality or unsafe herbal products (Busse 1999; Flaster 
1999; Silmon 1999). Unfavorable storage conditions or chemical treatment during 
storage may increase the levels of chemical and biological toxins. Accidental or 
intentional substitution with other plant species is also very common phenomena for 
many herbal products (Awang 1997; Koh and Woo 2000; Slifman et al. 1998).  
 
It has been found that certain herbal products were not of pure herbal origin but also 
may be adulterated with synthetic drug substances. Huang et al. reported that 
approximately 24% of 1609 Tradition Chinese Medicines samples analyzed in Taiwan 
were adulterated with synthetic drugs (Huang et al. 1997). Some serious adverse 
effects or death caused by these adulterants have been reported (Goudie and Kaye 
2001). The adulterants belonging to various pharmacological classes were 
summarized and reported (Liu et al. 2001). It is challenging, although not impossible, 
to screen out unknown compounds adulterated in herbal products during analysis due 
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to the interference caused by the contents of a myriad of constituents in complex 
matrix of herbal medicines.   
   
Unlike synthetic pharmaceutical drugs, which are single chemical entities and their 
activities could be easily standardized and reproducible potency is achievable, 
uniformity of herbal products was practically unattainable. Since every herbal 
medicinal plant contains various kinds of components, some of which may change or 
interact during the post-harvest processing and the manufacturing process. Till now, 
the purity and composition of many herbal products are not always assured and may 
vary considerably among various preparations and between batches, unlike synthetic 
pharmaceutical drugs (Raven et al. 1999). All of these make the quality control of 
herbal products extremely challenging and important.  
 
The safety, efficacy and quality issues of herbal medicines also depend on adequate 
regulatory system. Today, a wide range of conventional policies control the 
availability of herbal products worldwide. WHO reviewed the worldwide status of the 
regulatory situation in 1998 (World Health Organization 1998) and proposed 
appropriate advice on providing national regulatory guidelines of herbal products in 
2004 (World Health Organization 2004). Different regulatory system used among 
member States in WHO is mainly according to different regulatory categories for 
herbal medicines including prescription medicines, over-the-counter medicines, 
self-medication, dietary supplements, health food and functional foods. The different 
regulatory processes in different countries lead to different types of products available 
commercially, which complicates quality control of herbal products. However, 
resources are still insufficient to prevent activities leading to negative health 
experiences. With the widespread use of herbal products, people need more workable 
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regulatory policies and guidelines to ensure that these herbal commercial products are 
reliable, safe and effective.  
 
In conclusion, the differences in product characteristics, consumer use patterns, 
regulatory frameworks and the nature of the available scientific evidence present 
challenges for effectively incorporating herbal medicines into the modern medicinal 
practice.  
 
1.1.2. Methods for the quality control of herbal medicines 
According to the “General Guidelines for Methodologies on Research and Evaluation 
of Traditional Medicines” (World Health Organization 2000), “despite the long time 
use and popularity, traditional medicine has not been officially recognized in most 
countries. The quality and quantity of the efficacy and safety data on traditional 
medicine are far from sufficient to meet the criteria needed to support its use 
worldwide. The reasons for the lack of research data are due not only to health care 
policies, but also to a lack of adequate or accepted research methodologies for 
evaluating traditional medicine”. It is recognized that the current status can no longer 
ensure consumer’s confidence and protection from the adverse effects caused by 
herbal medicines. Both international and national policies are being evolved and 
implemented to address these concerns about the safe use of herbal medicines. It is 
essential to guarantee product efficacy and safety in humans, although the 
standardization of active components in herbal products may be not enough to ensure 
the efficacy and safety. The work can help to clarify the reliability and repeatability of 
pharmacological and clinical research and to understand their bioactivities and 
possible side effects of active compounds. 
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Therefore it is very important to comply with the analytical standards in 
manufacturing herbal products. Many standard operating procedures can be used to 
control the quality of herbal products, including good agricultural practices (GAP), 
good laboratory practices (GLP), good storage practices (GSP) and good 
manufacturing practices (GMP) for producing herbal products. In fact, the standards 
for quality control should be established before herbal products enter the markets. It is 
important to set up internationally acceptable quality control requirements suitable for 
herbal medicines. Without high quality products, the success of any clinical 
investigation of herbal medicines will be compromised.  
 
Traditional methods for species identification and quality control include 
morphological and microscopic methods, which are still widely used to distinguish 
the herbs. In recent years, molecular methods for the authentication of herbal 
medicines are showing great promise for complementing the traditional ones. The 
quality control of herbal medicines demands rapid, simple and accurate analysis. 
Advances in both biomedicine and analytical sciences help to improve and facilitate 
the identification and quality control of herbal products through qualitative and 
quantitative analysis of active constituents in herbal medicines.  
 
1.1.2.1. Chemical identification 
Herbal products are multicomponent mixtures in which the concentrations of active 
components are always in the lower milligram range per dose. All the factors 
influencing the quality of the herbal products (Section 1.1.1) make the chemical 
analysis more complex and challenging.  
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Among all the chromatographic methods, thin layer chromatography (TLC) is 
probably the earliest and most commonly used technique to assess the chemical 
markers of herbal medicines. High-performance liquid chromatography (HPLC) has 
now become a routine procedure to chemically identify herbal materials. Gas 
chromatography (GC) is a powerful separation technique for the analysis of volatile 
herbal components or derivatives. However, approximately 80% of all known natural 
compounds are non-volatile or thermally unstable and therefore incompatible with GC 
method. Capillary electrophoresis (CE) and high speed countercurrent 
chromatography are mostly applied in the separation of complex mixtures of herbal 
medicines (Ganzera 2008; Liang et al. 2004). These methods are mostly applied to the 
quality control of herbal medicines, provided that the identification of the active 
components has been verified by spectroscopic techniques.  
 
Furthermore, combination of chromatographic method with spectroscopic techniques, 
such as ultraviolet spectroscopy (Li et al. 2003), infrared spectroscopy (Wu et al. 
2008; Wu et al. 2009), mass spectrometry (Li et al. 2006a), nuclear magnetic 
resonance spectroscopy (Kang et al. 2008) etc, can be used to identify known 
compounds without isolation. These hyphenated technologies are applied for the rapid 
on-line separation and structural elucidation, showing greatly improved performances 
in terms of the elimination of instrumental interferences, the correction of retention 
time shift, high resolution of chromatographic separation and measurement precision. 
Among them, high-performance liquid chromatography with diode array detection 
(HPLC-DAD) only provides very limited structural information like UV spectrum. 
Standard compounds commercially unavailable in most cases are usually necessary 
for the characterization of individual chemical markers. The main drawbacks of 
HPLC-NMR include the low sensitivity of NMR and the use of solvent suppression 
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which often leads to the suppression of analyte signals that reside under or adjacent to 
the solvent peaks. Hence, some important structural information may be lost (Dias 
and Urban 2008; Dias and Urban 2009).  
 
Mass spectrometry (MS) is one of the most powerful techniques for the identification 
of unknown compounds in the extracts of natural products as well as the most 
selective technique for the quantification of known compounds. The wide application 
of MS in the analysis of herbal products follows the successful interface with a mass 
spectrometer detection system in the chromatographic method. Atmospheric pressure 
ionization (API) consisting of atmospheric pressure chemical ionization (APCI) and 
electrospray ionization (ESI) is the most successful interface used in hyphenated 
HPLC-MS technique. Therefore, HPLC-MS method combines the separation 
capabilities of HPLC and the great power in structural characterization of MS. In most 
studies on quality control of herbal medicines, HPLC-MS in combination with diode 
array detection technique can provide on-line UV and MS information at the same 
time for characterizing every peak in a chromatogram. High resolution mass 
spectrometry, such as orthogonal acceleration time-of-flight mass spectrometry 
(TOFMS) and Fourier transform mass spectrometry (FTMS) in combination with 
HPLC or GC can provide more accurate mass information for structural 
characterization of compounds. Matrix-assisted laser desorption / ionization-time of 
flight mass spectrometry (MALDI-TOFMS) is a new rapid analysis method being 
applied for direct analysis of small molecular weight pharmaceutical compounds in 
tissues and plant materials without sample extraction and purification (Ng et al. 2007; 
Wu et al. 2007b; Wu et al. 2007a). In summary, MS technology and its application in 
the analysis of herbal medicines have been reviewed (He 2000; Zeng et al. 2007; 
Yang et al. 2009). 
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Chromatographic fingerprint analysis using chromatographic techniques (e.g. HPTLC, 
HPLC, GC, and CE) was developed to construct specific peak patterns of recognition 
for multiple compounds in herbal medicines (Lau et al. 2004; Xie 2005; Xie et al. 
2006). The entire pattern of compounds can be used to determine not only the absence 
or presence of certain chemical markers or active components but the whole set of 
ratios of all detectable components. Some data analysis methods, such as hierarchical 
clustering analysis, local least square (LSS) and principal component analysis (PLA), 
were proposed to deal with the data sets of fingerprints, and further for quality 
evaluation of herbal medicines with chromatographic profiles (Li et al. 2004a; Zou et 
al. 2005). Thus, chromatographic fingerprinting analysis represents a comprehensive 
qualitative evaluation approach for the purpose of species authentication, evaluation 
of quality, and ensuring the consistency and stability of herbal products. It is obvious 
that the concepts of fingerprinting and pattern recognition are very important for 
quality assurance of raw herbal materials and herbal products. 
 
Chromatography and electromigration methods are recognized as the main techniques 
in this field due to their powerful separation efficiency and the capabilities to be 
combined with sensitive detection, which has been indicated by several recent reviews. 
Fingerprinting analysis has been accepted by WHO as a methodology for the 
assessment of herbal medicines (World Health Organization 1991). It is also currently 
required by the Chinese State Food and Drug Administration to be used to ensure the 
quality control of injectable herbal preparations and is promoted for use in the 




The concept of phytoequivalence was proposed in Germany in order to ensure 
consistency of herbal products (Tyler 1999). According to this concept, a chemical 
profile, such as a chromatographic fingerprint of a herbal product, should be provided 
and compared with the profile of a clinically proven reference product. The analytical 
monographs for botanicals are being developed by the United States Pharmacopeial 
Convention and some have been included in The United States Pharmacopeia, 32th 
Revision and The National Formulary, 27th Edition. In Germany, which is an 
important market for herbal medicines, the German Federal Health Agency has set up 
the commission E Group that reviews information on the safety and effect of herbal 
products and produces informative monographs. Since some non-marker components 
may contribute to the effect while some may even cause adverse effects, it is 
necessary to combine specific chromatographic fingerprinting analysis with 
pharmacological and clinical evidences for efficacy and safety. 
 
During the process of accepting and developing herbal medicine, it is necessary to 
combine quality control efforts with pharmacological and clinical evidence of efficacy 
and safety. More research focused on in vivo pharmacological studies in combination 
with the “-omics” technologies to measure the response of a test organism on 
treatment with herbal medicines, as well as with metabolomics to phytochemically 
characterize the medicinal plant (Fiehn et al. 2000; Grata et al. 2009). Links can be 
made between compounds present in a medicinal plant and activities observed in a 
model organism by using chemometric methods, such as multivariate analysis. By 
using metabolomics in combination with multivariate analysis, one can define the 
required profile of active components in herbal medicines related to their activities.  
 
1.1.2.2. Molecular-based methods 
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Deoxyribonucleic acid (DNA)-based (including DNA molecular markers and DNA 
sequences) authentication for the quality control of herbal materials may be the best 
molecular-based approaches to ascertain their identity and purity (Techen et al. 2004; 
Weising et al. 2005). DNA is the most unambiguous indicator of genetic identity and 
a DNA sequence is characteristic of a particular species which is not influenced by 
plant age, tissue type and environmental factors. This technology was successfully 
used to study natural hybridization between the species in addition to the adulteration 
of other herbs (Jain et al. 2008). Most of these DNA-based methods have been well 
described in several reviews (Lum and Hirsch 2006; Zhang et al. 2007). These 
methods are effectively used in the analysis of fresh, dried or powdered plant 
materials. This kind of technology is not used frequently and especially useful to 
differentiate closely related herbal medicines. 
 
The restriction of DNA-based methods is that they cannot be effectively employed for 
the final herbal products, such as extracts, tinctures, oils, and so on, which contain no 
plant cellular residue and genomic DNA cannot be isolated. Secondly, DNA-based 
markers may not correspond to the chemical profiles. Therefore, DNA-based 
molecular methods together with the chemical fingerprint for quality control of herbal 
medicines are necessary and have been investigated (Xia et al. 2005; Hong et al. 
2005). 
 
The advantages and limitations of above-mentioned methods for quality control of 
herbal medicine were summarized and reported by Zhao et al. (Zhao et al. 2007). It 
will change gradually from using single ingredient into using active, multiple 
ingredients, fingerprint and bio-determination for the complete quality control of 
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herbal medicines. Controlling herbal medicines as a whole will give sufficient 
assurance that herbal medicines are of the right quality for safe and effective use.  
    
The priority of researches on herbal medicine is to ensure quality and safety of the 
herbal products used by patients. Therefore, more research should focus on the 
development of modern analytical and biological approaches and set up guidelines to 
ensure the safety of herbal medicines. Many manufacturers have attempted to produce 
products containing suspected active ingredients at more consistent levels based on 
the standardized procedures, including the identification of the unique herbal specie, 
detection of the potential markers and the improvement of production process. 
 
1.2. Safety issues of Herbal Medicines 
1.2.1. Introduction 
While herbal products are increasingly being used, safety issues and the monitoring of 
adverse effects have not been emphasized. This popularity of herbal products renders 
the critical assessment of their safety an urgent necessity.  
 
The reasons for adverse reactions of herbal medicines include direct toxicity of herbal 
materials, allergic reactions, toxic effects from contaminants, adulterations of other 
herb or synthetic chemicals, and interactions with drugs or other herbs. The safety of 
herbal medicines and herbal related supplements deserve deep consideration, similar 
to drugs. Among them, herb-drug interactions, one of the important safety issues, are 




1.2.2. Herb-drug interactions 
Herbal medicines are taken not only by healthy people to protect themselves from the 
onset of some diseases or to improve their well being, but also by patients suffering 
from life-threatening conditions and simultaneously receiving drug treatment. About 
26% of presurgical patients were reported to take herbal supplements and OTC drugs 
concurrently (Tsen et al. 2000). 16~19% of adults in the United States who reported 
the use of one or more prescribed drugs also took a herb or dietary supplement 
preparation (Kaufman et al. 2002; Tindle et al. 2005; Kennedy et al. 2008). As the 
use of herbal medicines is growing steadily, the interactions between herbal products 
and drugs need to be addressed properly. The multitude of active ingredients in most 
herbal products obviously increases the likelihood of herb-drug interactions.  
 
Most people usually do not discuss with the physicians about their use of therapeutic 
drugs in combination with herbal medicines for enhancing health. It was shown in a 
survey that as many as 31% of the patients who used herbal products co-administered 
with prescribed drugs and about 70% of these patients did not regularly report the use 
of these products to their physicians (Mills et al. 2005). Combined use of herbal 
products and therapeutic drugs may increase or decrease the effects of each 
component, especially for drugs with narrow therapeutic ranges (e.g. digoxin, 
warfarin and midazolam). The resultant herb-drug interactions sometimes lead to 
clinically significant risks (Ruschitzka et al., 2000).  
 
Furthermore, herbal remedies and preparations are particularly popular among older 
people. The elderly are more likely to receive several pharmaceutical drugs 
(poly-pharmacy) at the same time and are also more sensitive to chemicals (Deahl 
1989; Izzat 1998; Morae 1996). Although many herbal medicines are safe, it must be 
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borne in mind that herbal products are sometimes intended to be taken over a long 
period of time, which implies the increased opportunity for enzyme inhibition or 
induction and other mechanisms of herb-drug interactions. 
 
The risk of potential herb-drug interactions has been a great concern for the safety 
evaluation of herbal medicines. Nowadays, more than 150 herbal medicines have 
been recognized to have potential herb-drug interactions (Izzo and Ernst 2001). 
Clinicians or pharmacists need reliable and independent information resources about 
the herb-drug interaction rather than rely on the literature provided by supplement 
manufacturers. Providing accurate and clinically reliable advice to people regarding 
the possibility of herb-drug interaction is a great challenge for healthcare 
professionals.  
 
1.2.3. Mechanisms of herb-drug interactions 
Herb-drug interactions can present serious threats to human health, although the 
relevant cause and effect relationships have not been well established. Synergistic or 
additive therapeutic effects may lead to unanticipated toxicities and will disturb the 
dosage regimen of long-term drug therapy. On the other hand, antagonistic herb-drug 
interactions will decrease efficacy or result in therapeutic failure for both of herbal 
medicines and drugs.  
 
Many herbal products are treated as ‘food supplements’ for regulatory purposes, 
although strictly speaking they should be considered as medicines based on a strict 
classification. They act as drugs following modern pharmacological principles. 
Herb-drug interactions which are based on the same principles as drug-drug 
interactions should not come to be a surprise (Izzo et al. 2002b). Mechanisms of 
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herb-drug interactions are intrinsically complex and usually classified into 
pharmacokinetic or pharmacodynamic interactions. Pharmacokinetic interactions 
include absorption, distribution, metabolism and elimination, while pharmacodynamic 
interactions are those where the effects of one drug are affected by the presence of 
another compound at the site of action. Pharmacodynamic interactions are less 
predictable and more difficult to identify. Furthermore, one should not lose sight on 
the fact that they also may interact via multiple mechanisms in vivo, e.g., 
drug-metabolizing enzyme inhibition and/or induction, protein-binding interactions, 
and/or absorption effects.  
 
1.2.3.1. Pharmacokinetic interactions  
Absorption 
Drugs and their metabolites are absorbed by passing through cell membranes which 
are embedded with numerous proteins, including transport proteins. These transport 
proteins in the membrane play an important role to influence the pharmacokinetics of 
many drugs. P-glycoprotein (P-gp) is one of the earliest to be discovered (Gottesman 
and Pastan 1993) and most thoroughly studied (Zhang 2001; Sharom 2006) transport 
proteins. It is an important transmembrane protein which belongs to the adenosine 
triphosphate (ATP)-binding cassette transporter superfamily and expresses not only in 
tumor cells but also in the plasma membranes of many normal tissues, where it serves 
as efflux transporter of xenobiotics (Gatmaitan and Arias 1993). Located at the apical 
surface of the epithelial cells, P-gp interferes with drugs absorption by pumping out a 
variety of orally administered xenobiotics into the intestinal lumen (Lown et al. 1997). 
After uptake by the enterocyte, many xenobiotics are either metabolized by 
cytochrome P450 or pumped back into the lumen by P-gp. Herbal medicines are 
known to modulate the function of membrane-bound transporters and therefore may 
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result in herb-drug interactions. St. John’s Wort induces intestinal P-gp and may 
decrease the absorption of common P-gp substrates, e.g., digoxin (Muller et al. 2004).  
 
Herbal medicines may interact with a drug at the site of absorption, changing the 
amount or its rate of absorption. Changes in gastric or intestinal pH value and 
gastrointestinal motility will influence absorption too. For example, guar gum reduces 
digoxin absorption. Herbal products are more likely to inhibit absorption by forming 
complexes with different substances, such as metal cations, tannins and polyphenols 
etc. It was reported that in vitro studies using Caco-2 cell monolayers suggested a 
possible interaction between green and black tea and folic acid at the level of 
intestinal absorption (Alemdaroglu et al. 2007). In another study, the low 
concentrations of green and black tea extracts were found to decrease the 
bioavailabilities of folic acid in healthy volunteers (Alemdaroglu et al. 2008).  
 
Distribution 
Some herbal products can also change the volume of distribution of a drug. 
Theoretically, a drug with high plasma protein binding capability and the resultant 
small volume of distribution can be displaced by herbal medicines by competing for 
the same binding sites. Aescin, an active ingredient of horse chestnut seed (Aesculus 
hippocastanum), may theoretically interfere with warfarin which is a highly plasma 
protein-bound drug (Rothkopf et al. 1977).  
 
Metabolism 
There are accumulating evidence of metabolism-based herb-drug interactions. Herbal 
medicines and other plant preparations are recognized as xenobiotics like 
pharmaceutical drugs by the human body. The immediate response of the body is to 
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eliminate them. Most of the xenobiotics (including herbal medicines) that gain 
assesses into the systemic circulation are lipophilic and difficult to be excreted. The 
human body renders these xenobiotics hydrophilic through metabolism to facilitate 
their excretion (Ioannides 2002).  
 
A number of enzyme systems adept at converting xenobiotics into polar metabolites 
are ubiquitous in the body and predominantly expressed in the liver, although they are 
also present in extrahepatic tissues such as the lung, kidney, gastrointestinal tract and 
gut mucosa. The representative phase I and phase II enzymes (Porter and Coon 1991; 
Rendic and Di Carlo 1997) are responsible for the metabolism of herbal medicines as 
well as synthetic drugs. Among these enzyme systems, the cytochrome P-450 (CYP) 
enzyme system is the major catalyst involved in phase I drug biotransformation 
reactions for xenobiotic metabolism. The human cytochrome P450 superfamily 
includes 57 genes and contributes to the metabolism of a large variety of xenobiotics, 
including endogenous substrates, drugs, external pollutants and herbal medicines. The 
CYPs catalyze reactions such as hydroxylation, dealkylation, oxidation, etc, in order 
to increase the polarity of substrate molecules and facilitate their excretion. The 
sequence of relative abundance of CYPs in human liver is 3A>2C>1A>2E>2A>2D, 
while that in the intestine is 3A>2C. The order of involvement or significance for 
CYPs in xenobiotic metabolism is as follow: 3A>2C>2D. These three CYPs are 
respectively responsible for the metabolism of 50, 25, and 20% of currently marketed 
pharmaceutical drugs (Guengerich 1997).  
 
Inhibition or induction of P450 enzymes can result in herb-drug interactions, which 
are of important clinical interest especially for some pharmaceutical drugs with 
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narrow therapeutic index. Their concentrations in plasma have to be maintained 
within a narrow concentration range to ensure maximum efficacy with minimum 
adverse effects. If some isoform enzymes of CYPs families which metabolize a 
particular drug are induced, the drug will be eliminated from the circulation more 
rapidly. On the other hand, the inhibition of enzymes leads to the increased 
concentration levels of drugs, which can be an advantageous mechanism unless drug 
serum concentrations reaches toxic levels. It is now established that herbal medicines 
can modulate the levels of hepatic and extrahepatic expression of CYPs and phase II 
enzymes, resulting in significant changes in the metabolism of pharmaceutical drugs, 
especially for those drugs with a low therapeutic index (Ruschitzka et al. 2000; Yue et 
al. 2000). Some of these interactions are serious and life threatening. For example, St 
John’s Wort lowered blood concentrations of cyclosporine in a kidney transplant 
patient (Mai et al. 2000). Furthermore, it significantly induced the apparent clearance 
of both S-warfarin and R-warfarin, which resulted in an obvious reduction in the 
pharmacological effect of rac-warfarin in healthy subjects (Jiang et al. 2004). 
Ginseng (Panax ginseng) interactions included decrease of International Normalized 
Ratio (INR) when used in combination with warfarin (Janetzky and Morreale 1997), 
and hypoglycemia in patients with type 2 diabetes mellitus when given concurrently 
with insulin or oral antidiabetic agents (Sotaniemi et al. 1995). 
 
It is apparent that interactions between herbal remedies and synthetic drugs are no 
longer just theoretically possible. They can be investigated by the modulation of 
specific cytochrome P450s on which critical bioactivation (or detoxification) is 
dependent (Foster et al. 2002; Rodeiro et al. 2009; Zou et al. 2002a). Over the last 20 
years, the modulation of drug-metabolizing enzymes has become one of the major 
focuses for the studies on herb-drug interactions. It is important to find out what kinds 
 20 
of drug-metabolizing enzymes are influenced by the intake of these herbal medicines. 
Some of the herb-drug interactions are now well documented and the underlying 
mechanisms are well understood (Goodwin et al. 2001; Peng et al. 2004). Among 
which, St John’s wort (Hypericum perforatum), Ginkgo (Ginkgo biloba), Garlic 
(Allium sativum), Ginseng (Panax ginseng), Kava (Piper methysticum) are well 
studied and summarized (Delgoda and Westlake 2004). But for the majority of 
herb-drug interactions, the valuable and powerful experimental data is still not 
available. As a result, it is necessary to further systematically evaluate the effects of 
herbal medicines and other remedies on the CYPs as well as other enzymes systems 
(e.g. phase II enzymes) that metabolize drugs. The results perhaps allow us to either 
alter the doses to take advantage of the interactions between herbal medicines and 
pharmaceutical drugs or to choose alternative combinations that are not prone to such 
interactions. Despite some successful studies, the complexity of the molecular 
mechanism of these interactions hinders our ability to predict the potential CYPs- 
mediated herb-drug interactions, either quantitatively or qualitatively.  
 
Elimination 
Some toxic herbs can impair renal or hepatic function and may decrease the excretion 
of some drugs. For example, St. John’s Wort may increase the renal excretion of 
digoxin, which is mediated by P-glycoprotein (Johne et al. 1999b).  
 
1.2.3.2. Pharmacodynamic interactions 
Pharmacodynamic herb-drug interactions can occur via the competition of drug 
transporters and binding sites on plasma proteins. Additive, synergistic or antagonistic 
effects are possible, which resulted from the combinations of drugs with some herbal 
products (Comelli et al. 2007). For example, ginkgo potentiates the antiplatelet effect 
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of aspirin (Rosenblatt and Mindel 1997). Conversely, a herb may directly be 
antagonistic to the action of a drug (e.g. green tea antagonizes the anticoagulation 
effect of warfarin (Taylor and Wilt 1999). In order to predict this type of herb-drug 
interactions, a certain amount of basic pharmacological knowledge is needed about 
the relevant bioactivities varying based on the combination of the drugs and herbal 
medicines. Unfortunately, here often lacks such kind of information. The importance 
of pharmacodynamic herb-drug interactions in clinical practice has not been properly 
evaluated. 
 
Since information on mechanisms involved in herb-drug interactions is incomplete. 
Some of the pharmacologically active herbal extracts are associated with varying 
degrees of toxicity in their own right (Ernst E. et al. 2006). The reported cases often 
do not allow a clear distinction between adverse events due to the intrinsic toxicity 
and those caused by herb-drug interactions. 
  
1.2.4. Approaches employed in the studies of herb-drug interactions 
1.2.4.1 Introduction 
Consumers have little information to make decisions about the safety, especially 
about potential herb-drug interactions. Healthcare professionals including physicians 
and pharmacists should recognize these interactions, as well as toxicity. The multitude 
of chemical components, combined with the fact that herbal medicines are variable 
and often contain undefined compositions renders any study on herb-drug interactions 
a complex and difficult task. 
 
To characterize the potential herb-drug interactions, it is urgent to establish the 
scientific basis by conducting studies with in vitro or in vivo experimental models and 
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the following well-designed clinical investigations. The knowledge about 
metabolism-based herb-drug interactions is expanding because of the significant 
advances in molecular biology, the increased availability of human tissues, the 
development of reliable models and sensitive bioassay methods, etc.  
 
1.2.4.2. In vitro models 
In vitro information can be used to guide the design of in vivo studies which are 
usually more expensive and time-consuming. Actually, in vitro experiments not only 
can improve the prediction about which drugs might show serious interaction 
problems, but also decrease the time and expenditure of the inevitable in vivo studies 
on interactions. In fact, in vitro methodology has become more ‘standardized’ and has 
been widely used by researchers. Since in vitro approaches can be used to screen large 
numbers of samples preclinically, the accurate forecast of herb-drug interactions may 
be predicted from sound knowledge of in vivo pharmacokinetics and the availability 
of validated models with in vitro-in vivo correlations. 
 
It has been just less than twenty years for the studies on screening herbal medicines in 
vitro. So there are limited practical experiences available, and until now the relevant 
experimental models have not been validated for extracts of herbal medicines. The 
extracts of herbal medicines are multi-component mixtures, and among the majority 
of the mixtures, the active constituents are generally unknown (Butterweck et al. 
2004). Nevertheless, these uncertainties make it worthy of evaluating the in vitro drug 
metabolism based on enzyme assays, and the results of those investigations are often 
used to predict in vivo herb-drug interactions. In fact, researches on correlation 
between in vitro and in vivo procedures have been critically investigated and 
commented.  
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Several in vitro models are used in studying herbal modulation effects on drug- 
metabolizing enzyme systems, including human liver microsomes, S9 fractions, 
isolated/cultured hepatocytes, liver slices and purified or heterologously expressed 
drug-metabolizing enzymes. Each model has its own scientific benefits as well as 
drawbacks and limitations (Butterweck and Derendorf 2008). Contradictions 
sometimes appeared in some reported studies, which need to be critically and 
carefully evaluated, especially with regard to the experimental methods and the 
interpretation of the data. A more likely explanation relates to the complexity of drug 
metabolism in cells and tissues, compared with those in the in vitro experimental 
systems where isolated enzymes or liver microsomes are simply mixed in a test tube. 
Significant differences may exit between the concentration of putative inhibitor 
presented to the enzyme in vitro and that occurring in vivo. There are several 
important limitations of in vitro screening for herb-drug interactions. Most of in vitro 
studies used for screening herb-drug interactions are based on enzyme assays. 
However, the enzymes are proteins and it was well recognized that tannins, which 
widely exist in most of the medicinal plants, can easily precipitate and therefore 
inactivate the activities of enzyme. More importantly, the amounts of tannins in these 
studied herbal extracts are unknown. Thus, the unspecific effects due to protein-tannin 
interactions rather than an inhibition effect of herbal medicines on enzymes cannot be 
completely excluded. Several studies (Foti et al. 2007; Takahashi et al. 2003) showed 
that almost every herbal extract tested in an in vitro screening assay can interact with 
CYP enzymes. The reliability of these studies is questionable, especially when 
concerning that the information on the amount of tannins in extracts used in these 
studies is lacking.  
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During the in vitro screening of herb-drug interactions, some CYP substrates have 
been selected specifically to form a fluorescent product to easily monitor the 
inhibition effect of interaction. In these procedures, it might lead to false positive or 
fake negative results, since herbal extracts often contain constituents with an intrinsic 
fluorescence which might interfere with these screenings. The intrinsic fluorescence 
of active components in herbal medicines might mask enzyme inhibition, whereas its 
quenching might mimic or simulate inhibition. This phenomenon was clearly 
elucidated in a study of Zou et al. (Zou et al. 2002b). The effects of intrinsic 
fluorescence and quenching in fluorescence based enzyme inhibition assays of 25 
components of some popular herbal products were elucidated. It was found that 
quercetin had the greatest effect and quenched the fluorescent product of CYP 2D6, 
2C19/1A2, and 3A4/2C9 by 33, 55 and 15% respectively, and thus showed a weak 
inhibition effect. On the other hand, the intrinsic fluorescence of yangonin exceeded 
the signal of the fluorescent products by 92-424%, hence simulating a false negative 
effect.  
 
Since the fluorescence and quenching problem are well known to researchers in these 
investigations (Bapiro et al. 2001), one should be cautious to evaluate the induction 
and inhibition effects of herbal medicines in fluorimetric assay protocols. Now the 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) method has been 
widely applied and shows a trend to substitute for the fluorescent assays. For the 
determination of IC50 value of CYP 3A4 activity for hypericin, which is an active 
compound in St. John’s Wort with an intensive native fluorescence, the results 
determined by the fluorimetric method were very different from that obtained by 
LC-MS/MS method (Budzinski et al. 2000; Obach 2000a).  
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In 2004, the German Federal Institute for Drugs and Medical Devices (Bundesinstitut 
für Arzneimittel und Medizinprodukte, BfArM) published a guideline (www.bfarm.de) 
which was updated in 2008 for the assessment of pharmacokinetic herb-drug 
interactions. It suggested that the chosen concentration of herbal medicines extract 
should be in accordance to their clinical relevance. However, unlike most synthetic 
drugs, the pharmacokinetic and bioavailability data are still not available for the 
majority of herbal products. More importantly, it is not known what is the actual 
concentration realized in those tissues of the human body that are involved in 
transportation or metabolism. Thus, in vitro screening of herbal extract in a clinically 
relevant concentration is still not possible (Gorski et al. 2004; Piscitelli et al. 2002; 
Strandell et al. 2004).  
 
1.2.4.3. In vivo studies using experimental animal models 
Sometimes in vitro evaluation may not accurately reflect the changes of herb-drug 
interactions observed in vivo and can not be extrapolated confidently to the in vivo 
situation. Although in vitro models are amenable to automation and develop quickly, 
in vivo studies are vital in providing evidence of the clinical importance (Lo et al. 
1995). A lot of information on herb-drug interactions came from the studies using 
animal models which were based on the presumption that rodents were excellent 
surrogate models for man.  
 
There are substantial species differences between rodents and man, especially in the 
expression and catalytic activities of CYPs enzyme systems (Nedelcheva and Gut 
1994). This phenomenon makes it difficult to extrapolate the data from animal studies 
to humans (Lin 1995). For example, nifedipine is metabolized by CYP 3A4 in adult 
human. But in rats, it is metabolized by several isoforms of CYPs such as CYP 2C11, 
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CYP 2B1, and CYP 1A1 (Guengerich et al. 1986). A rabbit model was excluded from 
interaction studies because the metabolism of one third of the drugs used in human 
involves other forms of CYP enzymes in rabbit. In contrast, most of the main CYP 
enzyme systems in human are found in the liver microsomes of pigs, minipigs and 
monkeys. Unfortunately, these models might be inappropriate for first screening 
purpose since they are relatively expensive. Eventually, human studies are still 
required to confirm the herb-drug interactions because of the species discrepancy 
between animals and human. 
 
Besides, knockout/transgenic strategies applied in rat and mouse models have also 
opened a new avenue for the selection of drug targets. This technology, once 
developed, might enable us to use such rodent models for CYP-mediated herb-drug 
interaction studies in the future.  
 
1.2.4.4. Clinical studies 
The herb-drug interactions are now becoming more common, with the popularity of 
complementary therapies and greater awareness of the potential food-drug/herb-drug 
interactions, although they are still rare when comparing with drug-drug interactions. 
Most of the available information about herb-drug interactions is based on in vitro 
data or in vivo by using experimental animal models. Even evidence of a biological 
effect has been demonstrated consistently in animal models or in vitro, it does not 
ensure the effect in man. For example, St. John’s Wort has been found to inhibit CYP 
2C9, CYP 2D6 and CYP 3A4 in vitro (Carson et al. 2000). However, it appeared to 
be an enzyme inducer in clinical practices. It was reported that St. John’s Wort 
reduced the serum concentration of amitriptyline, a substrate of CYP 2C9, CYP 2D6 
and CYP 3A4 (Breidenbach et al. 2000; Markowitz et al. 2000; Roots et al. 2000) 
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These contradictions may be caused by hyperforin, a main active component in St. 
John’s Wort. It is bound to a nuclear receptor which is called the pregnane X receptor 
(PXR). PXR is an orphan nuclear receptor that regulates the expression of CYP 3A4 
monooxygenase. The activation of PXR leads to an increase in CYP 3A4 availability 
and subsequently increase metabolism of drugs which are mainly metabolized by 
CYP 3A4. This phenomenon was not observed in vitro studies.  
 
Specific probe-substrates are used to explore the effects of herbal products on the 
activities of CYP enzymes in human. The ratios of serum and/or urinary metabolites 
to parent drugs obtained at specific time-points after oral administration provide good 
clearance estimations of various CYP substrates. However, sometimes it is difficult to 
predict the clinical significance of herb-drug interactions. A pharmacokinetic 
herb-drug interaction altering the drug concentration versus time profile may or may 
not be clinically relevant. The meaning of altered pharmacokinetic parameters must 
be interpreted with great care, since the relationships between drug concentration and 
effect or intensity of desired and/or undesired effects are usually not linear. The 
pharmacodynamics of many drugs follows the Emax model where the relationship 
between concentration and effect can be represented by a sigmoid curve. Small 
pharmacokinetic changes may still be clinically important for drugs with a narrow 
therapeutic index or a steep concentration-response relationship (Dresser et al. 2000). 
FDA has proposed a classification system for the clinical significance of drug 
interactions determined from in vivo studies, which is identical to that presented by 
industry (Bjornsson et al. 2003a). 
 
Most of the reported herb-drug interactions in clinical practice still came from case 
reports, which have to be interpreted with great caution, as casualty is not usually 
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established beyond reasonable doubt. Many examples of contradictions appear in 
these case reports and need to be critically and carefully evaluated, especially about 
the experimental methods and the interpretation of the data. At present, 
well-documented case reports can serve as a critical early warning system. 
 
Most of the information of herb-drug interactions came from theory, reviews, in vitro 
studies, in vivo studies using animal models or unvalidated case reports, which lacked 
further evaluation of the pharmacokinetic and/or pharmacodynamic background as 
well as the mechanisms and clinical interpretations involved in the interactions. 
Although systematic clinical studies are now also beginning to appear in the literature, 
the mechanisms of these herb-drug interactions are still far from being fully 
elucidated and many authors of clinical reports fail to adequately define the herbal 
products used. Most of the information about the herb-drug interactions is of widely 
varying quality and reliability. Even for the randomized controlled trials of herbal 
medicines, some important methodological components were incompletely reported 
including allocation concealment, method used to generate the allocation sequence, 
and whether an intention-to-treat analysis was used. In addition, key information 
unique to these clinical trials of the herbal products may be missing, such as the 
percentage of active components and type or form of the herbal medicine preparation. 
It is extremely important to identify and quantify the active components in herbal 
products because of the possibility of substitution, contamination or other forms of 
adulterations. Complete reporting of clinical trials is essential to allow reviewers, 
editors and clinician to reliably appraise and interpret results of these trials. It was 
suggested that clinical trialists should consult the extension of the Consolidated 
Standard of Reporting Trials statement specific to herbal medicines trials when 
designing and reporting clinical trials of herbal medicines. Further research about the 
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herb-drug interactions, which comes from well-designed controlled clinical studies 
(Goldman 2001), is needed to confirm and assess the clinical significance of the 
potential herb-drug interactions. Despite the absence of reliable data and uncertainty 
of the mechanism and extent of these interactions, many potential interactions are 
being highlighted instead (Izzo et al. 2002a; Miller 1998; Barnes 2003; Ang-Lee et al. 
2001; Abebe 2002). 
  
Studies of herb-drug interaction are still sparse for a number of reasons, and reliable 
results of these interactions are not available. An interaction may not be recognized 
and may only be reported if it is considered ‘serious’. It is difficult to assess the 
incidence of herb-drug interactions, and even more difficult to assess the reliability of 
these reports, which often just referred to the case reports or theoretical case not 
relevant to a clinical situation. Over interpretation of case reports may result in 
erroneous conclusions, which are misleading.  
 
Most of the reported herb-drug interaction studies focused on limited herbal products, 
such as ginseng, St John’s Wort, garlic, goldenseal, and Echinacea. It is far from 
extensive as a much broader range of herbal medicines is used in practice. The most 
commonly used herb medicines should be screened for the potential herb-drug 
interactions and the underlying mechanisms.   
 
In conclusion, referenced and educational information on herbal medicines should 
provide objective and complete information including adverse effects and interactions 
between herbal medicines and drugs, to help healthcare practitioners providing 
accurate information to consumers. The MayoClinic website (www.MayoClinic.com) 
provides a list of herbal medicines and some western drugs that should not be used 
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concurrently. However, to ensure that consumers are well protected, the information 
on the website includes some potential and theoretical interactions, and is not 
referenced to the scientific literature.  
 
Good communication between regulators, medicines practitioners, and the public is 
necessary for the safe use of herbal products. Armed with appropriate knowledge of 
adverse effects and any potential herb-drug interaction that might occur, the medical 
practitioners may guide people as to whether it is advisable to use herbal medicines.   
 
1.3. Herb-drug interaction between L. chuanxiong and aspirin 
Stroke is the third leading cause of death after heart disease and cancer. It was 
reported in several countries that stroke is the first leading cause of serious, long-term 
disability (American Stroke Association 2005; Bonita et al. 1990; Gunarathne et al. 
2009). Furthermore, the age standardized incidence of stroke and the economic 
burden of stroke-related medical care are increasing (American Heart Association 
2009). Prevention including changes of lifestyles and medicine treatments is 
considered to be the best approach to reduce the happening and medical expenditure 
of stroke (Goldstein et al. 2001). Antithrombotic treatment with aspirin is 
recommended for ischemic stroke or transient ischemic attack. The role of aspirin 
treatment in primary prevention among those at high risk of cardiovascular events is 
established. Aspirin is beneficial for patients with non-rheumatic atrial fibrillation and 
recent cerebral ischemia (Saxena and Koudstaal 2004).  
 
The interaction between herbal medicine and cardiovascular drugs is an important 
safety issue. In 2005, a study reported that as many as one-third of heart failure 
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patients may take alternative and complementary medicines (Zick et al. 2005). The 
commonly used herbal medicines, such as saw palmetto, ginkgo, St John’s wort, and 
hawthorn showed cardiac side effects and may have potential herb-drug interactions 
with cardiac medications (Beckert et al. 2007; Flattery 2008). It has been reported that 
garlic and ginkgo may interact with aspirin and cause severe spontaneous bleeding 
(Capasso et al. 2003). In view of high prevalence of herbal use in patients with 
antiplatelet or anticoagulation therapy, the interactions between commonly used 
herbal medicines and aspirin deserve deep concern and effort in the studies of 
potential herb-drug interaction.  
 
The dried rhizome of Ligusticum chuanxiong Hort. (Umbelliferae) is first recorded in 
the Divine Husbandman’s Classic of the Materia Medica (Shen Nong Ben Cao Jing). 
Based on the traditional theory, L. chuanxiong is warm in property and pungent in 
flavor, with functions of activating blood and promoting qi, expelling wind and 
stopping pain. It has been used to treat vascular disorders in China for thousands of 
years. Reputed for facilitating blood circulation and dispersing blood stasis, this herb 
is commonly prescribed for the treatment of angina pectoris, cardiac arrhythmias, 
hypertension, stroke, cerebral thrombosis, headache, gynecological disease, spasm, 
abdominal pain, etc.(Chen 1992; Hsu et al. 1986). 
 
In 2002, L. chuanxiong has been allowed by the Ministry of health, People’s Republic 
of China to be used as general food ingredients in food products (MOH 2002). It is 
also commonly used in Chinese and Japanese herbal mixtures. There are 
approximately sixty traditional formulae containing L. chuanxiong as listed in the 
Pharmacopoeia of the People’s Republic of China (The State Pharmacopoeia 
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Commission of P.R.China 2005), such as Wushicha capsule, ‘Peach Pit, Safflower 
and Four Ingredients Decoction’ and ‘Tea-Blended Ligusticum Powder’.   
 
In most oriental countries, combined use of herbal products and pharmaceutical drugs 
is common, especially for patients in the treatment of chronic diseases, such as 
cancers, diabetes, immunological and cardiovascular disorders. In some countries, 
especially in Asia, it is believed that food and medicine share the same origin based 
on the traditional theory and use. Chinese medicated diet is part of the Traditional 
Chinese Medicines (TCM) practices that has been used for centuries to promote 
human health and to prevent and cure diseases. One of its popular and important 
forms is drinking tonic soups which are prepared by boiling one or a more tonic 
Chinese medicinal herbs with pork or chicken and seasoning in water for 2-3 hours. 
People like drinking those tonic soups at the beginning of dinner, which are believed 
to have the effect on slowing the aging process and boosting the immune system 
(Zhang and Yu 2000). In Singapore, many families consume herbs in cooking soups 
and stews, especially for women after giving birth, patients after surgical operation 
and the elderly to recuperate their strength. L. chuanxiong is often used in all kinds of 
tonic soups with the effect of invigorating the vital energy and nourishing blood.  
 
The reported main active ingredients of L. chuanxiong are ferulic acid and 
tetramethylpyrazine (ligustrazine) (Tang et al. 1999; Xiao et al. 2002). These two 
compounds have significant effects on inhibiting platelet aggregation, reducing blood 
viscosity and haematocrit (Gao et al. 1989; Lin et al. 1991; Tan et al. 2003; Xiao et al. 
1994). Tetramethylpyrazine is chemically synthesized and marketed as 
LigustruzineTM. It is used in China to treat thrombotic diseases including myocardial 
and cerebral infarction (Zhang et al. 1994). Tetramethylpyrazine is also widely used 
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in China as a new kind of calcium antagonist for the treatment of coronary 
atherosclerotic cardiovascular disease and ischemic cerebrocardiac vascular disease. It 
has also been found to be more effective in protection against vascular endothelial cell 
injury (Chen 1999; Mei et al. 2004).   
 
L. chuanxiong has been reported to interact with aspirin to prolong the clotting time 
and bleeding time in laboratory mice (Gam et al. 2003). However, the mechanism on 
the basis of pharmacokinetics and pharmacological profiles in the interaction has not 
been elucidated. To date, there is no reported study on the mechanisms of potential 
interactions between L. chuanxiong and aspirin. To the best of our knowledge, there is 
no other reported interaction between L. chuanxiong and other drugs. Due to the 
clinical importance of anticoagulant/antiplatelet drugs and the increasing usage of 
herbal medicines, the effects of L. chuanxiong on drug metabolizing enzymes and its 
potential herb-drug interactions with aspirin will be elucidated. New knowledge and 
methodology for evaluating herbal medicines and potential herb-drug interactions in 
the coagulation cascade will be established to meet similar safety and efficacy 









1.4. Rationale, Hypotheses and Objectives 
Quality, safety and efficacy are important considerations for both approved drugs and 
herbal medicines. Despite the popular use of herbal medicines, their quality, efficacy 
and safety are still far from being well elucidated. Among them, quality is a 
paramount issue to ensure the efficacy and safety. More research to develop new 
analytical methods for the chemical identification of components to control the 
quality of herbal medicines is needed. In addition, the potential for herb-drug 
interactions needs to be carefully assessed to safeguard patients’ safety. 
 
We hypothesize that bulk powder of dietary supplement may contain unknown 
adulterants, and that L. chuanxiong may have a role to play in the modulation of drug 
metabolizing enzyme systems and may cause potential herb-drug interactions with 
aspirin in vivo. 
 
The overall objectives of the work presented in this thesis aims to develop methods 
and apply them for the assessment of quality and safety of herbal medicines. L. 
chuanxiong Hort. is a well known cardiovascular protective medicinal herb in Asia 
and is also commonly used in herbal mixtures and tonic soups. The quality control of 
L. chuanxiong is a challenge due to the instability of some bioactive components. We 
hypothesize that L. chuanxiong may have a role to play in the modulation of drug 
metabolizing enzyme systems and may cause potential herb-drug interactions with 
aspirin in vivo. 
 
In this project, two approaches to evaluate the quality of herbal medicines or herbal 
products are investigated. One approach is to screen for illegal adulterant added into 
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dietary supplement or herbal products. Due to the multitude of components and 
complexity of dietary supplements and herbal products, modern analytical 
technologies, including HPLC, IR, LC-MS/MS and NMR are used for the detection 
and identification of a PDE-5 inhibitor analogue in a bulk powder intended to be 
formulated or encapsulated into a botanical dietary supplement. Another approach is 
to establish a HPLC and LC-MS/MS method to detect and quantify 
tetramethylpyrazine, ferulic acid and other bioactive components especially different 
kinds of phthalides in the L. chuanxiong extracts. A new rapid and reliable 
LC-MS/MS method is to be developed to identify and characterize bioactive 
components in L. chuanxiong extracts using retention time (tR), high resolution mass 
data and multistage fragmentation patterns. 
 
Safety is an important consideration in the use of herbal medicines. Among the 
various safety issues (Section 1.2), herb-drug interaction is a concern and is often 
overlooked. Cytochrome P450, the most important drug metabolizing enzyme system, 
has been the major target for the studies on herb-drug interactions. To assess the 
potential herb-drug interaction of L. chuanxiong, the effects of its crude extract and 
reported active components (namely, tetramethylpyrazine and ferulic acid) on hepatic 
drug-metabolizing enzymes will be investigated. CYP 3A and CYP 2D activities are 
determined in Sprague-Dawley rat ex vivo, using midazolam and bufuralol as 
substrates respectively.  
 
It was reported that L. chuanxiong or its reported active components had effects on 
platelet aggregation. Another objective of the present study is to investigate the 
potential herb-drug interaction between L. chuanxiong and aspirin by measuring the 
pharmacokinetic parameters of aspirin and the resultant platelet aggregation effect in 
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SD rat. The ex vivo platelet aggregation effect in rats is investigated as an important 
index for the pharmacodynamic effect for the study of interaction. The kinetics of a 
single intraperitoneal (i.p.) injection or a single intravenous (i.v.) injection of 40 
mg·kg-1 aspirin are separately investigated in the L. chuanxiong extract treated and 
untreated groups of rats.  
 
 The specific objectives of this study are hence:  
1) to detect, purify and identify an unknown adulterant (PDE-5 inhibitor analogue) 
 from a premixed bulk powder intended as a botanical dietary supplement.  
2) to develop HPLC and LC-MS/MS methods to assess the quality of L. chuanxiong 
 by detecting and quantifying the bioactive components in L.chuanxiong, such as 
tetramethylpyrazine, ferulic acid and different kinds of phthalides.   
3) to study the effects of L. chuanxiong, tetramethylpyrazine and ferulic acid on the 
most important drug metabolizing enzymes CYP 3A and CYP 2D in SD rats ex 
vivo by using midazolam and bufuralol as substrates respectively. Furthermore, the 
effect of L. chuanxiong extract on pharmacokinetics of dextromethorphan (a CYP 
2D substrate) will be investigated in SD rats. 
4) to study the potential in vivo herb-drug interactions between L. chuanxiong and  
 aspirin by determining pharmacokinetic parameters of aspirin and the effect on 











A dietary supplement is defined under the Dietary Supplement Health and Education 
Act of 1994 (DSHEA in U.S.A.) as a product that is intended to supplement the diet 
and contains one or more of the following: vitamins, minerals, herbs or other 
botanicals, amino acids, or any combination of the above ingredients. The 
manufacturers of dietary supplements have the responsibility to ensure their safety 
before they are marketed. In the USA, FDA is responsible for taking action against 
any safety problems of these dietary supplement products after they reach the market. 
Adulteration with undeclared synthetic compounds in dietary supplements has been 
regarded as an important safety issue of dietary supplements and health products 
(Ernst 2002; Koh and Woo 2000), which can result in serious clinical consequences 
and sometimes is life threatening (Bryant et al. 2005; Ernst 2002; Poon et al. 2008).  
 
It was reported that over half of men between 40 and 70 years age had experienced 
erectile dysfunction (ED) and the number of men who have ED may reach to more 
than 330 million worldwide (Goldstein 2000). Sildenafil (Viagra®), vardenafil 
(Levitra®) and tadalafil (Cialis®) are licensed prescription drugs, specifically c-GMP 
phosphodiesterase type 5 enzyme (PDE-5) inhibitors, used for the treatment of ED 
(Brock 2000). The inhibition effect of PDE-5 enzyme results in higher level of cyclic 
guanosine monophosphate, which relaxes smooth muscles, promotes penile blood 
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flow and enhances erectile function (Lenk 2002). Their side-effects include headache, 
facial flushing, nasal congestion, dyspepsia, visual disturbances and serious 
cardiovascular adverse effects (Hazell et al. 2009; Reffelmann and Kloner 2006; 
Sunwoo et al. 2005; Trimarchi et al. 2008). They may also cause potential fatal 
drug-drug interactions with nitrates, erythromycin and HIV protease inhibitors 
(Langtry and Markham 1999). Thus the use of any prescribed PDE-5 inhibitors 
without the care of physician can be dangerous.  
 
Due to the size of the market for ED drugs, there is an increasing use of dietary 
supplements including herbal products working as substitutes in enhancing male 
sexual function. Yohimbine, citrulline, pyrano-isoflavones, berberine and forskolin, 
which are derived from natural products, have been reported to improve sexual 
performance (Drewes et al. 2003). Some traditional herbs, such as ginseng root 
(Panax gingseng C.A. Mey), lychee seed (Litchi chinesis Sonn.), barbary wolfberry 
fruit (Lycium barbarum L.), longan aril (Dimocarpus Longan Lour.), aweto 
(Cordyceps sinensis (Berk.) Sacc.), common peony root (Paeonia lactiflora Pall.), 
Chinese magnoliavine fruit (Schisandra chinensis (Turcz.) Baill), Indian bread (Poria 
cocos (Schw.) Wolf), shorthorned epimedium root (Epimedium brevicornum Maxim.) 
etc, may enhance male sexual performance. Many dietary supplements, especially 
those claimed to contain herbal materials, are sometimes regarded to be safer than 
those FDA-approved PDE-5 inhibitors and always accessible in local health stores or 
over the internet without strict regulation unlike drugs.  
 
Sildenafil, vardenafil and tadafil have been detected in some dietary supplements, 
herbal products or soft drinks which are claimed to be from natural origin 
(Abdel-Hamid 2006; Bogusz et al. 2006; Gratz et al. 2004; Zhu et al. 2005). In 
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addition, the analogues of FDA-approved PDE-5 inhibitors, including homosildenafil, 
thiosildenafil, piperidenafil, acetildenafil, benzamidenafil, aminotadalafil, 
thioquinapiperifil etc, have also been reported to be identified in some dietary 
supplements. The structures of the FDA-approved PDE-5 inhibitors and their 
analogues that have been detected in dietary supplements are given in Figure 2.1. 
According to the summarized information (Table 2.1), adulteration of PDE-5 
inhibitors and their analogues have been documented in many countries including US, 
Canada, Netherlands, Korea, Singapore, Japan and China. The number of case reports 
is still escalating. These analogues are structurally similar to the commercial PDE-5 
inhibitors, hence similar therapeutic effect might be expected. But to date there are no 
systematic studies on the efficacy and toxicology of these analogues. Consumers are 
at risk if dietary supplements are adulterated with approved PDE-5 inhibitors or their 
unapproved analogues. 
 
Hence the detection of such analogues is extremely important and timely. Without 
any given information, it is difficult to detect novel compounds adulterated in dietary 
supplements or herbal products during analysis. In addition, detection is also 
challenging due to the multitude of components in those products, especially of the 
herbal products. The modern analytical technologies (including high-performance 
liquid chromatography, infrared spectroscopy, gas chromatography-mass 
spectrometry, liquid chromatography-electrospray tandem mass spectrometry, nuclear 
magnetic resonance spectroscopy and capillary electrophoresis) emphasized on the 
chemical analysis of chemical constituents is used for the detection and identification 
of adulterants in dietary supplements (Singh et al. 2009) and have been well applied 
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Figure 2.1 Chemical structures of PDE-5 inhibitors and their analogues identified in 


























































































































Table 2.1 FDA-approved PDE-5 inhibitors and their analogues reported in dietary supplements/natural products.  
Adulterant Type of product Source Analytical methods References ( country) 
2009 
Sildenafil Capsules, 
tablets or herbal 
oils 
Purchased from local shops LC-PDA, LC-MS/TOF Savaliya A.A. et al. 2009, 
India 
Cyclopentynafil, N-octylnortadalafil Tablet Purchased over the internet HPLC, LC-MS, HR-MS, NMR, CD Hasegawa et al. 2009, 
Japan 
Homosildenafil, Piperidenafil, Sildenafil,      
Tadalafil, Thiosildenafil, 
Methisosildenafil, Thiomethisosildenafil, 
Capsules _ Ion mobility spectrometry Gryniewicz et al. 2009, 
USA 
Hydroxythiohomosildenafil Capsules Bought online HPLC, IR, LC-MS2, HR-MS, NMR Li et al. 2009, Singapore 
Thiosildenafil 
Thiomethisosildenafil  
Capsules _ LC-MS, MSn and chemical cleavage 
followed by LC-MS and GC-MS, 
NMR 





Capsules Seized by the Dutch 
authorities 
LC-MS, NMR Venhuis et al. 2008a, 
Netherlands 
Aminotadalafil and its stereoisomers A health food Submitted to authorities for 
analysis 
LC-MS Kurita et al. 2008, Japan 
Aminotadalafil, hydroxyhomosildenafil, 
methyl-1-(1,3-benzodioxol-5-yl)-2-( 
Capsules            
  
Purchased over the internet TLC, HPLC, LC-MS, FT-ICR-MS, 
NMR 




pyrido[3,4- b]indole-3-carboxylate    
Benzamidenafil Capsules Submitted to Singapore 
health Authority 
HPLC, IR, LC-MS2, HR-MS, NMR Zou et al. 2008b, 
Singapore 
Homosildenafil, Thiohomosildenafil Marihuana Marihuana is regularly 
checked in The Netherlands 
LC-MSn, MSn Venhuis and de Kaste 
2008, Netherlands 
Hydroxyvardenafil, Methisosildenafil Capsule , health 
food 
Seized by the Korea 
Authorities 
HPLC, EI-MS, IR, NMR Choi et al. 2008, Korea 
Thiohomosildenafil Capsule _ UV, LC-MS, IR, MS/MS, NMR Venhuis et al. 2008b, 
Netherlands 
Thiohomosildenafil, Thiosildenafil Capsule Submitted to Singapore 
health Authority 




Submitted to Singapore 
health Authority 
LC-UV, LC-TOF-MS, MS/MS, IR, 
NMR 




Tablets purchased at an porno shop 
in Japan or via the internet 
HPLC, LC-MS2, HR-MS, NMR Uchiyama et al. 2008, 
Japan 
(R)-Xanthoanthrafil Capsule Purchased over the Internet TLC, HPLC, LC-MS2,HR-MS, NMR, 
CD 
Kumasaka et al. 2008, 
Japan 
2-(2-ethoxyphenyl)-5-methyl-7-propyl- 
imidazo[5,1-f ][1,2,4]trizan-4(3H)-one                    
Herbal health 
product





Capsules Submitted by local health 
bureau 




Hydroxyacetildenafil, Sildenafil  
Hydroxyhomosildenafil  
health products Purchased from local 
convenience stores and 
pharmacies 
HPLC, LC-MSn Poon et al. 2007, Hong 
Kong, China 
Hydroxyhongdenafil, Pseudovardenafil Capsule, raw 
material  
_ HPLC, IR, HR-MS, NMR Park et al. 2007, Korea 
Methisosildenafil Capsule Purchased over the internet UV, LC-MS, MS2, NMR, chemical 
cleavage 
Reepmeyer et al. 2007, 
USA 
Nor-acetildenafil Capsule Purchased over the Internet LC-MS, MSn and chemical cleavage 
followed by LC-MS and GC-MS 
Reepmeyer and Woodruff 
2007, USA 
Piperidenafil Capsule Local markets of Taiwan IR, LC-MS2, NMR Lai et al. 2007b, Taiwan 
Sildenafil Pill Chinese herbal/patent 
medicines 
TLC, HPLC and GC-MS Miller G. and Stripp R. 
2007, USA 
2-(2-ethoxyphenyl)-5-methyl-7-propyl- 
imidazo[5,1-f ] [1,2,4] triazin-4(3H)- one 
Capsule                      Local markets of Taiwan LC-MS2, NMR Lai et al. 2007a, Taiwan 
2006 
Acetidenafil Tablet Local markets of Taiwan NMR, IR, HR-MS, LC-MS2 Lai et al. 2006,Taiwan 
Acetildenafil, Homosildenafil 
Hydroxyhomosildenafil 
bulk powders  _ HPLC, IR, LC-MS2, NMR Oh et al. 2006, Singapore 






Submitted to Singapore 
health Authority 




Capsule Submitted to Singapore 
health Authority 
HPLC, IR, LC-MS2, HR-MS, NMR Zou et al. 2006a, 
Singapore 
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_ HR-MS, LC-MSn Gratz et al. 2006, USA 
Hydroxyhomosildenafil 
Sildenafil, Yohimbine 
Capsules Local markets of Taiwan NMR, MS, IR, X-ray Lin et al. 2006, Taiwan 
Piperidenafil Capsule Bought over internet HPLC, MSn, LC-MS and chemical 
cleavage followed by LC- and GC-MS 
Reepmeyer and Woodruff 
2006, USA 
Sildenafil, Tadalafil Tablet, bulk 
herbal matrices 
From local market LC-MS2 Abdel-Hamid 2006, 
Kuwait 
Sildenafil, Tadalafil Capsules or 
powder 
Local markets of Saudi 
Arabia 
LC-MS2 Bogusz et al. 2006, Saudi 
Arabia 




Seized by SDA of P. R. 
China 
LC-MS2 Liang et al. 2006, China 
2005 
Sildenafil, Tadalafil Capsules, 
Tablets 
Purchased via internet or 
from local store  
LC-MS Fleshner et al. 2005, Canada 
Vardenafil Oral liquid From local super market LC-MS2 Zhu et al. 2005, China 





Seized by the Dutch health 
Authority 
LC-MSn, direct infusion MSn, NMR Blok-Tip L. et al. 2004, 
Netherlands 







Purchased through the 
internet 
HPLC and LC-MS Gratz et al. 2004, USA 
2003     
Homosildenafil Functional 
food 
Submitted for inspection UV, HPLC, IR, HR-MS, NMR Shin et al. 2003, Korea 
2002     




Capsule Submitted to the National 
Lab. of Foods and Drugs  




Inspection by National 
Institute 














This chapter reports the isolation and structural identification of a new acetildenafil 
analogue detected in a pre-mixed bulk powder. According to our knowledge, the 
powder was destined to be encapsulated and sold as a dietary supplement. 
 
2.2. Objective 
An unknown compound with similar UV spectrum pattern to that of acetildenafil (an 
analogue of sildenafil, Figure 2.1) was detected in the preliminary screening by thin 
layer chromatography (TLC) and high-performance liquid chromatography (HPLC). 
The objective of this work is to extract, isolate and purify an unknown compound 
present in a herbal pre-mixed powder and unambiguously elucidate it molecular 
structure using UV, infrared spectroscopy (IR), mass spectrometry (MS), 




2.3.1. Sample and reagents 
A light brown pre-mixed bulk powder was submitted to the Health Sciences Authority 
of Singapore for analysis. The acetildenafil standard was isolated and purified from 
another pre-mixed bulk powder and used as a laboratory standard (Oh et al. 2006). 
Five grams of the sample was extracted with 50 ml methanol by ultrasonication for 30 
min. The dried extract was reconstituted in methanol and dichloromethane (1:1, v/v). 
The target compound (acetildenafil) was then isolated and purified using 
normal-phase open-column chromatography (isocratic elution using dichloromethane 
and methanol, 20:1, v/v). Its purity was more than 98% as detected by HPLC.  
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Methanol (HPLC grade) was supplied by Labscan Asia Co., Ltd. (Bangkok, Thailand). 
Ammonium formate (97%) was purchased from Sigma-Aldrich (St. Louis, Mo, USA). 
Reagent grade methanol and chloroform were used for extraction and separation. 
Deuterated chloroform, dimethylsulfoxide-d6 (DMSO-d6), deuterium oxide (D2O) and 
internal standard tetramethylsilane (TMS), used for NMR analysis, were purchased 
from Sigma-Aldrich (Steinheim, Germany). Acetildenafil and the purified analogue 
were dissolved in deuterated chloroform at 12 mg·mL-1 for NMR studies at 298 K. 
Potassium bromide (KBr) powder used for IR analysis were purchased from 
Sigma-Aldrich. The 0.45 µm syringe nylon filters were supplied by Whatman 
International Ltd. (Maidstone, UK). MilliQ water for the HPLC analysis was 
deionized and passed through a Synergy Purification System (Molsheim, France). The 
sorbent used for open-glass column chromatography was silica gel 60 (Merck KgaA, 
Darmstadt, Germany).  
 
2.3.2. Extraction and isolation 
Two grams of the pre-mixed bulk powder were ultrasonically extracted in 50 ml 
methanol for 40 min in duplicate. The filtered extract was evaporated by a rotary 
vacuum evaporator at 120 mbar and 40◦C. The residue was reconstituted in 5 ml of 
methanol and filtered using a 0.45 µm membrane filter for semi-preparative HPLC 
separation. An Agilent 1100 series HPLC chromatograph with diode-array detector 
(Palo Alto, CA, USA), an Agilent Zorbax SB-C18 reversed-phase column (250 mm × 
9.4 mm I.D., 5 µm) were used. Methanol (A) and water (B) were used as mobile 
phase. Gradient elution started at 75% A, changing linearly to 100% A over 30 min.  
The flow-rate of mobile phase was 1.5 mL·min-1 and injection volume was 50 µL. UV 





For analysis by HPLC, an Agilent 1100 series HPLC chromatograph with diode-array 
detector (Palo Alto, CA, USA), with an Agilent Eclipse XDB C18 reversed-phase 
column (250 mm × 4.6 mm I.D., 5 µm) were used. Gradient elution started at 40% 
methanol with 60% 0.1 M ammonium formate, changing linearly to 100% methanol 
over 30 min. Flow- rate was 0.7 mL·min-1 and injection volume was 10 µL. The 
chromatograms were recorded at a wavelength of 254 nm.  
NMR 
1H- and 13C-NMR, DEPT and COSY data were acquired on a Bruker AVANCE 300 
spectrometer. HMBC data was obtained at 500M Hz on a Bruker AMX 500 
spectrometer (Bruker, Germany). NMR spectra were obtained using deuterated 
chloroform, DMSO-d6 and D2O as the solvents. Chemical shifts were reported in ppm 
using TMS as an internal standard. The data were processed using XWINNMR 
software (Bruker). The experimental conditions from a previous report (Shin et al. 
2004) were used with slight modifications. 
IR 
IR spectra in KBr disks were obtained on a Shimadzu IR Prestige-21 FTIR 
spectrometer (Shimadzu, Nakagyo-ku, Japan) and recorded over the spectral range 
4000-400 cm-1.  
MS 
ESI-MS and MSn analysis were performed in positive ion mode using a Finnigan 
LCQ ion-trap mass spectrometer (ThermoFinnigan, San Jose, CA, USA). The 
parameters for the direct infusion MSn analysis were listed below: sheath gas, 30 
(arbitrary units); auxiliary gas, 0 (arbitrary units); ionspray voltage, 5 kV; capillary 
voltage, 70 V; ion transfer capillary temperature, 200◦C. In the ESI-MSn experiments, 
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the source fragmentation was turned off and relative collision energy was adjusted 
from 25% to 45% for acetildenafil standard and the unknown compound. Data 
acquisition and analysis were accomplished using Xcalibur version 1.1. The accurate 
mass spectrum was acquired using a Finnigan/ MAT 95 XL-T mass spectrometer 
(Bremen, Germany).  
 
2.4. Results and discussion 
2.4.1. LC-UV 
An unknown compound (referred to as compound 1, Figure 2.1) was found to be the 
main component isolated from the pre-mixed bulk powder. From 2 g of the pre-mixed 
powder, about 240 mg of compound 1 with purity >95% was obtained as a yellow 
amorphous powder. HPLC chromatogram of compound 1 and acetildenafil are shown 
in Figure 2.2(a). Its UV spectrum (insert) was found to be identical to that of 
acetildenafil (with λmax at 235 and 280 nm). The retention time of compound 1 was 
shorter than that of acetildenafil, which indicated that compound 1 was more 
hydrophilic than acetildenafil. Figure 2.2(b) shows the chromatogram of an extract of 
the bulk powder, with compound 1 being the main peak detected at 254 nm. 
 
2.4.2. MS/MS and high-resolution MS analysis 
The molecular weight of compound 1 was determined to be 482 Da using ESI-MS. 
Accurate HR-ESI-MS measurement using compound 1 revealed [M+H]+ ion at m/z 
483.2714, corresponding to the molecular formula C25H34N6O4. Moreover, as shown 
in Figure 2.3(a), positive ion direct-infusion ESI-MS2 analysis of compound 1 
revealed a direct loss of water molecule from its [M+H]+ ion (m/z 483), giving rise to 












































Figure 2.2 (A) HPLC chromatogram of compound 1 and acetildenafil standards. Note 
the different retention times but the identical overlaid UV spectra (insert). (B)  
HPLC chromatogram of an extract of bulk powder with compound 1 being the main 
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The [M+H]+ (m/z) of acetildenafil is 467, 2 mass units larger than the [M+H-H2O]+ 
ion (m/z 465) of compound 1. Figure 2.3(b) shows the ESI-MS3 spectrum of the ion 
m/z=483→465. Compound 1 has more product ions in common with those of 
acetildenafil. The similarity in the mass spectral fragmentation pattern of compound 1 
and acetildenafil supports the contention deduced from the UV spectra that the main 
part of the structure of the two molecules is the same. The structure of compound 1 
was further elucidated using FTIR and NMR. 
 
2.4.3. IR analysis 
Its IR spectrum (Appendix Figure 1.) in KBr disk showed absorption bands 
characteristic of a hydroxyl group (υOH 3410 cm-1), amine (υN-H 3312 cm-1), carbonyl 
group (υC=O 1700 cm-1), aromatic ring (υC::C1606, 1500 cm-1) and ether group 
(υC-O-C1247, 1032 cm-1). Compared with acetildenafil (data not shown), the IR 
spectrum of compound 1 mainly differed in the intense absorption band of the 
hydroxyl group at 3410 cm-1.  
 
2.4.4. Structural identification of compound 1 with NMR  
1H-NMR, 13C-NMR, DEPT, 1H-1H COSY and HMBC spectral data of isolated 
acetildenafil and compound 1 were shown in Table 2.2. The spectroscopic numbering 
used is given in Figure 2.1. All NMR signals were assigned unequivocally according 
to the various NMR spectroscopic data.  
 
The NMR signals of acetildenafil agreed with published data (Blok-Tip et al. 2004; 
Shin et al. 2004a). It was clear that most of the 1H- (Appendix Figure 2.) and 
13C-NMR signals (Appendix Figure 3.) of compound 1 were similar to those of  
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Table 2.2 NMR data of compound 1 and acetildenafil. 
Acetildenafil Compound 1 No. 
1H(δH) 13C(δC) 
 
1H(δH) 13C(δC) DEPT* COSY HMBC 
3 - 146.7  - 146.7 0 - C-3/H-12, C-3/H-11 
5 - 147.5  - 147.4 0 - C-5/H-15 
6 10.95 (1H, br, s) -  10.90 (1H, br, s) - - - - 
7 - 153.8  - 153.8 0 - - 
8 - 124.5  - 124.5 0 - C-8/H-10 
9 - 138.5  - 138.5 0 - C-9/H-11 
10 4.27 (3H, s) 38.2  4.27 (3H, s) 38.2 3 - - 
11 2.95 (2H, t, J=7.5) 27.8  2.94 (2H, t, J=7.5) 27.8 2 H-11/H-12 C-11/H-13, C-11/H-12 
12 1.88 (2H, m, J=7.5,7.2) 22.4  1.88(2H, m, J=7.5, 7.2) 22.4 2 H-12/H-11, H-12/H-13 C-12/H-13, C-12/H-11 
13 1.05(3H, t, J=7.5) 14.1  1.04(3H, t, J=7.5 ) 14.1 3 H-13/H-12 C-13/H-12, C-13/H-11 
14 - 129.8  - 129.8 0 - C-14/H-18 
15 9.09 (1H, d, J=1.9) 132.3  9.08 (1H, d, J=1.9) 132.2 1 H-15/H-17 C-15/H-17 
16 - 120.2  - 120.2 0 - C-16/H-18 
17 8.14 (1H,dd,J=8.7, 1.9) 132.5  8.13(1H,dd, J=8.7, 1.9) 132.5 1 H-17/H-18, H-17/H-15 C-17/H-15 
18 7.10(1H, d, J=8.7) 112.6  7.10(1H, d, J=8.7) 112.7 1 H-18/H-17 - 
19 - 159.8  - 159.9 0 - C-19/H-15, C-19/H-17 
20 4.36 (2H,q,J=6.8) 65.8  4.37 (2H, q, J=6.8) 65.8 2 H-20/H-21 C-20/H-21 
21 1.62 (3H, t, J=6.8) 14.6  1.63 (3H, t, J=6.8) 14.6 3 H-21/H-20 C-21/H-20 
22 - 194.8  - 194.7 0 - C-22/H-23, C-22/H-15, C-22/H-17 
23 3.85 (2H, s) 64.5  3.86 (2H, s) 64.2 2 - - 
25,29 2.73 (4H, br, m) 53.2  2.74 (4H, br, m) 52.7 2 H-25, 29/H-26, 28 C-25,29/H-23 
26,28 2.63 (4H, br, m) 52.5  2.74 (4H, br, m) 52.9 2 H-26, 28/H-25, 29 C-26,28/H-30 
30 2.49 (2H, q, J=7.2) 52.2  2.66 (2H, t, J=4.9) 59.3 2 H-30/H-31 C-30/H-31 
31 1.12 (3H, t, J=7.2 ) 11.7  3.67 (2H, t, J=4.9) 57.5 2 H-31/H-30 C-31/H-30 
31-OH - -  4.25 (1H, br, s) - - - - 
δppm in CDCl3, J in Hz. * Number in DEPT is the number of attached protons 
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acetildenafil, except for the proton and carbon signals for H-31, H-30, C-31 and C-30. 
These were found to have shifted towards a lower field, indicating the presence of an 
electron-withdrawing group. In addition, a peak at δH 4.25 ppm disappeared upon 
D2O exchange, indicating the presence of a labile proton. From DEPT spectrum 
(shown in Appendix Figure 4.), the signal at δC 57.5 ppm indicated the presence of a 
secondary carbon instead of a primary carbon at C-31. Due to the molecular weight, 
which was 16 Da larger than that of acetildenafil and from the above NMR analysis, a 
hydroxyl group was expected to be present at C-31 in compound 1. The 1H-1H COSY 
(shown in Appendix Figure 5.) and HMBC spectra (shown in Appendix Figure 6.) of 
compound 1 were also obtained. The correlation between C-30 and the proton of 
hydroxyl group showed linkage of the hydroxyl group to C-31. These 
characterizations further confirmed the existence of the hydroxyl group in compound 
1 attached to C-31. Hence, based on the mass, infrared spectrum and NMR 
spectroscopic data, the structure of compound 1 was determined to be 
hydroxyacetildenafil, i.e. 5-(2-ethoxy-5-{[4-(2-hydroxyethyl) piperazine-1-yl] acetyl} 
phenyl)-1-methyl-3-propyl-1, 6-dihydro-7H-pyrazolo [4, 3-d] pyrimidin-7-one. 
 
Patients using this kind of product adulterated with analogue of PDE-5 inhibitors and 
claimed to be “natural” may experience serious adverse effects. It has been reported in 
Hong Kong that a young patient experienced ataxia after taking a health product for 
erectile dysfunction. The product was identified to be adulterated with acetildenafil 
(Poon et al. 2007). Similarly, the efficacy and safety of the analogue identified in this 






In this study, a new analogue of acetildenafil was isolated by semi-preparative HPLC 
and its structure was determined by UV, IR, high-resolution MS, MSn and NMR 
spectroscopy. This is the first report of hydroxyacetildenafil in a pre-mixed bulk 
powder, which was destined to be encapsulated and sold as a dietary supplement. This 
analogue was not approved as a drug. The supplier did not provide any further 
information and intentional adulteration was suspected. This compound should be 
included as a target compound when screening for adulterants in dietary supplements. 
 
The existence of PDE-5 inhibitors and their analogues in dietary supplements presents 
a challenge to regulators. With increasing usage of PDE-5 inhibitors and unknown 
efficacy and toxicity profiles of their analogues, the awareness and detection of such 















Chemical analysis of Ligusticum chuanxiong Hort. by high 
performance liquid chromatography and high performance 
liquid chromatography-diode array detection 
(DAD)-electrospray ionization mass spectrometry 
 
3.1. Introduction 
The dried rhizome of Ligusticum chuanxiong Hort. (Umbelliferae) is one of the 
famous cardiovascular protective medicinal herbs in China, Japan and Korea. It is 
traditionally prescribed for the treatment of migraine, anemia, ischemic stroke, angina 
pectoris, cardiac arrhythmias, hypertension and other cerebral vascular diseases (Chen 
and Chen 1992; Ju and Du 1995; Naito et al. 1995; Wang et al. 1994). Based on the 
phytochemical and pharmacological studies on the herb of L. chuanxiong, several 
types of bioactive constituents have been isolated and identified, including phenolic 
acids, alkaloids, and phthalides. Among them, ferulic acid, tetramethylpyrazine (also 
known as ligustrazine and chuanxiongzine) and various phthalides have been 
traditionally reported to be the representative bioactive constituents mainly 
contributing to the therapeutic effects of this herb (Kobayashi et al. 1987; Naito et al. 
1995; Peking institute of pharmaceutical industries 1977; Wang 1988).  
 
Ferulic acid, tetramethylpyrazine and Z-ligustilide (Figure 3.1) are usually chosen as 
chemical markers for the quality evaluation of L. chuanxiong (Li et al. 2001a; Li et al. 
2003; Li et al. 2006b; Lin et al. 2004). However, numerous reports have suggested 
that tetramethylpyrazine is either present in negligible quantity or even absent in L. 
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chuanxiong (Chan et al. 2007b; Li et al. 2003; Li et al. 2004b; Yi et al. 2006).  
Phthalide (3H-isobenzofuran-1-one) derivatives have also been proven to contribute 






Figure 3.1 Chemical structures of tetramethylpyrazine, ferulic acid and (Z)-ligustilide. 
 
Moreover, it is apparent that the analysis of selected marker compounds cannot reflect 
the inherent quality of the herbal products, especially when there are many minor 
bioactive components which also have complex interactions with each other as well as 
with the human body, exhibiting unknown synergism or antagonistic actions. The 
type and quantity of the bioactive constituents in L. chuanxiong, like other herbs, can 
vary with the geographical sources, growth environments, harvesting, processing and 
storage (Li et al. 2007; Zhong et al. 1996), hence influencing the quality of this herb 
and consequently its therapeutic outcomes. On the other hand, some of the ingredients, 
for example, coniferyl ferulate and most of the phthalides, were reported to be 
chemically unstable and thermolabile (Kobayashi et al. 1987; Lin et al. 1998; Lu et al. 
2005; Shi et al. 1995; Zhou and Li 2001), low in quantity, making it very difficult to 
purify them (especially the phthalides) by conventional phytochemical procedures (Li 
et al. 2001a). Based on the above considerations, it is necessary to establish a 
universal analytical method with which the comprehensive bioactive components in L. 
























Tetramethylpyrazine Ferulic acid (Z)-ligustilide
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L. chuanxiong has been analyzed by various methods, namely HPLC-UV (Li et al. 
2001b; Yan et al. 2005; Zhang et al. 1996), CE-UV (Chen et al. 1999; Ji et al. 1999), 
GC-MS (Hong et al. 2002; Li and Zhang 1993; Li et al. 2002) and LC-MS (Chen et al. 
2004; Li et al. 2003; Lu et al. 2004; Zhang et al. 2003a). LC–ESI-MS(n) has 
demonstrated its great advantages for structural analysis of phthalides in botanical 
extracts with high sensitivity, specificity, short analytical time and mild conditions for 
the detection. Furthermore, characteristic fragmentation pattern is more specific and 
reliable than HPLC retention time (tR), UV spectrum and molecular weight (or 
different quasi-molecular ions), for qualitative analysis of the components in extract. 
However, most reports available in this field focused on the identification of a few 
known bioactive components on the basis of literature data or the comparison with 
authentic or in-home standards (Chen et al. 2004; Li et al. 2003; Lin et al. 1998; Yi et 
al. 2006; Yi et al. 2007). For most of the reported MS-based analysis, at most 14 
phthalides can be simultaneously identified (Li et al. 2003), and these researchers 
cannot directly identify the numerous minor constituents reported by the previous 
phytochemical studies, let alone the novel compounds. Consequently, the analytical 
protocols cannot construct the complete profile of the total bioactive components in L. 
chuanxiong or its derived products.  
 
There have been a few studies on the structural characterization of phthalides in L. 
chuanxiong by ESI–MSn and LC–ESI-MSn relating to the tandem mass spectrometric 
analysis of phthalides (Niu et al. 2008; Teng et al. 2006; Yang et al. 2006; Zhang et al. 
2003a). However, to the best of our knowledge, they did not present global 
interpretation of MS fragmentation pathways of the phthalides based on good MS 
spectra, as well as the features of fragmentation patterns in product ion spectrum for 
the differentiation of certain isomers (Teng et al. 2006; Zhang et al. 2003a). There 
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were even some mistakes in the elucidation of complex fragmentation pathways (Niu 
et al. 2008; Yang et al. 2006). It means these reported characterizations are not the 
most reliable under the currently available methodologies or technological conditions. 
It is necessary to establish a novel and effective LC-MSn method to analyze L. 
chuanxiong. 
 
3.2. Objectives  
The first objective of this study is to establish HPLC and LC-MS/MS analytical 
methods to detect and determine the contents of tetramethylpyrazine and ferulic acid 
in different extracts of L. chuanxiong. The concentration levels of tetramethylpyrazine 
and ferulic acid in L. chuanxiong extracted by different methods were compared. 
 
The second objective of the present study is to develop an efficient mass 
spectrometric method for rapid profiling and structural characterization of the 
naturally occurring phthalides and related bioactive constituents in L. chuanxiong to 
improve the quality control of this herbal material. Comprehensive fragmentation 
rules of phthalides and related bioactive components in crude extract of L. chuanxiong 
are proposed. Most of the major and trace ingredients in L. chuanxiong are analyzed 
at the same time using positive ion LC–MSn techniques.  
 
3.3. Experimental  
3.3.1. Chemical and reagents 
Formic acid, acetic acid (ACS reagent), vanillin, tetramethylpyrazine, ferulic acid and 
the other chemicals (analytical grade) were purchased from Sigma (St. Louis, MO, 
USA). Methanol (HPLC grade) was supplied by Lab-scan Asia Co., Ltd. (Bangkok, 
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Thailand). Analytical-reagent grade methanol and ethanol were used for the extraction 
of L. chuanxiong. The 0.45 µm syringe nylon filters were supplied by Whatman 
International Ltd. (Maidstone, UK). MilliQ water for the HPLC analysis was 
deionized and passed through a Synergy Purification System (Molsheim, France). 
 
3.3.2. Materials and sample preparations 
Raw L. chuanxiong was bought from Tong-Ren-Tang Pharmaceutical Co. Ltd. 
(Beijing, P. R. China). Identity of the herb was confirmed by the physical appearance, 
microscopic identification, and physico-chemical analysis according to China 
Pharmacopoeia (The State Pharmacopoeia Commission of P.R.China 2005). Voucher 
specimens of the herbal material were deposited at the Department of Pharmacy, 
National University of Singapore. Crude L. chuanxiong powder was blended by a 
laboratory blender (WARING®, Torrington, U.S.A.), and the resultant powder was 
sieved through a No. 40 (425 µm) mesh size sieve.  
 
12.45 mg ferulic acid and 10.53 mg tetramethylpyrazine were weighed. Ferulic acid 
was dissolved in methanol/5% aqueous acetic acid (1: 4) and tetramethylpyrazine was 
dissolved in methanol/H2O (3:2) with a final volume of 50 mL, which worked as 
stock solutions for ferulic acid and tetramethylpyrazine. The calibration standards 
were prepared by diluting the stock solutions. Five tetramethylpyrazine concentrations 
were used for calibration: 2.106, 10.53, 21.06, 84.24 and 210.6 µg·mL-1. Five 
concentrations were used for calibration of ferulic acid: 2.49, 9.96, 24.9, 99.6, and 
249 µg·mL-1. Each concentration was prepared in triplicate. The calibration curves 
were constructed by plotting the peak areas of the analytes against the concentrations 
of the standard compound, using the external standard method to calculate. 
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The resultant L. chuanxiong powder was extracted using extraction methods A to G: 
A: Four grams of ground plant material were extracted with 40 mL methanol. The 
mixture was soaked over night and then refluxed for 30 minutes. The suspension 
was filtered through a filter paper. The extraction was repeated another time. The 
combined filtrates were concentrated using a rotary vacuum evaporator at 45~50 
◦C. The residue was then dissolved in 10 mL of 50% (v/v) methanol/5% aqueous 
acetic acid and filtered through a 0.45 µm nylon filter membrane. The sample was 
then injected into the HPLC systems for analysis. 
B: The procedures were the same as Extraction method A, except that the herb was 
extracted with water. 
C: L. chuanxiong powder (1.0 g) was placed into a test tube and extracted with10 mL 
methanol. The mixture was ultrasonically (230 V) extracted for 30 min. After 
soaking over night, the suspension was filtered through a filter paper. The 
extraction was repeated. The combined filtrates were concentrated using a rotary 
vacuum evaporator. The residue was then dissolved in10 mL of 50% (v/v) 
methanol/5% aqueous acetic acid and filtered through a 0.45 µm nylon filter 
membrane. Then the sample was injected into the HPLC systems for analysis. 
D: The procedures were the same as Extraction method C, except that the solvent was 
absolute ethanol. 
E: The procedures were the same as Extraction method C, except that the solvent  
was 50% aqueous methanol. 
F: The procedures were the same as Extraction method C, except that the solvent  
was 50% aqueous ethanol. 
G: The procedures were the same as Extraction method C, except that the solvent  
was 50% (v/v) methanol/5% aqueous acetic acid.  
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L. chuanxiong power (1.0 g, sieved through a No.40 (425 µm) mesh size) was 
immersed in 10 mL methanol for 1 h, then extracted by sonication at ambient 
temperature for 0.5 h and the supernatant was collected. The procedure was repeated 
twice. Total extracts were combined and filtered through a syringe nylon filter (0.45 
µm, Whatman, Maidstone, UK). An aliquot of the filtrate (10 µL) was injected for the 
LC-DAD-MS(n) analysis.  
 
3.3.3. Analysis 
3.3.3.1. HPLC Analysis 
An Agilent 1100 liquid chromatograph (Palo Alto, CA, USA) equipped with a 
G1322A vacuum degasser, a G1311A quaternary gradient pump, a G1316A column 
oven, a G1313A autosampler, and a G1315B photodiode array detection (DAD) 
system was used. The HPLC method was developed using a reversed-phase column 
(GL Sciences Inc., Inertsil ODS-3, 250 × 4.6 mm I.D., 5 µm). The binary gradient 
elution system consisted of (A) 0.5% aqueous acetic acid and (B) methanol, and 
separation was achieved using the following gradient: 
I: 0–5 min, 32% B; 5–40 min, 32–85% B for the calibration of tetramethylpyrazine 
and ferulic acid.  
II: 0–5 min, 32% B; 5–40 min, 32–85% B; 40–50 min, 85–100% B; 50–60 min, 100% 
B. for the extracts of L. chuanxiong   
The gradient program was modified according to a reported method (Li et al. 2003). 
The column temperature was kept at 25◦C. The flow rate was 1 mL·min-1 and the 
injection volume was 20 µL. The UV detection wavelength was set at 320 nm for 
ferulic acid and 280 nm for tetramethylpyrazine. At the same time diode array 
scanning range was from 190 to 400 nm. Data collection and processing were 
performed using Agilent ChemiStation data process system (Agilent Technologies). 
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Ferulic acid and tetramethylpyrazine were identified by the comparison of their 
retention times and their UV spectra with those of standard compounds. 
 
3.3.3.2. High resolution LC-MS Analysis 
An LTQ-Orbitrap hybrid mass spectrometer (Thermo Scientific, Bremen, Germany) 
equipped with a Surveyor HPLC system which consists of a Surveyor autosampler 
model Plus, a Surveyor quaternary gradient LC-pump, and a Surveyor photo diode 
array (PDA) model Plus detector was used. Chromatographic separation was 
performed on an ZORBAX RX-C18 column (150 mm × 2.1 mm I.D., 5µm; Agilent, 
USA) using a linear mobile phase gradient programmed from water containing 0.1% 
aqueous formic acid (A) and methanol (B). The flow rate of the mobile phase was set 
at 150 µL·min-1, and the injection volume was 10 µL. The gradient programme (B:A) 
was 20:80 (t = 0 min), 100:0 (t = 50 min), 100:0 (t = 60 min), 20:80 (t = 61 min), and 
20:80 (t = 65 min). The DAD detection wavelength range was set from 190 to 400 nm. 
The LC-MS analysis was performed in the positive FTMS mode (full-scan accurate 
mass range from 100 to 900 Da) at a resolution of 30 000 (FWHM as defined at m/z 
400) with the following source parameters: sheath gas flow rate, 20 arb; aux gas flow 
rate, 5 arb; spray voltage, 4 kV; capillary temperature, 275°C; capillary voltage, 49 V; 
and tube lens, 150V. External mass calibration was performed according to the 
manufacturer’s guidelines using a manufacturer-defined mixture of caffeine, the 
tetrapeptide MRFA, Ultramark 1621, sodium dodecyl sulphate, and sodium 
taurocholate. Acquisition and data processing were performed with Xcalibur v.2.0 
software. Theoretical mass and delta value (ppm) were calculated by using the 




3.3.3.3. LC-MS/MS Analysis 
The positive ion ESI-MS and ESI-MSn experiments were performed using a 3200 
Q-TRAPTM LC-MS/MS system from Applied Biosystems/MDS Sciex (Concord, ON, 
Canada) equipped with a TurboIonspray ion source. The filtered methanolic 
extractions was diluted with a buffer consisting of MeOH/H2O (80/20, v/v, 0.1% 
formic acid) to a concentration of 100 µg·mL-1. The solutions were introduced via a 
syringe pump at a flow rate of 10 µL·min-1. The ESI source conditions were set as 
follows: curtain gas, 10 (arbitrary units); spray voltage, 5.5 kV; nebulizer gas, 25 units, 
auxiliary gas, 0 units; declustering potential (DP), 15V. Nitrogen was used in all cases. 
The collision energy ranged over 20-25 eV, and the excitation energies ranged over 
30–40 eV. The full scan mass spectrum was acquired over the range of m/z 100-900. 
Both Q1 and Q3 were set at unit mass resolution. Data acquisition and processing 
were performed using Analyst software (version 1.4.2). Based on the tuned ESI 
source parameters, further on-line LC-MSn analyses were performed on an Agilent 
1100 Series liquid chromatography system, which was coupled to the 3200 
Q-TRAPTM tandem mass spectrometer, and consisted of a vacuum degasser, a 
quaternary pump, and an autosampler (Agilent Technologies, Waldbronn, Germany). 
The LC experimental conditions were same as those used on LTQ-Orbitrap hybrid 
mass spectrometer. The MSn conditions were the same as those above, except for 
curtain gas, 15 units; turbo gas temperature, 200 ◦C, and auxiliary gas, 20 units. 
 
For the detection and quantification of tetramethylpyrazine, the parameters and 
conditions of ESI-MS in positive MRM mode were optimized using flow injection 
analysis of the tetramethylpyrazine standard introduced via a syringe pump. The 
parameters are listed below: Declustering Potential, 90 V; Entrance Potential, 12 V; 
Collision Energy, 35 eV; Collision Cell Exit Potential, 3 V; Curtain Gas: 10 (units); 
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Temperature, 420 ℃; Gas1, 35 (units). The flow rate was 0.2 mL·min-1. Gradient 
elution was as follows: 20% B at 0 min, increased linearly to 100% B at 50 min and 
maintained at 100% B for 10 min, then dropped to 20% B in 5 min. The injection 
volume was 10 µL. The parent/daughter ion pair in MRM mode for 
tetramethylpyrazine was 137.1→121.0. The detection limit of tetramethylpyrazine 
was determined when the signal-to-noise ratio of the testing peak of 
tetramethylpyrazine was greater than five (S/N>5).  
 
3.3.4. Accuracy and Precision  
The HPLC quantitation method was validated for accuracy and precision by 
extracting L. chuanxiong in triplicate within one day (intra-day) and on different days 
(inter-day) (n=3). Known quantities of tetramethylpyrazine and ferulic acid were 
added into known amount of L. chuanxiong powder prior to the extraction. The 
resultant samples were then extracted and analyzed as describe in Section 3.3.2 and 
3.3.3. Quantities of tetramethylpyrazine and ferulic acid were calculated from their 
corresponding calibration curves. Each sample was analyzed in triplicate to determine 
the intra-day variation. And the inter-day reproducibility was determined by analyzing 
the samples on three separate days. The relative standard deviation (R.S.D.) was 
calculated and taken as a measure of precision. The percentage difference between 
amounts determined and spiked was considered as a measure of accuracy. 
 
Recovery of all the quantified components was determined by adding known 
quantities of tetramethylpyrazine and ferulic acid into herbal samples. The resultant 
samples were then extracted and analyzed as described in Section 3.3.2 and 3.3.3.  
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3.4. Results and Discussion 
As many bioactive components in L. chuanxiong had been isolated and identified, 
more and more papers began to focus on rapid analysis of them in raw material of L. 
chuanxiong or herbal products containing L. chuanxiong for quality control to assure 
the safety and efficacy of these related products. Since some of the reported active 
components in L. chuanxiong are unstable and may decompose at high temperature, 
GC and GC-MS technologies would not be the suitable analytical methods. HPLC or 
LC-MS methods are better for qualitative or quantitative analysis of these 
components.  
 
3.4.1. Quantification of tetramethylpyrazine and ferulic acid in L. chuanxiong by 
HPLC and LC-MS/MS methods 
The accuracy and precision of the analytical method were determined, including both 
inter- and intra-day variation. The results (Table 3.1.) indicated that the procedure was 
satisfactory for the quantification. Peak areas of tetramethylpyrazine or ferulic acid 
were plotted against analytes concentrations, and the standard curves were calculated 
using the linear regression relationship. For the quantification of tetramethylpyrazine 
and ferulic acid by HPLC, the calibration equations of tetramethylpyrazine and ferulic 
acid were y=16.806x-13.722 (r2=0.9994) and y=41.739x+49.696 (r2=0.999), 
respectively. Calibration curves were linear over the concentration ranges from 2.106 






Table 3.1 Precision and accuracy data for the quantification of ferulic acid and 
tetramethylpyrazine in extracts. 
 

















2.49 2.33+0.05 2.1 93.5  2.39+0.08 3.3 96.0 
24.9 23.9+0.20 0.8 96.0  24.1+0.22 0.9 96.8 
249 247.3+0.78 0.3 99.3  244.9+1.56 0.6 98.4 
Tetramethylpyrazine 
2.106 2.17+0.03 1.4 103.0  2.07+0.04 1.9 98.3 
21.06 20.88+0.09 0.4 99.1  20.74+0.27 1.3 98.5 
210.6 208.7+0.39 0.2 99.1  207.7+0.76 0.4 98.6 
       
 
For the extraction methods applied for L. chuanxiong, we had tried to extract L. 
chuanxiong with water or methanol with soaking and boiling, or extract with 50% 
(v/v), 100% methanol, 50% (v/v), or 100% ethanol in an ultrasonic water bath. The 
concentrations of tetramethylpyrazine and ferulic acid obtained by different extraction 
methods were determined using HPLC. The results were shown in Table 3.2. 
Tetramethylpyrazine cannot be detected in all the extracts L. chuanxiong by all 
extraction methods and ferulic acid was undetectable only in extracts obtained by 
methods A and B. The concentrations of ferulic acid in extracts obtained by methods 







Table 3.2 Concentrations of tetramethylpyrazine and ferulic acid in each extract. 
Extraction method tetramethylpyrazine (µg / g ) Ferulic acid (µg / g ) 
A ND ND 
B ND ND 
C ND 452.95 
D ND 203.22 
E ND 324.70 
F ND 574.25 
G ND 272.06 
ND: not detected 
 
As tetramethylpyrazine was not detected in all the extracts by HPLC method, the 
extracts of L. chuanxiong were also analyzed by a sensitive LC-MS/MS method to 
detect the presence of tetramethylpyrazine. The detection limit of tetramethylpyrazine 
was 1.3×10-8 g by LC-MS/MS and with this sensitivity, tetramethylpyrazine still 
could not be detected in all of the L. chuanxiong extracts (data not shown).  
 
Although tetramethylpyrazine and ferulic acid are regarded as active components and 
used as marker compounds for the quality control of L. chuanxiong, the concentration 
of tetramethylpyrazine was too low to be detected even by the LC-MS/MS method. 
This result was consistent with the recent reports (Yan et al. 2005; Li et al. 2004b). 
Ferulic acid was also found and isolated in other plants, such as Danggui (Radix 
Angelicae Sinensis) (Lu et al. 2005a) and Gaoben (Ligusticum Sinense Oliv.) (Zhang 
et al. 1996). In addition, tetramethylpyrazine was first isolated from L. chuanxiong 
and synthesized in 1977, and various pharmaceutical formulae containing synthesized 
tetramethylpyrazine have been clinically used in China for the treatment of 
cardiovascular and cerebral vascular diseases. As a result, tetramethylpyrazine and 
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ferulic acid appeared to be unsuitable marker compounds for the quality control of L. 
chuanxiong and herbal products containing L. chuanxiong as it was either not present 
or only present in very low concentrations.   
  
3.4.2. Analysis of phthalides and other related bioactive components using 
different kinds of MS methods 
3.4.2.1 Evaluation of LC-MS methods for profiling the constituents in L. 
chuanxiong  
From the previous section, it is clear that tetramethylpyrazine is not a suitable 
chemical marker for L. chuanxiong. In addition, most phthalides are unstable and not 
commercially available. In the absence of standard materials or readily available 
references, a novel and effective LC-ESI-MSn method was developed for rapid 
profiling and structure characterization of bioactive components in L. chuanxiong. 
 
To identify the chemical structure of the bioactive compounds in the L. chuanxiong 
extract, it was not enough to just detect their molecular ions even with a high 
resolution MS method. Fragmentation of the molecular ions could provide specific 
structural information for the characterization of bioactive components. Using a direct 
infusion method under tuned parameters (data not shown), both positive and negative 
ionization modes were tried. It was found that the better ionization efficiency and 
sensitivity for most of the interested components were obtained in positive ion mode. 
Hence, all the LC-ESI-MS(n) analysis were operated in positive ion mode.  
 
The general systematic method and strategy previously proposed (Qi et al. 2008; Ye 
et al. 2007; Zheng et al. 2008) for other herbal products was modified for this study. 
Briefly, published literature related to the phytochemical investigations on L. 
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chuanxiong and those about other umbelliferous medicinal plants were studied in 
detail, and all the reported phthalides as well as other related bioactive compounds 
from these plants were collated, e.g., the structure, molecular weight (molecular 
formula), UV maximum absorbance values, the relative content or ratio of the 
phthalides in herbs, etc. A review (Beck and Chou 2007) reported the phthalides 
present in different Ligusticum species including L. chuanxiong. It provided the solid 
foundation for structural characterization of phthalides in L. chuanxiong in this study, 
and LC-DAD-MS analysis was performed. The molecular formulae were established 
by high-accuracy [M+H]+ or [M+Na]+ ions, and the component was primarily 
identified by comparing its tR, UV absorption, molecular weight (quasi-molecular ions) 
and relative content with those from the literature. The mass error for molecular ions 
of most compounds identified in this study was within 5 ppm with external standard 
calibration on LTQ-Obitrap (Makarov et al. 2006), which made the tentative 
identification more reliable. When several close isomers equally matched the [M+H]+ 
or [M+Na]+ ions, the identity of an unknown compound was preferably assigned to a 
structure that had previously been reported from L. chuanxiong as the possibility was 
higher than any other isomeric structures. The chemical structures were further 
elucidated using the information from the fragment ions. Only when most of the 
diagnostic fragments can be reasonably rationalized, can the structural 
characterization of the component be confirmed.  
 
For novel compounds that have not been previously reported in L. chuanxiong, the 
structures were proposed mainly based on fragmentation patterns. Although there was 
structural diversity of phthalides in L. chuanxiong, a series of analogues of phthalides 
with the similar skeleton and different functionalities still may be present resulting 
from the common biogenetic origin. These compounds usually show similar MS 
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fragmentation patterns, and their structural elucidation can be achieved. The 
relationship between structures and fragmentation behavior can facilitate the 
characterization of the new constituents in L. chuanxiong.  
 
We herein studied the fragmentation patterns of the certain typical phthalides and 
related compounds, and then applied the rules to the structural elucidation of novel 
derivatives with the similar basic skeleton. Altogether, 70 compounds in the methanol 
extract of L. chuanxiong were identified or tentatively identified, including major 
components and those present at trace levels. To explore the possible isomers and to 
obtain preliminary information of the compounds in this extract, LC–DAD-MS 
analyses with high resolution were performed using LTQ-Orbitrap. The chemical 
structures of the identified monomeric and dimeric compounds are illustrated in 
Figure 3.2. The peaks were mainly numbered according to their elution order in the 
LC-UV chromatogram (Figure 3.3). Hence, the detected component was similarly 
numbered. The nomenclature of their skeleton is based on that of Z-ligustilide (30) 
shown in Figure 3.2 (A). Fig. 3.3 shows the resultant LC-UV chromatogram and total 
ion current (TIC) chromatogram of the L. chuanxiong extract. The chromatographic 
and spectrometric data of the main bioactive constituents were summarized and listed 
in Table 3.3 and 3.4. To obtain more detailed structural information and further 
confirm the identification, LC-MSn spectra were acquired on 3200 Q-TRAPTM and the 
data were summarized in Table 3.5. Unlike ion trap mass spectrometers used in other 
reports (Ding et al. 2008; Niu et al. 2008; Teng et al. 2006; Yang et al. 2006; Zhang 
et al. 2003a), 3200 Q-TRAPTM can produce extensive fragmentations of the precursor 
ions in MS2 spectra, providing more specific spectra patterns as well as the diagnostic 





















































































































































Figure 3.2. (A) Chemical structures of some monomeric constituents identified 



































































Figure 3.2. (B) Chemical structures of some known dimeric phthalides identified 











































Figure 3.3. LC-DAD-MS chromatograms of the methanol extract of L. 
chuanxiong herb.  
(A) DAD chromatogram with a scan range of 190~400nm,  









Table 3.3. Chromatographic and spectrometric data of the main bioactive constituents detected in the methanol extract of L. chuanxiong, 
including the monomeric phthalides and related bioactive compounds. 


















1 5.03 280 371.17007 371.17004 0.068 C18H26O8 370 
4,5-dihydro-3-butyl-phthalide-4-O-hexoside 
(1) a 
2 5.54 278 369.15433 369.15439 -0.175 C18H24O8 368 3-butylphthalide-4-O-hexoside (2) a 
3 6.12 — d 153.05449 153.05462 -0.855 C8H8O3 152 Vanillin (3) 
4 6.32 295sh, 322 195.06508 195.06518 -0.541 C10H10O4 194 Ferulic acid (4) 
5 7.27 279 227.12799 227.12778 0.899 C12H18O4 226 Senkyunolide J (5) 
6 8.90 276 225.11226 225.11214 0.552 C12H16O4 224 Senkyunolide I (6) 
7 9.03 276 207.10190 207.10157 1.588 C12H14O3 206 (Z)-6,7-epoxyligustilide (7) 
8 9.49 276, 328 223.09693 223.09648 1.991 C12H14O4 222 Senkyunolide D (8) 
9 9.76 277 225.11241 225.11214 1.218 C12H16O4 224 Senkyunolide H (9) 
10 13.59 285, 323 205.08598 205.08592 0.288 C12H12O3 204 3-butylidene-7-hydroxyphthalide (10) 
11 13.73 283, 324 207.10167 207.10157 0.478 C12H14O3 206 Senkyunolide F (11) 
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Table 3.3. (continued) 
 


















12 16.77 286, 322 221.11739 221.11722 0.764 C13H16O3 220 2-(1-oxopentyl)-benzoic acid methyl ester 
(12) 
13 17.25 269, 329 205.08617 205.08592 1.214 C12H12O3 204 Senkyunolide B (13) 
14 17.75 282 207.10162 207.10157 0.236 C12H14O3 206 3-butylidene-6-hydroxy-5,6-dihydrophthalide 
(14) a 
15 17.89 271, 341 209.11758 209.11722 1.716 C12H16O3 208 Senkyunolide K (15) c 
16 18.55 256, 280 205.08592 205.08592 -0.005 C12H12O3 204 Senkyunolide C (16) 
17 19.10 290 207.10164 207.10157 0.333 C12H14O3 206 4-hydroxy-3-butylphthalide (17) 
18 19.90 279 209.11725 209.11722 0.138 C12H16O3 208 Senkyunolide G (18) 
19 19.97 279 279.15930 279.15908 0.767 C16H22O4 278 Senkyunolide M (19) 
20 21.04 270, 305, 
317 
379.11578 379.11521 1.504 C20H20O6 356 Coniferyl ferulate (20) b 
21 21.37 282 279.15933 279.15908 0.874 C16H22O4 278 Senkyunolide Q (21) 
22 23.73 280 193.12257 193.12231 1.364 C12H16O2 192 Senkyunolide A (22) 
23 24.69 228, 275 191.10688 191.10666 1.170 C12H14O2 190 3-butylphthalide (23) 
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Table 3.3. (continued) 
 



















24.74 274 241.10722 241.10705 0.703 C12H16O5 240 Senkyunolide R (24) or 
Senkyunolide S (25) 
26 25.12 275, 315 195.13797 195.13796 0.069 C12H18O2 194 Cnidilide (26) 
27 26.48 287, 326 191.10675 191.10666 0.490 C12H14O2 190 (E)-ligustilide (27) 
28 26.67 282, 322 195.13797 195.13796 0.069 C12H18O2 194 Isocnidilide (28) c 
29 27.56 269, 322 195.13808 195.13796 0.632 C12H18O2 194 Neocnidilide (29) 
30 27.87 282, 325 191.10667 191.10666 0.071 C12H14O2 190 (Z)-ligustilide (30) 
31 28.31 234, 261, 313 189.09141 189.09101 2.135 C12H12O2 188 (E)-butylidenephthalide (31) 
32 31.24 234, 261, 313 189.09134 189.09101 1.764 C12H12O2 188 (Z)-butylidenephthalide (32) 
a
 Potentially new compounds from L. chuanxiong; 
b
 The labeled compositions are detected as [M+Na] + ions, while the other compositions are all detected as [M+H] + ions; 
c
 Not previously reported in L. chuanxiong. 
d
 UV absorption maximum unavailable because of low intensities. 
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Table 3.4. Chromatographic and spectrometric data of the multimeric phthalides detected in the methanol extract of L. chuanxiong.* 
[M+H]+ or [M+Na] +  (m/z) Peak 
No. tR (min) 











33 8.27 286, 328 475.22964 475.23024 -1.262 226, 226 C24H36O8 Dimer (33) a 
34 14.80 281, 314 421.19885 421.19854 0.723 194, 204 C24H30O5 Dimer (34) a 
35 20.56 280 421.19901 421.19854 1.103 192, 206 C24H30O5 Dimer (35) a 
36 22.98 273 421.19763 421.19854 -2.174 194, 204 C24H30O5 Dimer (36) a 
37 23.69 — b 423.21463 423.21420 1.026 194, 206 C24H32O5 Dimer (37) a 
38 25.58 275, 314 383.22168 383.22169 -0.016 190, 192 C24H30O4 Dimer (38) 
39 26.40 — b 411.25064 411.25058 0.143 194, 194 C24H36O4 Dimer (39) a 
40 26.60 — b 423.21466 423.21420 1.097 192, 208 C24H32O5 Dimer (40) a 
41 or 
42 26.82 — 
b
 397.20145 397.20095 1.257 190, 206 C24H28O5 
Chuanxiongnolide A 
(41) or B (42) 
43 27.00 272 421.19827 421.19854 -0.654 190, 208 C24H30O5 Dimer (43) a 
41 or 
42 
28.81 271, 314 397.20105 397.20095 0.250 190, 206 C24H28O5 Chuanxiongnolide A 
(41) or B (42) 
44 29.12 273 379.19049 379.19039 0.274 188, 190 C24H26O4 Ansaspirolide (44) 
45 29.18 — b 435.17798 435.17781 0.390 206, 206 C24H28O6 Dimer (45) a 
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Table 3.4. (continued) 


















46 31.82 274, 314 395.18524 395.18530 -0.154 190, 204 C24H26O5 Dimer (46) 
47 32.19 272 381.20581 381.20604 -0.593 190, 190 C24H28O4 Dimer (47) 
48 33.08 279 381.20651 381.20604 1.243 190, 190 C24H28O4 Riligustilide (48) 
49 33.53 273, 322 385.23688 385.23734 -1.185 192, 192 C24H32O4 Dimer (49) 
50 33.83 276, 322 383.22137 383.22169 -0.825 190, 192 C24H30O4 3,8-dihydro-diligustilide (50) 
51 35.70 275 383.22186 383.22169 0.453 190, 192 C24H30O4 (3′R)-Z-3′,8′-dihydro-6,6′,7,3a′-diligustilide 
(51) c 
52 35.93 — b 385.23703 385.23734 -0.795 192, 192 C24H32O4 Dimer (52) 
53 36.00 279 381.20596 381.20604 -0.200 190, 190 C24H28O4 Senkyunolide O (53) 
54 36.43 — b 377.17563 377.17474 2.370 188, 188 C24H24O4 Dimer (54) 
55 36.57 281 413.23230 413.23225 0.119 190, 222 C25H32O5 Wallichilide (55) c 
56 36.77 282 383.22229 383.22169 1.575 190, 192 C24H30O4 Dimer (56) 
57 37.02 282 381.20624 381.20604 0.535 190, 190 C24H28O4 Tokinolide B (57) 
58 37.38 277 381.20691 381.20604 2.292 190, 190 C24H28O4 Levistolide A (58) 
59 37.38 277 383.22147 383.22169 -0.564 190, 192 C24H30O4 Senkyunolide P (59) 
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Table 3.4. (continued) 
[M+H]+ or [M+Na] +  (m/z) Peak 
No. tR (min) 











60 38.89 275 683.35699 683.35544 2.268 190, 192, 278 C40H52O8 Trimer  (60) a 
61 39.81 269 611.29852 611.29792 0.973 190, 190, 208 C36H44O7 Trimer  (61) a 
62 40.60 272 613.31409 613.31358 0.839 190, 192, 208 C36H46O7 Trimer  (62) a 
63 41.31 277 783.38788 783.38674 1.455 190, 190, 190, 190 C48H56O8 Tetramer (63) a 
64 44.63 — b 609.28149 609.28228 -1.289 188, 190, 208 C36H42O7 Trimer  (64) a 
65 47.18 269 609.28210 609.28228 -0.288 190, 190, 206 C36H42O7 Trimer  (65) a 
66 48.03 — b 573.32196 573.32107 1.559 188, 190, 194 C36H44O6 Trimer (66) 
67 48.15 — b 599.33563 599.33431 2.201 188, 194, 194 C36H48O6 Trimer  (67) a 
68 48.21 — b 799.37793 799.38166 -4.660 380, 396 C48H56O9 Tetramer (68) a 
69 49.85 — b 599.33392 599.33431 -0.652 192, 192, 192 C36H48O6 Trimer  (69) a 
70 52.10 — b 573.32166 573.32107 1.036 190, 190, 192 C36H44O6 Trimer (70) 
71 53.21 — b 571.30566 571.30542 0.427 190, 190, 190 C36H42O6 Trimer (71) 
a
 The labeled compounds are detected as [M+Na] + ions, while the other compounds are all detected as [M+H] + ions. 
b
 UV absorption maxima are unavailable because of low intensities. 
c
 Not previously reported in L. chuanxiong. 
* Among the identified compounds, except the known dimeric phthalides, all the other detected multimeric phthalides may be the potentially  
new compounds, not previously reported in L. chuanxiong herb or even the resultant artifacts of processing, storage etc. 
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No. tR (min) Assigned Identity 
[M+H]+ or 
[M+Na] +  
(m/z) 
Main product ions (m/z) 
1 5.03 4,5-dihydro-3-butyl-phthalide-4-O-hexoside (1) 371 MS
2
 [371]: 371, 209, 191, 163, 153, 145, 135, 127, 109 
2 5.54 3-butylphthalide-4-O-hexoside (2) 369 MS
2
 [369]: 369, 207, 189, 161, 151 
3 6.12 Vanillin (3) 153 MS
2
 [153]: 153, 135, 125, 111, 110, 97, 93, 65 
MS3 [153→111]: 111, 93 
4 6.32 Ferulic acid (4) 195 MS
2
 [195]: 195, 177, 149, 145, 134, 117, 89 
MS3 [195→177]: 177, 149, 145, 117 
5 7.27 Senkyunolide J (5) 227 MS2 [227]: 227, 209, 191, 173, 163, 153, 149, 145, 135, 121, 119, 107, 105, 93 
6 8.90 Senkyunolide I (6) 225 MS
2
 [225]: 225, 207, 189, 179, 171, 165, 161, 151, 147, 143, 133, 119 
MS3 [225→207]: 207, 189, 179, 171, 165, 161, 147, 143, 133 
7 9.03 (Z)-6,7-epoxyligustilide (7) 207 MS2 [207]: 207, 189, 179, 171, 165, 163, 161, 153, 151, 149, 147, 145, 143, 133 
8 9.49 Senkyunolide D (8) 223 MS2 [223]: 223, 205, 177, 149 
9 9.76 Senkyunolide H (9) 225 MS2 [225]: 225, 207, 189, 179, 165, 161, 147, 133, 119 
10 13.59 3-butylidene-7-hydroxyphth
alide (10) 205 
MS2 [205]: 205, 187, 169, 163, 159, 149, 145, 131 
MS3 [205→187]: 187, 169, 159, 145, 131 
11 13.73 Senkyunolide F (11) 207 MS2 [207]: 207, 189, 161, 137, 123 
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 (Table 3.5 continued) 
Peak 
No. tR (min) Assigned Identity 
[M+H]+ or 
[M+Na] +  
(m/z) 
Main product ions (m/z) 
12 16.77 2-(1-oxopentyl)-benzoic 
acid methyl ester (12) 221 
MS2 [221]: 221, 189, 161, 85 
13 17.25 Senkyunolide B (13) 205 MS
2
 [205]: 205, 187, 169, 163, 161, 159, 149, 145, 131 
MS3 [205→187]: 187, 169, 159, 145, 131 
14 17.75 3-butylidene-6-hydroxy-5,6-
dihydrophthalide (14) 207 
MS2 [207]: 207, 189, 171, 161, 153, 151, 147, 145, 133 
15 17.89 Senkyunolide K (15) 209 MS
2
 [209]: 209, 191, 173, 163, 153, 145, 135 
MS3 [209→191]: 191, 173, 163, 145, 135 
16 18.55 Senkyunolide C (16) 205 MS
2
 [205]: 205, 187, 169, 161, 159, 149, 131 
MS3 [205→187]: 187, 169, 159, 141, 131 
17 19.10 4-hydroxy-3-butylphthalide 
(17) 207 
MS2 [207]: 207, 189, 161, 151 
18 19.90 Senkyunolide G (18) 209 MS
2
 [209]: 209, 191, 173, 163, 155, 153, 149, 145, 135 
MS3 [209→191]: 191, 173, 163, 155, 149, 145, 135 
19 19.97 Senkyunolide M (19) 279 MS
2
 [279]: 279, 261, 251, 243, 233, 205, 191, 173, 149 
MS3 [279→261]: 261, 243, 233, 205 
20 21.04 Coniferyl ferulate (20) 379 a MS2 [379]: 361, 347, 217, 203, 199, 185 
21 21.37 Senkyunolide Q (21) 279 MS
2
 [279]: 279, 261, 251, 243, 233, 205, 191, 173, 149 
MS3 [279→261]: 261, 243, 233, 205 
22 23.73 Senkyunolide A (22) 193 MS
2
 [193]: 193, 175, 165, 157, 147, 137, 133, 119, 105, 93, 91 
MS3 [193→147]: 147, 119, 105, 93, 91 
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(Table 3.5 continued) 
Peak 
No. tR (min) Assigned Identity 
[M+H]+ or 
[M+Na] +  
(m/z) 
Main product ions (m/z) 
23 24.69 3-butylphthalide (23) 191 MS
2
 [191]: 191, 173, 155, 153, 145, 143, 135, 131, 128, 117, 105, 103, 91 
MS3 [191→145]: 145, 143, 128, 117, 105, 91 
24 or 
25 
24.74 Senkyunolide R (24) or 
Senkyunolide S (25) 241 
MS2 [241]: 241, 223, 213, 197, 195 
26 25.12 Cnidilide (26) 195 MS2 [195]: 195, 177, 149 
27 26.48 (E)-ligustilide (27) 
191 
MS2 [191]: 191, 173, 163, 155, 153, 149, 145, 143, 135, 131, 129, 128, 119, 117, 115, 105,  
                   103, 93, 91 
MS3 [191→145]: 145, 143, 128, 119, 117, 115, 105, 103, 93, 91 
28 26.67 Isocnidilide (28) 195 MS
2
 [195]: 195, 177, 159, 149, 135, 125, 121, 107, 93 
MS3 [195→177]: 177, 159, 149, 135, 133, 131, 117, 107, 93 
29 27.56 Neocnidilide (29) 195 MS
2
 [195]: 195, 177, 167, 159, 149, 135, 125, 121, 107, 93 
MS3 [195→177]: 177, 159, 149, 135, 133, 131, 107, 93 
30 27.87 (Z)-ligustilide (30) 
191 
MS2 [191]: 191, 173, 163, 155, 153, 149, 145, 143, 135, 131, 129, 128, 119, 117, 115, 105,  
                   103, 93, 91 
MS3 [191→145]: 145, 143, 128, 119, 117, 115, 105, 103, 93, 91 
31 28.31 (E)-butylidenephthalide (31) 189 MS
2
 [189]: 189, 171, 161, 153, 152, 147, 145, 143, 133, 129, 128, 117, 115, 105, 91 
MS3 [189→171]: 171, 153, 152, 143, 129, 128,115 
32 31.24 (Z)-butylidenephthalide (32) 189 MS
2
 [189]: 189, 171, 161, 153, 152, 147, 145, 143, 133, 129, 128, 117, 115, 105, 91 
MS3 [189→171]: 171, 153, 152, 143, 129, 128,115 
33 8.27 Dimer (33) 475 a MS2 [475]: 475, 249 
34 14.80 Dimer (34) 421 a MS2 [421]: 421, 227, 217 
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(Table 3.5 continued) 
Peak 
No. tR (min) Assigned Identity 
[M+H]+ or 
[M+Na] +  
(m/z) 
Main product ions (m/z) 
35 20.56 Dimer (35) 421 a MS2 [421]: 421, 229, 215 
36 22.98 Dimer (36) 421 a MS2 [421]: 421, 227, 217 
37 23.69 Dimer (37) 423 a MS2 [423]: 423, 229, 217 
38 25.58 Dimer (38) 
383 
MS2 [383]: 193, 191, 175, 173, 147, 145, 137, 105, 91 
MS3 [383→193]: 193, 175, 147, 137, 121, 105 
MS3 [383→191]: 191, 173, 163, 155, 153, 149, 145, 143, 135, 117, 115, 105, 103, 93, 91 
39 26.40 Dimer (39) 411 a MS2 [411]: 217 
40 26.60 Dimer (40) 423 a MS2 [423]: 423, 231, 215 
41 or 
42 
26.82 Chuanxiongnolide A (41) or 
B (42) 397 
MS2 [397]: 397, 379, 207, 191, 189, 161, 137, 123 
43 27.00 Dimer (43) 421 a MS2 [421]: 421, 231, 213 
41 or 
42 
28.81 Chuanxiongnolide A (41) or 
B (42) 397 
MS2 [397]: 397, 379, 207, 191, 189 
44 29.12 Ansaspirolide (44) 379 MS2 [379]: 191, 189, 173, 171, 153, 145, 143, 117, 91 
45 29.18 Dimer (45) 435 a MS2 [435]: 435, 229 
46 31.82 Dimer (46) 395 MS2 [395]: 395, 205, 191, 177 
47 32.19 Dimer (47) 381 MS
2
 [381]: 191, 173, 155, 149, 145, 143, 135, 131, 129, 117, 105, 103, 91 
MS3 [381→191]: 191, 173, 155, 153, 149, 145, 117, 91 
 85 
(Table 3.5 continued) 
Peak 
No. tR (min) Assigned Identity 
[M+H]+ or 
[M+Na] +  
(m/z) 
Main product ions (m/z) 
48 33.08 Riligustilide (48) 381 MS
2
 [381]: 191, 173, 163, 155, 149, 145, 117, 105 
MS3 [381→191]: 191, 173, 163, 155, 153, 149, 145, 143, 129 
49 33.53 Dimer (49) 385 MS
2
 [385]: 385, 367, 349, 193, 175, 157, 147, 137, 105 
MS3 [385→193]: 193, 175, 147, 137 
50 33.83 3,8-dihydro-diligustilide 
(50) 383 
MS2 [383]: 383, 365, 193, 191, 175, 173, 163, 155, 147, 145, 137, 135 
MS3 [383→193]: 193, 175, 147, 137, 121, 105 
MS3 [383→191]: 191, 173, 155, 153, 145, 143 
51 35.70 (3′R)-Z-3′,8′-dihydro-6,6′,7,
3a′-diligustilide (51) 383 
MS2 [383]: 383, 365, 193, 191, 175, 173, 163, 155, 147, 145, 137, 135 
MS3 [383→193]: 193, 175, 147, 137, 121, 105 
MS3 [383→191]: 191, 173, 163, 155, 153, 149, 145, 143, 135, 117, 115, 105, 93, 91 
52 35.93 Dimer (52) 385 MS
2
 [385]: 385, 367, 349, 193, 175, 157, 147, 137, 105 
MS3 [385→193]: 193, 175, 147, 137 
53 36.00 Senkyunolide O (53) 381 MS
2
 [381]: 191, 173, 163, 155, 153, 149, 145, 143, 135, 117, 91 
MS3 [381→191]: 191, 173, 163, 155, 153, 149, 145, 143, 135, 117 
54 36.43 Dimer (54) 377 MS2 [377]: 189, 171, 153, 145, 143, 128, 117, 115, 91 
55 36.57 Wallichilide (55) 413 MS
2
 [413]: 191, 173, 155, 149, 145, 131, 117 
MS3 [413→191]: 191, 173, 163, 155, 153, 117, 107 
56 36.77 Dimer (56) 
383 
MS2 [383]: 383, 365, 347, 193, 191, 175, 147, 137, 105 
MS3 [383→193]: 193, 175, 147, 137, 121, 105 
MS3 [383→191]: 191, 173, 163, 155, 153, 149, 145, 135 
57 37.02 Tokinolide B (57) 
381 
MS2 [381]: 191, 173, 163, 155, 149, 145, 143, 135, 117, 105, 91 
MS3 [381→191]: 191, 173, 163, 155, 153, 149, 145, 143, 135, 131, 121, 117, 107, 105, 93,  
                             91 
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(Table 3.5 continued) 
Peak 
No. tR (min) Assigned Identity 
[M+H]+ or 
[M+Na] +  
(m/z) 
Main product ions (m/z) 
58 37.38 Levistolide A (58) 
381 
MS2 [381]:  191, 173, 163, 155, 149, 145, 135, 117, 105, 91 
MS3 [381→191]: 191, 173, 163, 155, 153, 149, 145, 143, 135, 131, 121, 117, 107, 105, 93,  
                             91 
59 37.38 Senkyunolide P (59) 
383 
MS2 [383]: 365, 337, 193, 191, 175, 173, 163, 147, 145, 137, 135, 105, 91 
MS3 [383→193]: 193, 175, 147, 137, 121, 105 
MS3 [383→191]: 191, 173, 163, 155, 153, 149, 145, 143, 135, 117, 105, 91 
60 38.89 Trimer  (60) 683 a MS2 [683]: 683, 405, 301, 215 
61 39.81 Trimer  (61) 611 a MS2 [611]: 611, 421, 403, 377, 231 
62 40.60 Trimer  (62) 613 a MS2 [613]: 613, 421, 231 
63 41.31 Tetramer (63) 783 a MS
2
 [783]: 783, 593, 403, 213 
MS3 [783→403]: 403, 213 
64 44.63 Trimer  (64) 609 a MS2 [609]: 609, 421, 213 
65 47.18 Trimer  (65) 609 a MS
2
 [609]: 609, 419 
MS3 [609→419]: 419, 229 
66 48.03 Trimer (66) 573 MS2 [573]: 573, 379, 191 
67 48.15 Trimer  (67) 599 a MS2 [599]: 599, 405, 217 
68 48.21 Tetramer (68) 799 a MS2 [799]: 419, 403 
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(Table 3.5 continued) 
Peak 
No. tR (min) Assigned Identity 
[M+H]+ or 
[M+Na] +  
(m/z) 
Main product ions (m/z) 
69 49.85 Trimer  (69) 599 a MS2 [599]: 599, 407, 215 
70 52.10 Trimer (70) 573 MS2 [573]: 573, 381, 363, 193, 191 
71 53.21 Trimer (71) 
571 
MS2 [571]: 571, 553, 381, 363, 335, 191 
MS3 [571→381]: 381, 191, 173 
MS3 [571→191]: 191, 173, 163, 155, 153, 149, 145, 143, 135, 117 
 
a






These 70 identified compounds represented the major components of the L. 
chuanxiong extract. Among them, 31 compounds were monomeric phthalides and 
related bioactive compounds while the others were the known or unknown multimeric 
phthalides. 
 
3.4.2.1. Rapid profiling and structural characterization of non-phthalide 
components 
Among these detected non-phthalide components in L. chuanxiong, ferulic acid (4) is 
the most important based on its extensively reported bioactivities. Although coniferyl  
ferulate (20) is the precursor of ferulic acid and has relatively high abundance in the 
extract (as shown in Fig. 3.4(A)), it is likely to be hydrolyzed into ferulic acid to a 
variable extent, and ferulic acid is supposed to be the principal functional compound 
which replaces coniferyl ferulate in L. chuanxiong (Kobayashi et al. 1987; Lu et al. 
2005a). Hence, ferulic acid is selected as an example for the analysis of other related 
components in the extract of L. chuanxiong. Fig. 3.4 shows the ESI-MSn spectra of 
[M+H]+ ion at 6.32 min corresponding to ferulic acid. By comparing the UV spectrum, 
tR and MS fragmentation with the ferulic acid standard, the component was identified 
as ferulic acid (4). The fragmentation pathways further confirmed its existence (as 
shown in scheme 3.1). Briefly, the [M+H]+ ion (m/z 195) could yield the product ion 
at m/z 177 by the loss of H2O through specific elimination and cyclization reaction. 
The resultant m/z 177 presented fragments at m/z 149, 145, 134, 117. In these cases, 
the fragmentations could be explained by successive neutral or radical losses, i.e., CO 









































Figure 3.4 ESI-MSn spectra of ferulic acid (4). (A) MS2 spectrum of [M+H]+ ion 
at m/z 195; (B) MS3 spectrum of ion at m/z 177; and (C) MS3 spectrum of ion at 
m/z 149. 
 




































Scheme 3.1. Proposed fragmentation pathways of non-phthalide components 






























































































































In this part of the study, tetramethylpyrazine was not detected by LC-MS/MS at a low 
detection limit of 1.3×10-8 g. In addition, tetramethylpyrazine was not detected by 
high resolution LC-DAD-MS. Since its first isolation from L. chuanxiong in 1977, 
tetramethylpyrazine has been considered as one of the active components contributing 
to the therapeutic effects of L. chuanxiong (Li et al. 2001c; Shih et al. 2002; Zhang et 
al. 2003b). In several reports, tetramethylpyrazine had been used as a chemical 
marker for the quality control of L. chuanxiong ( Chen et al. 1999; Sun et al. 2001) or 
L. chuanxiong-containing pharmaceutical preparations (Zhao et al. 1991). However, 
in these studies, the identification of tetramethylpyrazine present in L. chuanxiong 
samples was simply conducted by an apparent comparison of the retention time of the 
chromatographic peak in the tested samples with that of tetramethylpyrazine standard 
only. Such confirmation of the presence of tetramethylpyrazine is inadequate and thus 
the subsequent quantification of tetramethylpyrazine maybe unreliable. In addition, 
tetramethylpyrazine was also not dectected in various L. chuanxiong samples tested 
(Chen et al. 2004; Li et al. 2003; Li et al. 2004b; Yi et al. 2006; Yi et al. 2007). This 
was consistent with our current findings. These results were in a good agreement with 
ours. Based on the above information, tetramethylpyrazine is not the main component 
in L. chuanxiong and should not be considered as the marker compound for the 
quality control of L. chuanxiong. 
 
Similarly, the content of vanillin (3) is so low that its UV spectrum could not be 
acquired even though its tandem mass spectra were obtained. Its proposed 
fragmentation was shown in Scheme 3.1. In addition, it was interesting to note that 
2-(1-oxopentyl)-benzoic acid methyl ester (12) was also detected and identified 
(fragmentation shown in Scheme 3.1). Although this component is not a true 
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phthalide, as a biogenetic precursor, its 4,5-dihydro analogue is a building block for 
dimer 55 and is thus implicated as a possible biosynthetic metabolite.  
 
3.4.2.2. Rapid profiling and structural characterization of phthalides 
Chemical markers of phthalides, component 22, 30 and their isomers 
It is clear from Figure 3.3(A) that peaks 20, 22 and 30 were the three most prominent 
components in the LC-UV chromatogram, while the intensities of peaks 22, 30 and 
the co-eluted peaks 57, 58, 59, are the highest in the TIC chromatogram (Fig. 3.3(B)). 
The results from LC-DAD-MS analysis showed that UV spectra (λmax) and molecular 
formulae originating from the dominant [M+H]+ ions of peaks 22 and 30 matched 
those of senkyunolide A and Z-ligustilide well, respectively. Their retention time (tR) 
and relative contents are also consistent with those published (Li et al. 2003; Yi et al. 
2007; Zschocke et al. 2005). Hence, the two components were preliminarily identified 
as senkyunolide A and Z-ligustilide. Actually, Z-ligustilide and senkyunolide A have 
been reported to be the two phthalides with the highest abundance in different herbal 
samples resulting from L. chuanxiong (Chan et al. 2007a; Chan et al. 2007b; Li et al. 
2007; Yi et al. 2006). In this study, the corresponding fragmentation mechanisms of 
these components were elucidated in detail, providing a solid foundation for the 
tentative identification of peak 22 and 30.  
 
For component (22), Fig. 3.5 (A) shows the product ion spectra of its [M+H]+ ion at 
m/z 193. The main product ions were yielded at m/z 175, 165, 157, 147 and 137, etc. 
Its fragmentation behavior was proposed and summarized in Scheme 3.2. More than 
one pathway could account for these fragments, and the fragmentation pathways 
mainly involved side-chain cleavage of butyl and the opening of the five-member 










































Figure 3.5 Product ion spectra of [M+H]+ ions of (A) Compound 22 
(senkyunolide A), (B) Compound 23 (3-butylphthalide), and (C) Compound 30 
((Z)-ligustilide). 
 














































produced by the loss of H2O from the protonated molecule; the following loss of CO 
and propene (C3H6) from the m/z 175 ion separately yielded the base peak m/z 147 
and a weak m/z 133 ion. In particular, the m/z 175 ion underwent successive loss of 
H2O to yield an ion at m/z 157 on the basis of hydrogen rearrangement, which was 
not previously reported for this type of compound. It was noteworthy that the 
precursor ion m/z 193 can directly eliminate butylene (C4H8) to obtain the prominent 
m/z 137 ion with the characteristic abundance. The pair of ions at m/z 147 and m/z 
137 with high intensity characterizes the fragmentation pattern of this component. The 
[M+H]+ ion can also generate the fragment at m/z 165 by the loss of CO in one step. 
Over the low mass region, there were several clusters of product ions, such as those 
with m/z values of 119, 105, 93 and 91. They originated from the intermediate ion at  
m/z 147 which was in the equilibration with different forms of resonance hybrid. The 
elucidation of all the fragmentation pathways and corresponding structures of 
fragments reasonably confirm that the peak was likely to be senkyunolide A. 
 
For component (30), the MS2 spectrum of the [M+H]+ ion (m/z 191) is shown in Fig. 
3.5 (C). The proposed fragmentation pathways are listed in Scheme 3.2. Similar to 
those i-cleavage and hydrogen rearrangements leading to the lactone ring-opening in 
senkyunolide A, for this component, there are also losses of H2O and CO, yielding the 
fragments at m/z 173, 163, 155, 145, etc. However, different from senkyunolide A, 
there were direct eliminations of propene (C3H6) as well as butylene (C4H8) from the 
side-chain of m/z 191 ion, producing m/z 149, 135, respectively, and the abundance 
of the m/z 135 ion was very low. The features of the pair of ions at m/z 149 and m/z 
135 can also be used to characterize this compound. In addition, it was obvious that 
there were more fragments within the clusters of ions in the low mass region,  
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Scheme 3.2. Major fragmentation pathways proposed for the protonated molecules 
([M+H]+) of senkyunolide A (22), 3-butylphthalide (23) and (Z)-ligustilide (30). 
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including m/z 130, 117, 105, 91, etc. Hence the structure of Z-ligustilide can be 
verified for this component, on the basis of these fragmentation patterns.  
 
Since it is relatively easy to identify and confirm the two components by the above 
strategy, senkyunolide A and Z-ligustilide can serve as the two chemical markers and 
their comprehensively elucidated fragmentation patterns can guide the 
characterization of the other trace phthalides, which have the same skeleton but 
different functionalities, present in methanol extract of L. chuanxiong. At the same 
time, the analysis based on structure-fragmentation relationship using these marker 
compounds can also benefit the assignment of fragments, as well as the differentiation 
of isomers.  
 
The only structural difference between senkyunolide A and Z-ligustilide lies in the 
substituent at C-3, i.e., senkyunolide A has a butyl group while Z-ligustilide bears the 
butylidene group. They can be well distinguished in the product ion spectra by the 
characteristic fragments as well as corresponding abundances originating from direct 
loss of C3H6 and C4H8 from the molecular ions. The same features were observed 
distinctly in the fragmentations of the other components of phthalides. Similarly, the 
detected phthalides can be classified into two main types on the basis of the different 
substituent with butyl or butylidene at C-3. In addition, with the extension of the 
conjugated system, there are more fragments produced by the different resonance 
status of intermediate ion over the low mass range (as shown in Fig. 3.5 (C)).  
 
On the other hand, the LC–DAD-MS analysis has also indicated that senkyunolide A 
has no isomer, while Z-ligustilide has two isomers eluting separately at 24.69 min 
(Peak 23) and 26.48 min (Peak 27). LC-MSn analysis showed that component 27 gave 
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a similar MS2 spectrum to that of Z-ligustilide, except for a few slight differences in 
the relative abundance of several ions; while the fragmentation pathways of 
component 23 were substantially identical to those of senkyunolide A with a mass 
shift of 2 Da, although their spectra patterns seem mildly different (shown in Fig. 3.5 
(B) and Scheme 3.2). Consequently, based on the combination of their fragmentations, 
as well as the reported data, including UV spectra (λmax), tR, and their relative contents, 
components 23 and 27 were reliably assigned as 3-butylphthalide and E-ligustilide, 
respectively. 
 
Up to now, despite the numerous reports on the wide range of bioactivities of 
phthalides, investigations concerning the mode of action are few, and their exact 
mechanisms remain unknown (Lim et al. 2006; Liu et al. 2005). It seems that charge 
or electron transfer-based mechanisms, such as actions on ion channels and 
oxidation-reduction reactions, may account for some of their bioactivities (Chan et al. 
2007a; Chou et al. 2008; Dietz et al. 2008; Yu et al. 2008). Considering the regularity 
between structure and fragmentation behavior, these dissociation mechanisms may be 
helpful for the studies on the bioactivities of various phthalides. Thus, future work on 
their structure-activity relationship as well as other pharmacological evaluations of 
various phthalides could be conducted. 
 
Other low abundance phthalides 
Based on the above strategy and typical fragmentation rules of chemical markers 
(especially compounds 22 and 30), the other low abundance phthalides in the 
methanol extract of L. chuanxiong were also identified and profiled. The 
chromatographic and spectrometric data of the main bioactive constituents including 
monomeric phthalides are presented in Table 3.3, while those of multimeric 
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phthalides are presented in Tables 3.4. The multi-stage mass spectrometric data of 
main components detected in L. chuanxiong by LC-MSn are presented in Table 3.5. 
The corresponding fragmentation pathways were proposed and summarized in 
Scheme 3.3.  
 
Due to various isomerizations, some of the identified components showed the 
superimposable MSn spectra and fragmentation patterns. Thus only the fragmentation 
pathways of the representative compounds from the different pairs of isomers were 
displayed in scheme 3.3, and there were three types of isomers. The first type 
belonged to stereoisomers, including composition 6 and 9, 21 and 19, 29 and 28; the 
second type came from geometrical isomers, i.e., composition 30 and 27, 32 and 31; 
the third type contained position isomers which only differed in the position of a same 
substituent, including composition 13 and 16. As for composition 1 and 2, they were 
novel glycosides and would be discussed in the following sections. It is apparent that 
most of the phthalides from L. chuanxiong listed by Beck and Chou (Beck and Chou 
2007) were detected and properly identified in this study. Most of the cited literature 
in this review provided physico-chemical properties of the reported phthalides, 
including UV maximum absorbance wavelength (λmax) and relative contents of 
isomers, etc. They afforded the necessary phytochemical information for the reliable 
identifications. 
 
It was especially noteworthy that several components were isolated and identified in L. 
chuanxiong for the first time in this study. Three new compounds, including 
4,5-dihydro-3-butyl-phthalide-4-O-hexoside (1), 3-butylphthalide-4-O-hexoside (2) 
and 3-butylidene-6-hydroxy-5,6-dihydrophthalide (14), as well as other four  
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Scheme 3.3. Proposed fragmentation pathways of the low abundance phthalides 
identified in positive ion mode in this study. 
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compounds not previously reported in L. chuanxiong, i.e., senkyunolide K (15), 
isocnidilide (28), (3′R)-Z-3′,8′-dihydro-6,6′,7,3a′-diligustilide (51) and wallichilide  
(55) were detected. Figure 3.6 shows the product ion spectra of the potentially novel 
compounds 1, 2 and 14. The corresponding structural characterizations of these 
components are presented below.  
 
The extract ion chromatography (XIC) at m/z 209 ([M+H]+) indicated that there were 
two peaks at 17.89 min (composition 15) and 19.90 min (composition 18) with the 
characteristic fragmentation patterns of phthalides. Based on the comprehensive 
review of Beck and Chou, there were only two compounds in Umbelliferae plants 
with molecular weight at 208 Da, i.e., Senkyunolide G and K, among which only 
Senkyunolide G has been reported existing in L. chuanxiong. For composition 18, 
after losing a water (H2O) from the precursor ion at m/z 209, the resultant fragment 
m/z 191 presented the fragmentation pathways similar to those of (Z)-ligustilide (30). 
It implied that there may be a hydroxyl group at C-3 or C-8, leading to the assignment 
of composition 18 as Senkyunolide G. For composition 15, the precursor at m/z 209 
underwent the side-chain cleavage of butyl, dehydration, and the opening of the 
five-member cyclic ring of the lactone with elimination of H2O and CO. Most of these 
dissociations were resemble to those of senkyunolide A (22) (as shown in scheme 3.3), 
thus composition 15 was identified as Senkyunolide K.  
 
For composition 1 at 5.03 min, a hexose can be directly eliminated from the precursor 
ions at m/z 371, yielding the product ion at m/z 209. The subsequent fragmentations 
of this fragment generally match those of composition 15 (as shown in Figure 3.6 (A) 
and Table 3.5). Hence, it is reasonable to conclude that composition 1 may be a 






































Figure 3.6 The representative product ion spectra of the potentially new 
compounds from L. chuanxiong:  
(A) 4,5-dihydro-3-butyl-phthalide-4-O-hexoside (1),  
(B) 3-butylphthalide-4-O-hexoside (2), and   






Similar to the cases of composition 15 and composition 18, there were four 
components at m/z 207 ([M+H]+) with the characteristic fragmentation patterns of 
phthalides. Using the same method, a similar deduction is applicable to compounds 7, 
11, 14 and 17, and they were accordingly identified (Scheme 3.3). Furthermore, 
composition 2 was assigned as the hexose glycoside of composition 17 or its isomers 
(Figure 3.6 (B) and Table 3.5). When the analytical protocol was repeatedly applied to 
the new composition 28, they can also be characterized. As for the new composition 
51 and 55, they were multimeric phthalides and can only be tentatively identified 
based on the physico-chemical properties, such as UV spectra as well as the 
phytochemical information summarized in the comprehensive review. 
 
In contrast to these novel compounds, there were also some known components which 
had been isolated and reported from L. chuanxiong, but were not detected in this study, 
including senkyunolide E, (E)-senkyunolide E, senkyunolide L, senkyunolide N 
(Naito et al. 1992) and 3,6,7-trihydroxy-4,5,6,7-tetrahydro-3-butyl phthalide (Li et al. 
2006c). This may be due to the different sources of herbal material. In addition to the 
monomeric phthalides, all the known dimers in L. chuanxiong were found, including 
chuanxiongnolide A (41) or B (42), ansaspirolide (44), riligustilide (48), 
3,8-dihydro-diligustilide (50), senkyunolide O (53), tokinolide B (57),levistolide A 
(58), senkyunolide P (59) in this L. chuanxiong extract, based on the retention time 
(tR), UV spectra, molecular weight (molecular fomulas), as well as the literature data. 
At the same time, the other dimers and different trimers and tetramers, were 
unexpectedly found in the extract for the first time. Actually, although the monomeric 
phthalides, such as senkyunolide A and Z-ligustilide, are unstable and are easily 
changed into other phthalides through oxidation, hydrolysis, isomerization, 
photodegradation, photochemical reaction, or polymerization, there were only reports 
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about limited dimers originating from some common monomeric units, such as 
Z-butylidenephthalide (MW=188 Da), Z-ligustilide (MW=190 Da), E-ligustilide 
(MW=190 Da) and senkyunolide A (MW=192 Da). In this study, numerous dimers, 
trimers and tetramers were identified, consisting of the blocking units with the same 
molecular weights as those of the above common ones (188 Da, 190 Da, 192 Da), as 
well as with those of the other monomeric phthalides listed in Table 3.3. The dimer at 
37.38 min (peak 58, Levistolide A), trimer at 48.03 min (peak 66) and the tetramer at 
41.31 min (peak 63) were shown as examples to illustrate the representative 
fragmentations.  
 
It should be admitted that, owing to the limitation of mass spectrometry in 
differentiating the isomers, these novel multimeric phthalides cannot be identified 
with absolute certainty. However, the structural information originating from the 
tandem mass spectrometric analysis clearly clarified the type and quantity of the 
blocking units of each multimetric phthalide, which provided the clues to rapidly 
profile the existence of more complex phthalides and effectively guide the further 
phytochemical investigations on L. chuanxiong for new compounds. 
 
As shown in the product ion spectrum of levistolide A in Figure 3.7 (A), the 
protonated dimeric molecule ion at m/z 381 can yield the base peak of the protonated 
monomer ion at m/z 191. In the MS3 spectrum of m/z 191 (data not shown), it was 
observed that the main product ions were identical to those of the m/z 191 ion 
([M+H]+) in the fragmentation of Z-ligustilide. The data clearly demonstrated that this 
compound comprised a ligustilide unit. Since there was only one [monomer+H]+ ion 
at m/z 191, the result indicated the compound had a structure comprising of two 






































Figure 3.7 The product ion spectra of multimeric phthalides: (A) Dimer (58, 
Levistolide A); (B) Trimer (66); and (C) Tetramer (63). 
 








































protonated trimer at m/z 573 by the loss of monomeric unit (194 Da). With successive 
loss of another monomeric unit (188Da), the m/z 191 ion ([monomer+H]+) was 
further obtained. It was obvious that this trimer consisted of three monomeric units 
with the corresponding molecular weights of 194 Da, 188 Da and 190 Da, in which 
the latter two monomers may form a dimer with a molecular weight of 378 Da. Based 
on the above discussion, peak 63 was identified as tetrameric phthalide derivatives, 
comprising four monomeric units with the molecular weight of 190 Da each (as 
shown in Fig. 3.7(C)). Further structural information (connection points, 
stereochemical configuration, isomeric monomers, etc) of these multimers could not 
be obtained by tandem MS analysis. This work provided valuable information for 
rapidly detecting such multimers in complex extracts of L. chuanxiong. Besides being 
naturally occurring (Kaouadji et al. 1986), considering their fairly low contents in the 
extract, these multimers could also arisen due to the processing, storage, or other 
treatment steps related to the herb.  
 
3.5. Conclusion 
Tetramethylpyrazine and ferulic acid are traditionally regarded as the marker 
compounds for the quality control of crude herbal materials and products containing L. 
chuanxiong.  In this study, a HPLC method was successfully developed for the 
quantification of ferulic acid in various L. chuanxiong extracts prepared using 
different extraction methods. The quantities of ferulic acid in L. chuanxiong extracts 
were found to be very low. In addition, tetramethylpyrazine could not be detected in 
all of these L. chuanxiong extracts by HPLC method. A triple quadrupole LC-MS/MS 
Q-TRAPTM system allowing the simultaneous monitoring of more than one pair of 
parent/daughter fragment ions was developed to conduct the quantitative analysis of 
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tetramethylpyrazine by multiple reaction monitoring (MRM). However, 
tetramethylpyrazine was still not detected in various L. chuanxiong extracts. Hence, 
the results of this study suggested that tetramethylpyrazine and ferulic acid could not 
be used as chemical markers to assess the quality of L. chuanxiong. 
 
A rapid and robust analytical method using LC-DAD-MSn techniques for screening 
phthalides and related bioactive components in crude herbal extract was also 
established for the global qualitative analysis of L. chuanxiong. By comparing their 
retention time (tR), UV, etc with the literature data and natural products information in 
reference, a total of 70 compounds were identified or tentatively characterized based 
on a combination of tR, high resolution mass data, and their multistage fragmentation 
behaviors. Several components are reported in L. chuanxiong extract for the first time. 
Consequently, the majority of the chemical compounds in L. chuanxiong were 
profiled. Further work on the analysis of L. chuanxiong from different GAP sources 
using the method developed is needed to establish acceptable limits of variation and 
to set criteria for quality control. 
 
This study can lead to the better quality control of L. chuanxiong, and may also 
facilitate other research, such as exploring the metabolism of extracts of L. 
chuanxiong or similar investigations on other umbelliferous medicinal plants. These 
results in our study would give helpful chemical information and provide a valuable 
aid for structure-related investigation of similar phthalides in other medicinal herbs, 




Chapter 4  
Studies of effects of Ligusticum chuanxiong Hort. and its 




Concomitant use of herbal products with drugs may result in pharmacokinetic or 
pharmacodynamic herb-drug interactions. Herb-drug interactions are always hard to 
be detected and are sometimes reported as adverse drug reactions. Adverse drug 
reaction has been reported to be the fourth leading cause of death (Bates 1998; 
Lazarou et al. 1998). Among the reported adverse reactions, there existed multiple 
case reports and series of herb-drug interactions which have easily been neglected 
(Fugh-Berman and Ernst 2001; Izzo 2005; Williamson 2003). Nowadays, cytochrome 
P450 binding has been a major focus for herb-drug interactions in the research field as 
well as for drug-drug interactions evaluated by pharmaceutical industry.  
 
Modulation of the drug-metabolizing enzymes is one of the main causes of herb-drug 
interactions. Cytochrome P450-dependent monooxygenase is the primary enzyme 
system which catalyzes the oxidation of many endogenous and exogenous substances 
including steroids, drugs, chemical pollutants and dietary materials (Venkataramanan 
et al. 2006; Mandlekar et al. 2006). The modulation of drug metabolizing enzymes by 
herbal products was also reported to be involved in carcinogen activation and 
detoxication. For example, a series of studies showed that rosemary extracts inhibited 
cytochrome P450 that activated carcinogens in human cells in vitro (Offord et al. 
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1995; Offord et al. 1997) and enhanced the conjugating enzymes activities involved 
in carcinogen detoxication pathway in vivo (Singletary 1996; Singletary and Rokusek 
1997). 
 
The cytochrome enzyme system comprises a group of enzymes with different 
functions. In mammals, liver is the important detoxication organ having most 
abundant of drug-metabolizing enzymes. The relative content of the major P450 
enzymes in the human liver has been determined in several studies. On average, CYP 
3A4 is quantitatively the most important (average 30 to 40% of the total P450 protein 
in the liver), with CYP 2C (20%), CYP 1A2 (13%), CYP 2E1 (7%), CYP 2A6 (4%), 
CYP 2D6 (2%) and CYP 2B6 (<1%) present in somewhat lower quantities (Shimada 
et al. 1994). However, a very different picture emerges when evaluating the extent to 
which P450 enzymes are responsible for drug elimination processes. CYP 3A4 is 
responsible for approximately 50% of the P450-mediated metabolism of marketed 
pharmaceuticals (Nebert and Russell 2002), and CYP 2D6 has a disproportionate 
share (~25%) in comparison to the amount of enzyme present in the liver.  
 
P450 inhibition studies using liver microsomes (from experimental animal or human) 
or recombinant enzymes incubating with model substrates of specific P450s have 
been well developed as in vitro methods for quantitative predictions of inhibition 
potency in vivo (Bjornsson et al. 2003b; Ito et al. 1998). Inhibition of 
drug-metabolizing enzymes at the protein level can be broadly classified as 
competitive, non-competitive or mechanism-based. The mechanism can be more 
complex if allosteric effects are involved in interactions between substrate and 
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inhibitor. This is an important mechanism and is also the subject of many studies 
about the herb-drug interactions. 
 
On the contrary, quantitative predictions of induction in vivo on the basis of in vitro 
data are less well established. Because induction is subject to important species 
difference, prediction of possible induction effect on P450s in human cannot rely on 
animal studies (Lin and Lu 1998). Herbal medicines can cause induction effects on 
drug metabolizing enzymes (DMEs: phase I and phase II) and transporters at the 
transcriptional level and mediated via different kinds of receptors such as the 
pregnane X receptor (PXR), constitutive androstane receptor (CAR) and the aryl 
hydrocarbon receptor (AhR) (Mandlekar et al. 2006).  
 
The substrates (such as terfenadine, erythromycin, lovastatin) overlap between CYP 
3A4 and P-gp has been well-documented and recently it is also becoming increasingly 
apparent that the regulation of them may also be coordinately taken effect. For 
example, the inducers of prototypical phase I enzyme also increased the mRNA levels 
of transport proteins in cells or in vivo (Kim et al. 1999). Therefore, CYP 3A4 and 
P-gp may act in tandem as a barrier to oral delivery of many drugs and determine their 
bioavailability (Wacher et al. 1995). It was shown that the interactions between 
substrates and CYP enzymes or P-gp transporter do not follow simple enzyme 
kinetics (Zhou et al. 2004; Zhou et al. 2005). Their kinetic behavior can be 
categorized into three types: competitive inhibition, non-competitive inhibition and 
co-operative stimulation. The increasing activity of dipotassium glycyrrhizinate on the 
intestinal absorption of drugs has been demonstrated in an in vitro study using Caco-2 
 118 
cell monolayers and in an in vivo study of absorption in rats (Imai et al. 1999; Sakai et 
al. 1999). Despite some successful studies, the complexity of the molecular 
mechanism for these interactions still hinders our ability to predict the potential of 
CYP or P-gp mediated herb-drug interactions, either quantitatively or qualitatively.  
 
Due to its high abundance in the liver and major role in the metabolism of numerous 
drugs in the market, CYP 3A4 has been a main target in most of drug-drug and 
herb-drug interaction studies (Foster et al. 2002). CYP 2D6 is of relatively minor 
quantitative importance in human liver. However, CYP 2D6 shows 
debrisoquine/sparteine-type genetic polymorphism in human (Gonzalez et al. 1988) 
and participates in the metabolism of many drugs, including β-blocking agents, 
antiarrhythmic agents, antidepressants, and so on. This kind of genetic polymorphism 
is one of the well studied P450-dependent polymorphism in humans and has been 
identified to be due to genetic defects in the CYP 2D6 gene in the poor-metabolizer 
(PM) phenotype. About 7% of the Caucasian population has been identified to be of 
PM phenotype, whilst only 1-2% of Asians and Blacks are known to be of PM status 
(Bertilsson 1995). For these reasons, both CYP 3A4 and CYP 2D6 are considered to 
be the most important isozymes for the investigation of herb-drug interactions via 
cytochrome P450.  
 
Although many herb-drug interaction studies with normal volunteer have been 
performed and published, in vitro investigations assessing both potential for 
interactions as well as the mechanisms by which herbal medicines may interact with 
metabolic enzymes and transporters account for the majority of research be performed 
and published to date. Using specific substrates as “biomarkers/multibiomarkers of 
effects” relating to CYPs changes provides a good criterion for the study of 
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xenobiotic influences on individual CYP form. Based on the clinical experiences from 
some well-known drug interactions, FDA in USA and the Pharmaceutical Research 
and Manufactures of America have taken efforts to establish some general guidelines 
to help pharmaceutical industries, physicians and patients interpreting the clinical 
significance of drug interactions (Bjornsson et al. 2003b; Huang 2003). Currently, 
many different strategies can be applied in the unambiguous identification of the 
modulation effects of CYP isoforms by natural products, which have been 
summarized and discussed in Chapter 1.  
 
Midazolam has been reported to be a reproducible probe that allows quantitative 
determination of the modulation potential of CYP 3A4 (Wrighton et al. 2000). It is 
metabolized predominantly to 4-hydroxymidazolam, and to a lesser extent to 
1'-hydroxymidazolam (Ghosal et al. 1996). Its major metabolic pathway is shown in 
Figure 4.1. It is widely used for predicting CYP 3A-mediated drug-drug interactions 
(Streetman et al. 2000). Determination of midazolam 4-hydroxylation for the study of 
modulation effect on CYP 3A4 has been well established and reported (Kenworthy et 
al. 1999; Ma and Lau 1996).  
 
Bufuralol, a β-adrenoreceptor antagonist, has been widely used as a good substrate for 
determining the levels of liver microsomal CYP 2D protein (Kronbach et al. 1987). 
This probe drug is predominantly metabolized by CYP 2D in human and rat liver 
microsomes (Gonzalez et al. 1988; Dayer et al. 1987), resulting in the formation of 
1'-hydroxybufuralol (Figure 4.1). Bufuralol is reported to be metabolized to 
1'-hydroxybufuralol by CYP 2D6 and therefore has been widely used in vitro for the 

















       Figure 4.1. Metabolic reactions of the substrates examined in this study. 
 
1'-hydroxylation activity in hepatic microsomes of Sprague-Dawley (SD) rat was 
assayed as described previously (Kronbach et al. 1987) with some modification in our 
work. Dextromethorphan is another useful probe to phenotype persons as either 
extensive (EM) or poor (PM) metabolizers of drugs oxidized by CYP 2D6 in man and 
CYP 2D1 in Sprague-Dawley (SD) rat model (Gut et al. 1986; Mimura et al. 1994). It 
is metabolized to dextrorphan (DOR) through O-demethylation in human (Fig. 4.1) 
(Barnhart 1980). It is also an active ingredient in many over-the-counter formulations 
for cough, which make it a highly concerned in the study of drug interactions. 
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is known about the ability of these products to inhibit or induce P450 expression. 
Therefore, the profound studies on the modulation effects of drug-metabolizing 
enzymes have been accepted as a prudent approach to predict and hence avoid these 
adverse herb-drug interactions.  
 
The dried rhizome of Ligusticum chuanxiong Hort. is traditionally used for the 
treatment of cardiovascular and gynecological disorders. As introduced in Chapter 1, 
it is a widely used herbal medicine and is also consumed in tonic soups. Clearly, more 
studies are needed in order to assess the potential effect of L. chuanxiong on drug 
metabolizing enzymes and to better guide rational usage of this herbal medicine. 
 
4.2. Objective 
The objective of this study is to investigate the effects of L. chuanxiong Hort. and its 
reported active components (tetramethylpyrazine and ferulic acid) on hepatic 
drug-metabolizing enzymes, mainly CYP 3A and CYP 2D to determine the potential 
of L. chuanxiong in affecting CYP 3A and CYP 2D mediated phase I metabolism in 
the male Sprague-Dawley (SD) rats ex vivo. To further confirm the induction effect of 
L. chuanxiong on CYP 2D, the effects of 14-day treatment of L. chuanxiong on the 
pharmacokinetics of dextromethorphan (CYP 2D probe drug) are also investigated in 
male SD rats in vivo. 
 
4.3. Materials and Methods 
4.3.1. Chemicals and Reagents 
Bovine serum albumin standard, Folin & Ciocalteu’s phenol Reagent, β-Nicotinamide 
adenine dinucleotide phosphate sodium salt (β-NADP-Na), glucose-6-phosphate 
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dehydrogenase (G6P-DH), β-D-glucose 6-phosphate disodium salt hydrate (G6P) and 
heparin sodium salt (180 units/mg) were purchased from Sigma-Aldrich (St Louis, 
MO, U.S.A.). HPLC-grade acetonitrile and methanol were obtained from J. T. Baker 
(Phillipsburg, NJ, U.S.A.). All other chemicals and solvents were of analytical grade 
or of the highest purity and obtained from Merck Chemical Co. (Darmstadt, Germany) 
or Sigma-Aldrich (St Louis, MO, U.S.A.). MilliQ water for the HPLC analysis was 
deionized and passed through a Synergy Purification System (Molsheim, France). 
  
Midazolam (Roche Pharma Inc., Humacao, Puerto Rico) was purchased from the 
Pharmacy store in National University Hospital. 4-hydroxymidazolam, bufuralol and 
1'-hydroxybufuralol were supplied by Ultrafine Chemical Company (Manchester, 
UK). Tetramethylpyrazine, ferulic acid, dextromethorphan hydrobromide, 
dextrorphan and chlorpheniramine were obtained from Sigma-Aldrich (St Louis, MO, 
U.S.A.).  
 
4.3.2. Preparation of L. chuanxiong crude extract 
Dried roots of Ligusticum chuanxiong Hort. were purchased from Tong-Ren-Tang 
Pharmaceutical Co. Ltd. (Beijing, P. R. China). 350 g of the dried herbal materials 
were refluxed in 2100 ml 75% ethanol aqueous solution for 15 min and repeated one 
time more. The mixed extract was filtered through a filter paper (Whatman 
International Ltd., Maidstone, UK) and mixed together. The filtrate was concentrated 
using a rotary vacuum evaporator. The LC-DAD chromatogram of the L. chuanxiong 
extract is shown in Appendix (Figure 7). Then the dried extract was resuspended in an 
appropriate volume of 25% aqueous 1,2-propanediol to give a solution at the 
concentration of 1 g·mL-1 (calculated at the level of L. chuanxiong herbal material). 
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4.3.3. Animal treatments 
Adult male Sprague-Dawley rats, weighing 250±50 g were obtained from the 
Laboratory Animal Center (National University of Singapore, Singapore), at least one 
week before the experiments. They were housed in a temperature-controlled room (22
±2°C) with a light cycle of 12 h. The rats were fed a rodent chow and had tap water 
ad libitum. Thirty rats were randomly assigned to 5 experimental groups with six rats 
per group. The rats were treated in compliance with the Institutional Animal Care and 
Use Committee (IACUC) of National University of Singapore and in accordance with 
the guidelines of the National Advisory Committee for Laboratory Animal Care and 
Research (NACLAR) in Singapore. Tetramethylpyrazine (30 mg·kg-1 b.w., 5 mL·kg-1, 
i.p.), ferulic acid (50 mg·kg-1 b.w., 10 mL·kg-1, p.o.) or ethanol L. chuanxiong crude 
extract (2 or 10 g dry herbal material·kg-1 b.w., 10 mL·kg-1, p.o.) were separately 
administered to each group of rats for 14 days consecutively. Control groups received 
vehicle (25% aqueous 1, 2-propanediol, 10 mL·kg-1, p.o.) only. The rats were weighed 
every day to monitor any influence of the treatments on growth rate. 
 
4.3.4. Preparation of rat hepatic microsomes 
The rats were killed by the use of CO gas after 14 days treatment. Subsequently, the 
livers were rapidly removed and weighed, and then flushed with ice-cold 1.15 % (w/v) 
KCl solution until no blood was left. The liver samples were cut with scissors and 
homogenized with four volumes of ice-cold 0.1 M Tris-HCl buffer (pH 7.4, 
containing1.15% KCl) using a homogenizer (PowerGen model 125, Fisher Scientific, 
PA, USA). Microsomes were prepared by differential centrifugation reported 
previously (Zhao and Ishizaki 1997). After centrifugation at 9,000 g (Beckman Avanti 
TM
 J-25 Centrifuge) for 30 min, the resultant supernatant was then centrifuged for 60 
 124 
min at 105,000 g in a preparative ultracentrifuge (Beckman Optima TM XL-100K). 
The final microsomal pellet was resuspended gently with a hand-driven Potter 
Elvehjem homogenizer in 10 mM Tris-HCl buffer (pH 7.4), containing 1 mM EDTA. 
All the procedures were carried out at 4°C after the livers have been removed. The 
microsomes were immediately frozen and stored at -80°C until use. Under a short 
period of storage, the activities of cytochrome P450 were stable (Bauer et al. 1994).  
 
4.3.5. Determination of the microsomal protein concentration  
The microsomal protein concentration was determined using Lowry method (Lowry et 
al. 1951) with bovine serum albumin (BSA) as a reference substance. 
Reagent A: 2% NaCO3 in 0.1N NaOH 
Reagent B: 0.5% CuSO4·5H2O in 0.1% sodium potassium tartrate 
Reagent C (alkaline copper solution): Mix 50 mL of Reagent A with 1 mL of 
Regent B. Discard after 1 day.  
Bovine serum albumin (BSA) standard solution (1 mg·mL-1): 4 mg BSA in 4 
mL 0.1N NaOH working as a standard stock solution. 
Various kinds of reagents or solutions were added into the test tubes as described 
below: 
A series of dilutions of 1 mg·mL-1 BSA standard stock solution were prepared to give 
the final concentration ranges from 40 to 200 µg·mL-1 of the BSA standard solutions. 
1 mL of the blank (MilliQ water), diluted solutions of BSA standards or microsomal 
sample solutions (containing 10-100 µg of protein) were separately mixed and 
votexed with 3 mL of Reagent C and the solutions were allowed to stand for 10 
minutes or longer at room temperature. 0.4 mL of Folin-Ciocalteu’s reagent was 
pipetted into each mixture solution with thorough mixing. After 30 minutes or longer 
incubation time, the absorbance values of BSA standard solutions or unknown 
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microsomal solutions at 680 nm were recorded using a SHIMADZU model UV-1601 
UV-Visible spectrophotometer.  
 
The standard curve was constructed by plotting the average values of absorbance at 
680 nm against BSA standard concentrations. All samples were prepared and 
determined in triplicate. The protein concentration of each rat hepatic microsomal 
solution was determined according to the standard curve.   
 
4.3.6. Determination of total microsomal P450 content 
Cytochrome P450 exhibits a characteristic absorbance around 450 nm in the reduced 
state bound to CO. Based on this mechanism, total microsomal P450 content was 
determined with Omura and Sato method (Omura and Sato 1964). 2 mL of 
microsomal solutions from each treated rat were prepared with 100 mM phosphate 
buffer (pH 7.4) at the protein concentration of 0.5 mg·mL-1. About 0.7 mL of 
microsomal solutions was used to record the base-line by a UV-Visible 
spectrophotometer. Then the microsomal solution was mixed well with 20 µL of 
Na2S2O4 solution (200 mg·mL-1, working as the reducing agent). CO gas was bubbled 
through the solution for 1 min. Then the resultant solution was transferred into the 
sample cell to be scanned from 500 to 400 nm in the UV spectrometer. The difference 
in spectral absorbance between 450 nm and 490 nm was recorded. The P450 content 
of microsomal solution was then calculated using the following equation:  
P450 nmol·mg-1 protein = (ΔA450-490× 1000) / (91×content of protein) 
All determinations were carried out in triplicate. 
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4.3.7. Determination of the activities of CYP 3A in rat hepatic microsomal 
samples by use of midazolam as the substrate 
Microsomal incubations 
The basic incubation medium contained 1 mg protein·mL-1 of rat liver microsoms, 
phosphatic buffer (100mM, pH 7.4) and NADPH-generating system (3.3 mM glucose 
6-phosphate, 0.4 U glucose 6-phosphate dehydrogenase, 1.3 mM NADP and 1.3 mM 
MgCl2) at a final volume of 200 µL and was preincubated at 37°C for 5 min. The 
components of NADPH-generating system were dissolved thoroughly and mixed just 
prior to use, and the remaining mixture was discarded due to the breakdown of the 
generated NADPH. Midazolam (460 µM) in 16.7% methanol, used as the 20-fold 
concentrated solution, was added into the solution to start the reactions. The mixture 
was incubated at 37°C in a shaking water bath (LabTech TM, model LSB-030S, 
Korea) for 15 min and the reaction was stopped by adding 200 µL cold methanol. All 
reactions were performed in triplicate. Denatured protein was removed by 
centrifugation (12,000 g, 5 min) and 100 µL aliquot of the supernatant was injected 
for HPLC analysis.  
 
HPLC analytical methods 
An Agilent 1100 series HPLC-DAD analytical system was used for the quantitative 
determination of 4-hydroxymidazolam. The diode array detector was optimized and 
set with the maximum absorption wavelength at 220 nm with bandwidths of 4 nm. 
The reference wavelength was 550 nm with a 100 nm bandwidth. An Agilent Zorbax 
C18 column (250 × 4.6 mm I.D., 5 µm) with a Phenomenex C18 guard column was 
used. An isocratic mobile phase consisted of methanol, acetonitrile and 10 mM 
phosphatic buffer (pH 7.4) (v/v/v: 38: 24: 38). The flow rate was 0.7 mL·min-1.  
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Standard curves and validation of the quantification method 
Known quantities of 4-hydroxymidazolam were added into the microsomal solutions 
denatured by heat, and then the mixture were prepared as the microsomal incubation 
system. Standard solutions of 4-hydroxymidazolam in the concentration range of 
1.5-35 µg·mL-1 were prepared. The standard curve was obtained by plotting the peak 
area of 4-hydroxymidazolam (average of triplicate injections) against known 
concentrations. The data was subject to the linear regression analysis. 
 
To assess the accuracy and precision of the analytical method, known amounts of 
4-hydroxymidazolam were prepared following the same procedure used by 
microsomal solutions for the establishment of standard curve. The obtained 
4-hydroxymidazolam solutions served as the quality control (QC) samples at the 
concentrations of 1.5, 7.5 and 35 µg·mL-1. Intra-day values were determined by 
preparing and analyzing QC samples for five replicates at three concentrations on the 
same day. Inter-day precisions were assessed by analyzing QC samples each day for 
five days. Relative standard deviation (RSD) values and relative error (RE) were 
calculated and used as the index of precision and accuracy respectively.  
 
4.3.8. Determination of the activities of CYP 2D in rat hepatic microsomal 
samples by use of bufuralol as the substrate 
Microsomal incubations 
The incubation system contained 1 mg protein·mL-1 of rat liver microsomes, 0.1 M 
Tris-HCl buffer (pH 7.4) and NADPH-generating system (13.2 mM glucose 
6-phosphate, 1.6 U glucose 6-phosphate dehydrogenase, 5.2mM NADP and 26 mM 
MgCl2) at a final volume of 200 µL. The mixture was preincubated at 37°C for 5 min. 
Bufuralol was added as 20-fold concentrated solution (dissolved in methanol: 
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Tris-HCl buffer = 1:9) to start the reaction. The system was kept at 37°C for 15 min 
with gentle shaking and the reactions were stopped by addition of 200 µL ice cold 
methanol. Denatured protein was removed by centrifugation (10,000 g, 5 min) and 20 
µL aliquot of the supernatant was injected for liquid-chromatography-tandem mass 
spectrometry (LC-MS/MS) analysis. 
 
Quantification by use of LC-MS/MS 
The quantitative determinations of (+)-bufuralol and (+)-hydroxybufuralol were 
carried out using Q-TRAPTM LC-MS/MS system from Applied BiosystemsTM/MDS 
SCIEXTM (Foster City, CA USA) in the positive multiple reaction monitoring (MRM) 
mode. The MRM method parameters used in the LC-MS/MS analysis of bufuralol 
and 1'-hydroxybufuralol were optimized and listed as follows: curtain gas, 25 units; 
ionspray voltage, 5.5 kV; desolvation temperature, 320 °C; collision gas, high; 
declustering potential, 63 V; collision energy, 25.7 eV; entrance energy, 8.6 V; 
collision cell exit potential, 3.7 V; nebulizer gas (gas 1), 30 units and heater gas (gas 
2), 40 units. For MRM detection of 1'-hydroxybufuralol, the ion pair 278.1→186.1 
was selected. An Agilent 1100 Series liquid chromatography system (Agilent 
Technologies, Waldbronn, Germany), consisting of a vacuum degasser, a quaternary 
pump, and an autosampler, was coupled to the Q-TRAPTM tandem mass spectrometer 
for the analysis. Chromatographic separation was performed on an Agilent Zorbax 
RX-C18 (2.1 × 150 mm, I.D., 5µm). The gradient program of mobile phase was 
followed as below: 0–5 min, 30-60% methanol; 5–15 min, 60% methanol. The flow 
rate was 0.2 mL·min-1. Data acquisition and processing were performed using Analyst 
1.2.1 software (Applied Biosystems). 
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The calibration standards were prepared by diluting a 1'-hydroxybufuralol stock 
solution (13.57 µM). Five 1'-hydroxybufuralol concentrations were used for 
calibration: 22.62, 45.24, 135.73, 452.42, 1357.26 nM. Each concentration was 
prepared in triplicate.  
 
4.3.9. Effects of high dose of L. chuanxiong extract in on CYP 2D in SD rats in 
vivo using dextromethorphan as substrate  
Preparation of the standard dextromethorphan (DEM) and dextrorphan (DOR) 
samples 
Stock solutions of DEM and DOR were diluted with methanol/H2O (5:5, v/v). 
Working plasma standards were prepared by adding appropriate amount of mixed 
DEM, DOR and chlorpheniramine (I.S.) stock solutions (200 µL) and NaHCO3 
solution (pH 10.0, 100 µL) into blank rat plasma. For each of the standard solutions of 
DEM and DOR at six different concentrations, triplicate samples (n=3) were 
prepared. 
 
LC-MS/MS Analysis System 
Quantification of dextromethorphan (DEM) and dextrorphan (DOR) by use of 
LC-MS/MS was carried out according to the reported method (Bolden et al. 2002) 
with a slight modification. A Q-TRAPTM LC-MS/MS system from Applied 
BiosystemsTM/MDS SCIEXTM (Foster City, CA USA) coupled to an Agilent 1200 
Series HPLC system (Agilent Technologies, Waldbronn, Germany) was used. The 
mass spectrometer is a hybrid triple quadrupole/linear ion trap mass spectrometer 
equipped with a Turbo Ionspray ion source, operated in the positive ionization mode. 
The chromatographic separation was run on an Agilent Zorbax RX-C18 
reversed-phase column (150 × 2.1 mm I.D., 5 µm) protected by a SecurityGuard C18 
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column (4 mm × 3.0 mm I.D., 5 µm, Phenomenex, Torrance, CA, USA). The isocratic 
elution system consisted of 40% aqueous formic acid (0.1%, v/v) and 60% methanol 
with the flow rate at 0.15 mL·min-1. The injection volume was 10 µL. The tuning 
parameters were optimized for DEM, DOR and CP separately by using flow injection 
analysis (FIA). The optimized parameters are listed as follows: curtain gas, 10 units; 
ionspray voltage, 4.5 kV; desolvation temperature, 450 °C; collision gas, high; 
declustering potential, 60 V; collision energy, 40 eV; entrance potential, 5.5 V; 
collision cell exit potential, 2.5 V; nebulizer gas (gas 1), 25 units, and heater gas (gas 
2), 30 units. MRM method was used to quantify dextromethorphan, dextrorphan and 
chlorpheniramine (I.S.) using the transitions m/z 272 → m/z 147 for DEM, m/z 258 → 
m/z 157 for DOR and m/z 275 → m/z 230 for CP (I.S.), respectively. Both Q1 and Q3 
were set at unit mass resolution. Data acquisition and processing were performed 
using Analyst 1.4.1 software. 
 
Animal treatment 
Twelve male Sprague-Dawley rats were randomly divided into two groups. One 
group was treated with the extract of L. chuanxiong (10 g herbal material·kg-1·d-1) for 
14 days and another group with 25% aqueous propylene glycol for 14 days. On the 
last day of the treatment, all the rats were anesthetized with an intraperitoneal (i.p.) 
injection of ketamine (100 mg/kg body weight)/xylazine (5 mg/kg body weight) 
(Bedford Laboratory, Bedford, OH). The injection volume was approximately 2 ml/kg. 
The right jugular vein of each rat was catheterized with a PE-50 cannula (Beno et al. 
2001; Uhing and Arango 1997). Briefly, the fur around the ventral right side of the 
neck was shaved. The skin was sterilized with 70% alcohol. A 1.5 cm length incision 
was made, and the neck muscle was gently separated to expose the right jugular vein. 
A small nick was made, and a 15 cm long beveled-end piece of PE-50 tubing (I.D. 
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0.58 mm, O.D. 0.965 mm, Clay Adams brand, Becton Dickinson, Sparks, MD) was 
inserted and pushed into the right atrium. The cannula was anchored with suture 
thread and the cannula was exteriorized through the skin at the back of the neck. The 
muscle and skin were then closed with suture. The blood flow was examined and the 
tubing was filled with heparinized (50 IU·mL-1) normal saline solution. The rats were 
kept in cages and allowed to recover overnight before dosing, with food and water 
given ad libitum. After each blood sample withdrawal, rats were immediately 
transfused with an equal volume of normal saline solution. The plasma was separated 
and stored at -80°C until use.  
 
Collection and handling of blood samples 
DEM was administered at the dose of 30 mg·kg-1 in all the experiments. The solution 
of DEM for injection was prepared by dissolving 150 mg DEM in 0.9% saline to 
achieve a final concentration at 5 mg·mL-1. The solution was then filtered through a 
sterile 0.22 µm filter membrane to remove any particles and microorganism. For 
pharmacokinetic study of dextromethorphan, 200 µL of blood was collected from the 
jugular vein with a chilled 1-mL plastic syringe containing 2 U heparin salt. Blood 
samples were taken immediately at 5, 10, 20, 40, 60 min, 2 h, 4 h, 6 h, 8 h and 10 h 
after intraperitoneal (i.p.) injection. Time 0 was recorded as the time when half of the 
dose had been administered. The blood samples were mixed gently and immediately 
placed in an ice bath and centrifuged at 6, 000 g for 10 min at 4°C.  
 
For each whole blood sample, 0.1 mL plasma was harvested and mixed with 0.1 mL 
chlorpheniramine solution (internal standard, 25 µg·mL-1, dissolved in mobile phase). 
50 µL formic acid and 1.5 mL dichloromethane were added into each sample and the 
mixture was vortexed 30 sec for two times. The organic phase was transferred into 
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another polypropylene tube and evaporated under vacuum to dryness. The residue was 
frozen in -80 °C freezer before analysis. Residue was dissolved in 1 mL of mobile 
phase and centrifuged at 10,000 g for 10 min. The supernatant was transferred into a 
HPLC vial and a 2 µL portion was injected on column. DEM and DOR concentrations 
were determined by LC-MS/MS within 4 weeks after sample collection.  
 
Pharmacokinetic data analysis 
The plasma concentration-time data for each rat were analyzed by a two-compartment 
open model utilizing WinNolin 5.2 software (WinNonlinTM; Pharsight, Mountain 
View, CA). The peak concentration (Cmax) was taken as the maximum observed value 
and the time to peak concentration (Tmax) as the time corresponding to to this value. 
The area under the plasma concentration-time curve (AUC0-tlast) from time 0 to the last 
sampling time (tlast) was calculated using the linear trapezoidal rule. Residual AUC 
after tlast (AUCtlast-∞) was calculated using the concentration at the last sampling time 
(Clast) divided by the terminal elimination rate constant (β) which was calculated by 
linear least-squares regression of the last three time points in the nature log 
concentration-time profile. The total area under the plasma concentration-time curve 
from time zero to infinity (AUC0-∞) was calculated as the sum of AUC0-tlast and 
AUCtlast-∞.  
 
For intravenous dose (Di.v.):  
A bi-exponential decline after an intravenous bolus dose is associated with a 
two-compartment model.  
                      C=A·e-α·t+B·e-β·t                        Equation 4-1 
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Half life of distribution phase (t1/2, α) and terminal phase (t1/2, β), plasma Clearance (Cl), 
volume of the central compartment (Vc), mean residence time (MRT), and volume of 
distribution at steady state (Vss) were calculated using the standard procedure 
(Gabrielsson and Weiner 2000) and were listed below: 
             t1/2, α=0.693 / α                    Equation 4-2 
 t1/2, β= 0.693 / β                     Equation 4-3 













                  Equation 4-6  
Vss=MRT·Cl                          Equation 4-7  
Vss is the sum of central Vc and peripheral Vt volume terms. 
                          
 
For intraperitoneal dose (Di.p.): 
Bioavailability (F) of the intraperitoneal dose was estimated by comparing the 
respective AUCs with that obtained from the intravenous dose. 
 
4.3.10. Data Analysis 
Data were expressed as mean ± S.D. (standard deviation), which were calculated 
using Microsoft Excel program. For comparison of statistical significance between 
control and treated groups, one-way ANOVA with the Student-Newman-Keuls 
post-hoc test for multiple comparisons was performed using SPSS (version 11.5) 
(SPSS Inc., Chicago, USA). The statistical significance of difference for calculated 
pharmacokinetic parameters between control and L. chuanxiong pre-treated groups 
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was evaluated using two tailed, independent-samples t-test. A value of p<0.05 was 
considered to be statistically significant.  
 
4.4. Results  
4.4.1. Growth characteristics and hepatic cytochrome P450 in SD rats 
The body weights at necropsy, weights of the livers and the ratios of liver weight to 
body weight of the different groups of rats were determined and the results were 
presented in Table 4.1. The body weight was found to be affected by the 
administration of L. chuanxiong extracts. In low (CXL) and high (CXH) dosage of L. 
chuanxiong groups, the body weights were lower than those in the control group, 
whereas the liver weights of rats in each of the treated groups were not significantly 
different from those in the control group. The ratios of liver weight to body weight in 
rats treated with a high dose of L. chuanxiong crude extract (CXH) tend to be higher 
when compared to the control values and this change was statistically different 
(*p<0.05) in high dose of L. chuanxiong treatment group (Table 4.1). 
 
Table 4.1 Effects of L. chuanxiong extracts, tetramethylpyrazine and ferulic acid on 
the growth characteristics of rats.  
 






Control  25% aqueous 
1,2-propanediol 
379 + 21 15.8 + 0.4 4.17 + 0.20 
FA  (50 mg·kg-1·d-1) 358 + 14 14.0 + 1.4 3.90 + 0.23 
TMP  (30 mg·kg-1·d-1) 348 + 17 14.3 + 1.4 4.08 + 0.29 
CXL  (2 g herb·kg-1·d-1) 326 + 27* 14.4 + 1.3 4.46 + 0.69 
CXH  (10 g herb·kg-1·d-1) 333 + 21* 17.5 + 1.1 5.26 + 0.35* 
Results were expressed as mean + s.d., n=6 per group. *p<0.05 compared with blank 
group. 
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4.4.2. Protein concentration and P450 content in rat hepatic microsomes  
For the determination of the protein concentrations, the average values of the 
absorbance at 680 nm for the series of standard bovine serum albumin solutions were 
shown in Table 4.2 and the standard curve for quantification of protein concentration 
was shown in Figure 4.2.  
 
The protein concentration of each individual rat was determined and the results were 
listed in Table 4.3. It was found that the protein concentrations of rat hepatic 
microsomes in group pre-treated by tetramethylpyrazine were lower than those of the 
control group. The cytochrome P450 contents (per mg of microsomal protein) in 
pre-treated groups with L. chuanxiong extracts, tetramethylpyrazine or ferulic acid 






Figure 4.2 The standard curve for the determination of the concentrations of protein in 
rat hepatic microsomes.  
 
Table 4.2 Absorbance of the standard bovine serum albumin solutions. 
 
Absorbance at 680 nm Concentrations of BSA 
solutions (µg·mL-1) 1 2 3 Mean CV% 
40 0.148 0.145 0.149 0.147 1.41% 
50 0.288 0.312 0.308 0.303 4.26% 
100 0.541 0.542 0.505 0.529 3.99% 
150 0.782 0.761 0.733 0.759 3.24% 



















0 50 100 150 200 250
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Table 4.3 The concentrations of protein in hepatic microsomes of rats (mg·mL-1). 
 
  * p<0.05 
 
 
Table 4.4 The cytochrome P450 contents in hepatic microsomes of rats (nmol·(mg 
protein)-1). 
group Blank FA TMP CXL CXH 
0.498 
 
0.533 0.576 0.586 0.556 
0.522 0.529 0.531 0.548 0.497 
0.562 0.518 0.526 0.571 0.583 
0.477 0.526 0.564 0.529 0.561 
0.539 0.491 0.495 0.533 0.577 




0.494 0.532 0.547 0.521 0.546 
Average 0.515 0.522 0.540 0.548 0.553 





Groups Control FA TMP CXL CXH 
14.07 11.48 10.84 12.73 13.21 
15.03 10.96 11.58 15.05 16.09 
13.63 12.06 11.43 12.76 16.19 
15.17 12.75 11.06 15.07 16.43 
15.65 13.82 12.61 16.97 16.81 
Protein 
Concentration 
14.09 14.75 15.16 12.64 16.82 
Average 14.61 12.64 12.11* 14.20 15.93 
SD 0.79 1.44 1.61 1.78 1.37 
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4.4.3. Ex vivo CYP 3A activity in rats using midazolam as substrate. 
The pKa of midazolam is 6.0. It is water soluble at pH<4, but is highly lipophilic at 
physiological pH (Blackett et al. 1988). Therefore, an organic solvent should be used 
in the microsomal medium to dissolve this substrate. In this study, the stock solution 
of midazolam was prepared in 16.7% (v/v) methanol. Solutions containing 
4-hydroxymidazolam can be stored in short-term (5 days) in a freezer (at -20°C). For 
the quantification of 4-hydroxymidazolam in unknown samples, the microsomal 
reactions were thus carried out on different batches on different days. The dissolved 
samples for quantification were kept in refrigerator before analysis.  
 
At a low pH, midazolam is positively charged at the imidazole nitrogen, entailing 
similar retention behavior as its metabolite. Retention times of midazolam and 
4-hydroxymidazolam were highly dependent on the pH of the mobile phase. By using 
a buffer with pH 7.2, which is above the pKa of midazolam, separation was achieved 
for this microsome incubation system. The percentage of mobile phase and its flow 
rate were slightly adjusted according to the reported method (Ring et al. 1995). The 
selectivity of the quantification method was achieved by baseline separation. Figure 
4.3 shows the chromatogram obtained after the extraction of spiked 
4-hydroxymidazolam in boiled microsomal solution. With the chromatographic 
conditions used, the peaks of midazolam (retention time 17.28 min) and 
4-hydroxymidazolam (10.44 min) were fully resolved and essentially symmetrical. 
Their peaks were free of any interfering elutes, which might come from the 













Figure 4.3 HPLC chromatogram of midazolam and its metabolites formed in                 
rat hepatic microsomal solution.   
 
The external standard method was used in the calibration and evaluation of the 
microsomal samples. The standard calibration curve of 4-hydroxymidazolam was 
y=140.99x-144.84, which was linear in the range of 1.5 - 35 µg·mL-1 with a coefficient 
of determination at 0.9997 (Figure 4.4). The concentrations of 4-hydroxymidazolam 








Figure 4.4 Standard curve of 4-hydroxymidazolam. 
 
 


















The extraction recovery of 4-hydroxymidazolam in microsomal solutions was in the 
range of 99-102% at three concentration levels (Table 4.5). Table 4.6 shows the 
inter-day and intra-day precisions of 4-hydroxymidazolam, which were established at 
three different concentrations by adding these standard solutions to boiled microsomal 
solutions. This quantification method was validated in rat hepatic microsomal solution 
with all the inter-day and intra-day coefficients of variation less than 5%.  
 
Table 4.5 Extraction recovery of 4-hydroxymidazolam from microsomal solutions. 
 
 









Added (µg·mL-1) Recovery (%) RSD (%) 
1.5 101.7 + 3.1 3.02 
7.5 99.8 + 0.5 0.50 



























The activities of CYP 3A of hepatic cytochrome in SD rat treated with crude L. 
chuanxiong extracts, tetramethylpyrazine or ferulic acid were not significantly 
different from those in the control group (shown in Table 4.7). It was observed that 
tetramethylpyrazine caused a weak inhibition of CYP 3A activity although the 
inhibition was not statistically significant.  
 













Group Control TMP FA CXL CXH 
178.1 149.7 168.0 182.7 156.4 
182.1 152.1 171.7 193.2 176.8 
177.6 167.1 197.8 169.4 183.4 
160.4 193.0 182.3 186.6 187.1 




182.8 153.4 168.2 172.0 181.5 
Average 174.6 163.9 176.8 181.1 178.5 
SD 9.1 16.3 11.5 9.0 11.4 
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4.4.4. Ex vivo CYP 2D activity in rats using bufuralol as substrate 
It was reported that 1% (v/v) solvent does not significantly inhibit the reactions of 
bufuralol in micorsomal incubation system (Yamazaki et al. 1994). For current work, 
bufuralol was dissolved in the mixed buffer of methanol/Tris-HCl (v: v = 1:9). The 
concentration of bufuralol stock solution was 20 times higher than that of its final 
working solution in the microsomal incubation system. As a result, the final reaction 
microsomal incubation system contained 0.5% (v/v) methanol, which were used to 
dissolve bufuralol.  
 
The calibration equation of 1'-hydroxybufuralol was y=990.52x+16717 (R2=0.9999). 
The calibration curve was linear over the concentration range from 22.0 ng·mL-1 to 
4.4 µg·mL-1 (Fig. 4.5). This LC-MS/MS quantification method was validated for 
linearity, precision and accuracy for the determination of 1'-hydroxybufuralol in 




































Table 4.8 Extraction recovery of 1'-hydroxybufuralol in microsomal solutions (n=5). 
 
 




The activity of CYP 2D of hepatic cytochrome in the CX-H group was significantly 
higher than that in the control group (P<0.05), indicating an induction effect caused 
by the14-day pretreatment of high-dose L. chuanxiong extract. In contrast, the CYP 
2D activities in the other treated groups were not significantly different from those in 
the control group (Table 4.10). Thus, tetramethylpyrazine (30 mg·kg-1 b.w., ip, 
pretreatment for 14 days), and ferulic acid (50 mg·kg-1 b.w., oral, pretreatment for 14 
days) are unlikely to be responsible for the induction effect on hepatic CYP 2D 
observed in SD rat. Other components present in the extract of L. chuanxiong may 
modulate this induction effect. This also implies the importance of studying the herb 
as a whole, since we may probably miss some certain effect if using only the active 




Added (ng·mL-1) Recovery (%) RSD (%) 
22 98.9 + 2.9 2.97 
220 101.9 + 1.4 1.41 
4400 97.2 + 1.6 1.61 






22 21.7  0.2 0.8  -1.3 0.4 
220 222  0.2 0.8  1.2 0.9 
4400 4280  1.6 1.2  -2.7 -1.3 
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Table 4.10 Activities of CYP 2D using bufuralol as a substrate in treated rat hepatic 
microsomes (nmol·(mg·h)-1). 
 
* p<0.05 compared to blank 
 
4.4.5. In vivo CYP 2D activity in rats using dextromethorphan as substrate 
The ESI-MS2 mass spectra of dextromethorphan (DEM) and dextrorphan (DOR) are 
shown in Figure 4.6. Their parent ions at m/z at 272.3 and 258.3 were separately 
selected for the subsequent quantitative analysis. Under the current chromatographic 
conditions, dextromethorphan (tR=3.75 min), dextrorphan (tR=2.74 min) and 
chlorpheniramine (tR=3.18 min) could be rapidly eluted and fully resolved. Figure 4.7 
shows the total ion chromatograms (TIC) of blank plasma extract, standard curve 
sample containing 10 µg·mL-1 DEM and 10 µg·mL-1 DOR and a 20-min plasma 
sample from a high dose of L. chuanxiong pretreated rat after a single dose of 30 
mg·kg-1 by intraperitoneal (i.p.) injection of DEM.   
 
 
Group Control TMP FA CX-L CX-H 
55.66 54.62 59.98 53.82 59.36 
54.45 55.66 58.64 58.21 59.13 
57.31 60.36 52.87 57.02 67.18 
48.44 54.99 53.58 56.44 58.44 




54.17 50.90 57.88 55.54 60.75 
Average 53.61 55.40 56.41 56.62 60.85* 

























 +EPI (258.50) CE (45): 0.447 to 1.012 min from Sample 1 (DOR) of DORMS2.wiff (Turbo Spray) Max. 6.5e5 cps.


































DEM m/z 272 → m/z 147 

















































Figure 4.7 MRM chromatograms of (A) a blank rat plasma sample; (B) a blank rat plasma sample spiked with DEM, DOR and I.S. at the concentration of 10 µg·mL-1, 
10 µg·mL-1and 12.5 µg·mL-1respectively; (C) a rat plasma sample obtained at 20 min after a single i.p. administration of 30 mg· kg -1 DEM. Peak I, DEM; Peak II, 
DOR; Peak III, I.S. 
 





Based on the LC-MS/MS analysis, the ratios of peak area of DEM or DOR to that of 
CP (I.S.) were used to calculate the compounds’ concentrations. Standard plasma 
samples were prepared by spiking drug-free plasma with known amounts of DEM and 
DOR to produce concentration range of 0.5-500 µg·mL-1. The calibration curves for 
DEM and DOR were linear over the investigated range of 0.5-500 µg·mL-1. The 
calibration equation for DEM was y=0.2102x+0.5246 (R2=0.9995) and it was 
y=0.0774x-0.0746 (R2=0.9997) for DOR.  
 
The absolute recovery of DEM and DOR was expressed in the form of percentage of 
the concentrations of DEM and DOR obtained from the analysis to their expected 
concentrations, respectively. Blank rat plasma was spiked with DEM and DOR to 
give the final concentration of 0.5, 10 and 500 µg·mL-1. Replicate (n=5) samples at 
these three concentration levels were prepared by a liquid-liquid extraction similar to 
the method for plasma samples as described in section 4.3.9 and the results were 
shown in Table 4.11. The resultant precision and accuracy for the determination of 
DEM and DOR in rat plasma samples were shown in Table 4.12. 
 
Table 4.11 Recovery of dextromethorphan and dextrorphan in blank rat plasma. 
 
 
Added (µg·mL-1) Recovery (%) RSD (%) 
Dextromethorphan   
 0.5 103.6 + 1.83 1.77 
10 98 + 2.02 2.06 
500 97. 6 + 4.17 4.27 
Dextrorphan   
0.5 101.3 + 3.62 3.58 
10 97.4 + 1.17 1.21 
500 95.4 + 3.90 4.09 
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Table 4.12 Precision and accuracy for the determination of dextromethorphan and 
dextrorphan in blank rat plasma.  
 
Plots of mean DEM and DOR concentrations in plasma measured versus post-dose 
time after a single i.p. dose with 30 mg·kg-1 DEM to rats pre-treated with or without L. 
chuanxiong were present in Figure 4.8. Each time point represented 5 rats. 
Disappearance of DEM and DOR from plasma appeared to follow a biexponential 
declines. The calculated pharmacokinetic parameters of DEM and DOR in the 













Figure 4.8 Mean plasma concentrations of dextromethorphan and dextrorphan versus 
time after a single intraperitoneal (i.p.) dose of 30 mg·kg -1 of dextromethorphan to 
rats treated or untreated with L. chuanxiong extract (n=5 each group). 






Dextromethorphan       
0.5 0.48  5.8 3.7  -4.0 -2.1 
10 9.72  1.9 1.5  -2.8 -2.1 
500 470  2.3 3.7  -5.9 -2.4 
Dextrorphan       
0.5 0.51  4.5 3.8  2.6 -1.1 
10 10.1  2.2 2.3  1.3 0.5 

























Table 4.13 Effect of L. chuanxiong extract on mean pharmacokinetic parameters of 
dextromethorphan and dextrorphan after a single i.p. administration of 
dextromethorphan in rats.  
 
PK parameters (units) Control L. chuanxiong 
Dextromethorphan   
Tmax (min)  10 + 0 9.3 + 1.9 
Cmax (µg·mL-1) 264.19 + 68.38 314.16 + 84.89 
t1/2, β (hr) 3.47 + 0.57 3.56 + 0.81 
AUC0-tlast (µg·hour·mL-1) 736.9 + 154.75 738.46 + 115.62 
AUC0-∞ (µg·hour·mL-1) 739.24 + 155.77 740.31 + 115.24 
AUC0-∞ /Dose (hour·kg·µg·mL-1·mg-1) 24.7 + 5.2 24.8 + 4.0 
Dextrorphan   
Tmax (min)  10 + 0 9.3 + 1.9 
Cmax (µg·mL-1) 255.77 + 89.87 218.81 + 50.29 
AUC0-∞ (µg·hour·mL-1) 676.75 + 171.19 478.2 + 71.04 
 
All values were expressed as mean + SD 
 
The maximal plasma concentrations of dextromethorphan occurred at 10 min after 
administration of 30 mg·kg -1 i.p. dose of dextromethorphan. No significant difference 
was observed in all the calculated pharmacokinetic parameters of dextromethorphan 
and dextrorphan (Table 4.13) after a single i.p. administration of 30 mg·kg -1 
dextromethorphan between the groups pre-treated with L. chuanxiong extract and the 
control group, suggesting no obvious effects of L. chuanxiong pretreatment on CYP 





4.5. Discussion  
Researchers are becoming increasingly aware that some exogenous compounds such 
as herbs or food may cause drug interactions via cytochrome P450 system. In the 
present study, the ability of L. chuanxiong to modulate CYP 3A and 2D activities was 
studied ex vivo in Sprague-Dawley (SD) liver microsomes and in vivo in SD rat. 
Although marked species difference in the expression of cytochrome P450 has been 
reported (Silva et al. 1998), there is a realistic limit to the number and scope of 
clinical herbal-drug interaction studies that can be performed due to the ethical 
constraints and other limitations. Alternative approaches, such as in vitro models and 
in vivo animal models, can be used to verify prospective herb-drug interactions and 
investigate the mechanisms in greater depth. SD rat was reported to be a useful animal 
model to study the CYP 2D6 oxidative polymorphism, and serves to mimic human 
poor metabolizer (PM) and extensive metabolizer (EM) subjects, respectively 
(Aldabbagh et al. 1981; Boobis et al. 1986; Zysset et al. 1988). 
 
We aim to evaluate not only the effects of tetramethylpyrazine and ferulic acid (the 
reported active constituents in L. chuanxiong), but also the effects of the whole herb 
(root) as the extract for two reasons: (i) it is traditionally taken as the whole herb 
(root); and (ii) there might be other compounds besides tetramethylpyrazine and 
ferulic acid in L. chuanxiong which are able to modulate CYP activities. Such 
information is important for the proper evaluation of the efficacy and safety of L. 
chuanxiong. The administered dosages of tetramethylpyrazine, ferulic acid and L. 
chuanxiong extract were chosen based on the dose ranges that have been commonly 
used in other pharmacological studies (Chang et al. 1998; Chang et al. 1999; 
Kawabata et al. 2000; Kim et al. 2003). 
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In this study, we determined the effects of L. chuanxiong extract on hepatic 
drug-metabolizing enzymes, especially CYP 3A and CYP 2D to provide further 
information on the assessment of possible herb-drug interaction with L. chuanxiong. It 
was demonstrated that the body weights of SD rats were reduced by feeding with low 
(2 g herb·kg-1·d-1) or high dose (10 g herb·kg-1·d-1) of L. chuanxiong extracts for 14 
days. The relative liver weights in rats pretreated with a high dose of L. chuanxiong 
extract were significantly higher than those in the control group. The protein 
concentrations of rat hepatic microsomes in tetramethylpyrazine pre-treated group 
were lower than those in the control group. 
 
Feeding rats with a high dose (10 g herb·kg-1·d-1) of L. chuanxiong extracts for 14 
days did not appear to affect CYP 3A, but significantly increased CYP 2D activities 
in male SD rats in ex vivo experiments. Due to the complex mechanisms of induction 
effect on CYPs, further experiments were carried out to confirm the induction effects 
of L. chuanxiong extract pre-treatment on CYP 2D activity. It was found that the 
pharmacokinetic parameters of dextromethorphan and dextrorphan after a single 
intraperitoneal administration of 30 mg·kg -1 dextromethorphan (a CYP 2D substrate) 
were similar in both groups treated and untreated with L. chuanxiong extract, 
suggesting no obvious effects of L. chuanxiong pre-treatment on CYP 2D in SD rats 
in vivo, despite the enzyme induction effect seen ex vivo.  
  
The mechanisms of induction effect on CYPs are more complex than that of 
inhibition effect. Some drugs which cause enzyme induction with repeated dosing in 
vivo often demonstrate inhibition in in vitro assays. For example, St. John’s Wort 
significantly altered the pharmacokinetics of co-administered drugs in vivo, but in 
vitro studies showed the mechanism to be enzyme induction, rather than inhibition 
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effects (Durr et al. 2000; Obach 2000b). The effects of St. John’s Wort on the 
pharmacokinetics of other drugs may be the results from induction of intestinal 
p-glycoprotein, as well as intestinal and hepatic CYP 3A4 isozymes (Johne et al. 
1999a; Cheng 2000). In the previous Section 4.4.4, the pre-treatment with a high dose 
of L. chuanxiong extract showed induction effect on CYP 2D ex vivo in SD rats. To 
further confirm this induction effect, another in vivo experiment was carried out. In 
this part of the study, it was found that the in vivo pharmacokinetic parameters of 
dextromethorphan and dextrorphan were not different between the group pre-treated 
with L. chuanxiong extract and the control group. Dextromethorphan rather than 
bufuralol was selected due to cost considerations and the former serves as alternative 
choice of substrate for CYP 2D. It has been shown to be a useful probe to evaluate the 
debrisoquine-type hydroxylator in man (Schmid et al. 1985) and in an animal model 
(Zysset et al. 1988).  
 
The difference in the effects on CYP 2D caused by a high dose of L. chuanxiong 
extract pre-treatment observed in ex vivo and in vivo may be due to the different 
enzyme substrates and different study systems employed. Animal models typically 
lead to poor predictions of the induction effects in human (Hewitt et al. 2007), 
therefore, human derived in vitro models are preferred for the confirmation of CYP 
2D6 effect in human caused by L. chuanxiong in the future. Further studies on the 
level of the genes coding for CYP 2D are needed to elucidate the mechanisms and 
significance of the induction effect on CYP 2D in SD rat. In addition, there is the need 
to further study the bioactive constituents in the L. chuanxiong extract which are 
responsible for the induction effect of CYP 2D.  
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Together with the results from Chapter 3, the concentrations of ferulic acid were low 
in all the extracts prepared with different extraction methods and tetramethylpyrazine 
cannot be detected by HPLC as well as LC-MS/MS method at the limit of detection 
(LOD) of 1.3×10-8 g. Further ex vivo results confirm that induction effect of L. 
chuanxiong on CYP 2D in SD rat liver microsomes observed in this study is not due 
to tetramethylpyrazine or ferulic acid. In the herbal materials or related products, only 
constituents associated with its bioactivity or standardization for the purpose of 
quality control can be defined as appropriate marker compounds. The present findings 
of ex vivo study also indicate that the two compounds, tetramethylpyrazine and ferulic 
acid, are not suitable marker compounds in L. chuanxiong. 
 
4.6. Conclusion 
The observed ex vivo induction effect on CYP 2D in SD rats caused by the 
pretreatment of high dosage of L. chuanxiong extract might have toxicological and 
clinical consequences since CYP 2D is the major isozyme present in human liver. The 
clinical implication of this phenomenon can prove highly important particularly when 
chronic patients are on long term drug treatments. Under these circumstances, indeed, 
the reversal of CYP induction effects on CYPs cannot occur in the presence of L. 
chuanxiong. In general, an increase of the biotransformation of ubiquitous pretoxics 
(cotoxicity) and premutagens (comutagenicity) as well as the overproduction of 
oxygen centered radicals associated with CYP induction can occur. The routine L. 
chuanxiong consumers under CYP 2D induction might therefore be predisposed to the 
associated adverse effects. This study may also be helpful for the development of 
guideline of rational administration precautions to be taken for using this herbal 
medicine. 
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Both CYP 3A and CYP 2D are responsible for the metabolism of a wide variety of 
commonly prescribed medications. Although species differences make it difficult to 
extrapolate the induction effect in the rat study to human directly, caution should be 
paid to the possible herb-drug interactions for patients concurrently using L. 

















Chapter 5  
Herb-drug interactions between Ligusticum chuanxiong 
Hort. extract and Aspirin 
 
5.1. Introduction  
Thrombotic vascular diseases continue to be one of the greatest causes of mortality 
and morbidity (Steg et al. 2007). Advances in the understanding of the central role of 
platelets in the pathophysiology of thrombotic vascular diseases have spurred in-depth 
investigation into the mechanisms of aspirin and the clinical utility of this agent in the 
treatment of common cardiovascular disorders. Aspirin (Acetylsalicylic acid, ASA, 
pKa=3.6) was first introduced to the market as a non-steroidal anti-inflammatory drug 
(NSAID) with antipyretic, analgesic and antiplatelet properties (Jack 1997). 
Convincing clinical experiences show that the use of aspirin can reduce the risk of 
ischemic heart disease (Levin 2005; Ridker et al. 2005; Tognoni et al. 2001), such as 
the incidence of myocardial infarction, stroke (Dalen 2009), thrombotic 
manifestations of ischemic stroke (Sandercock et al. 1997) and vascular mortality in 
patients with transient ischemic attacks. Aspirin has been proven to be of significant 
benefit in unstable angina (Theroux et al. 1988), for the prevention of coronary 
bypass graft occlusion (Gavaghan et al. 1991) and cerebrovascular diseases (Tijssen 
1998). Nowadays aspirin is employed in the prophylactic treatment of transient 
cerebral ischemia to reduce the incidence of recurrent myocardial infarction and to 
decrease mortality in patients with postmyocardial infarction (Baigent et al. 1998).  
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Aspirin shows its antithrombotic effect through the following mechanism. 
Cyclooxygenase (COX), which exists ubiquitously throughout the human body, can 
facilitate the production of various prostaglandins. There are two isoforms of COX 
including COX-1 and COX-2. COX-1 plays a vital role in platelet aggregation 
through the production of thromboxane A2 (TXA2). It is also involved in vascular 
regulation and renal function via a homeostatic interplay of vasoconstriction and 
vasodilatation mediated by TXA2 and prostacyclin (PGI2) (Fitzgerald 1991). TXA2 
also helps G-protein coupled platelet activation. Aspirin reduces the production of 
TXA2 from arachidonic acid in platelets by irreversibly acetylating and thus inhibiting 
COX-1 (Hennekens et al. 1989; Pedersen and FitzGerald 1984b). The aspirin-induced 
inhibition of TXA2 synthesis can last for long time, which is approximately 7-10 days 
or even almost for the life time of the platelet. Aspirin, at relatively high doses (above 
3 g·day-1), also causes a reduction in prothrombin, a plasma factor involved in blood 
clotting. Antithrombotic therapy has been shown to be effective in preventing 
secondary strokes. Inhibition of platelet function by aspirin may reduce the formation 
of thrombi, thereby reducing the incidence of cardiovascular diseases (Brouwers and 
de Smet 1994). 
 
The antiplatelet effect of aspirin is associated with prolonged bleeding time and 
inhibition of TXA2-dependent platelet aggregation. These effects occur even before 
aspirin is detectable in the peripheral blood, owing to the exposure of platelet to 
aspirin in the portal circulation. The plasma elimination half-life of aspirin is only 20 
minutes; however, since platelets cannot generate new COX, the effects of aspirin last 
for the duration of the life of the platelet (≈10 days). After a single dose of aspirin in 
human, platelet COX activity recovers by ≈10% per day as a function of platelet 
turnover (Burch et al. 1979). Although it may take 10 days for the total platelet 
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population to be renewed, and thus restore normal COX activity, it has been shown 
that if as little as 20% of platelets have normal COX activity, hemostasis may be 
normal (Patrono et al. 1985; Bradlow and Chetty 1982).  
 
Platelet hyperaggregation is a common manifestation of certain hemopathologic and 
cardiovascular diseases. The inhibition of prostaglandin synthesis is responsible for 
the therapeutic effects of aspirin but also results in the alteration of normally 
protective prostaglandin functions, which cause potentially serious adverse effects of 
aspirin including gastric ulcers, renal failure, and impaired platelet function with 
resultant hemorrhagic complications (Riegger et al. 1991; Hennekens 1989; He et al. 
1998).  
 
Aspirin is a weak acid (pKa=3.6) and exhibits a pH-dependent absorption. It is more 
rapidly absorbed from the duodenum than from the stomach due to the relatively 
greater surface area of the duodenum. Despite the extensive absorption following oral 
administration, only 50-75% of aspirin reaches the systemic circulation (Rowland et 
al. 1972). It is most likely that the enzymatic hydrolysis accounts for the loss of 
aspirin prior to its absorption, which has been demonstrated in rat and human. The gut 
wall metabolism and first-pass effect may account for the presystemic loss of aspirin 
(Levy et al. 1967; Levy and Angelino 1968).  
 
Aspirin is extensively distributed throughout body fluids and rapidly converted to 
salicylic acid (SA, pKa 3.0) via deacetylation by endogenous esterases in liver 
(Rowland et al. 1972; Morgan and Truitt 1965), serum (Morikawa et al. 1979) and 
intestine (Harris and Riegelman 1969; Spenney 1978). This results in a short 
elimination half-life (15-20 minutes) of aspirin in human blood. While salicylic acid 
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has a long half life (about 12 hours) (Rowland et al. 1972). Aspirin esterase in aspirin 
metabolism exhibits interspecies variation. It was found that the rat hydrolyzed aspirin 
rapidly and that the rate of aspirin hydrolysis for dogs was comparable to human 
(Morgan and Truitt 1965). Kidney and liver in rats possessed relatively high aspirin 
esterase I and II activities as compared to other tissues which exhibited less than 10% 
of the maximum activity (100%) found in the kidney (Ali and Kaur 1983). 
 
Salicylic acid is considered to be a key active metabolite of aspirin in vivo because it 
shows some equipotent pharmacologic effects as aspirin. Salicylic acid is eliminated 
from the body by renal excretion and by hepatic biotransformation to salicyluric acid, 
salicyl acyl glucuronide, and salicyl phenolic glucuronide (Marson and Winer 1981). 
To a minor extent, salicylic acid is also hydroxylated to form gentisic acid, some of 
which is conjugated with glucuronide to form gentisuric acid (Wilson et al. 1978; 
FitzGerald and Sherry 1982). Figure 5.1 shows the metabolic transformations of 
aspirin and salicylic acid in human and rat in human and rat. The excretion ratio of 
free salicylic acid is variable, which depends upon the dosage and the urinary pH 
(Tsuchiya and Levy 1972). It was reported that a change in urine pH from 5 to 8 
resulted in a twenty-fold increase in the renal clearance of free salicylate (Smith et al. 
1946).  
 
The binding of aspirin and salicylic acid to serum proteins plays a role in their 
distribution throughout the body. Salicylic acid is strongly bound to blood protein, 
especially to albumin (80% to 90%) (Needs and Brooks 1985). This results in a 
greater volume of distribution for aspirin when compared to salicylic acid (Davidson 

















Figure 5.1 Metabolic pathways of aspirin and salicylic acid in human and rat.  
 
as naproxen and phenylbutazone, aspirin is not highly bound to albumin in plasma. 
The interaction of aspirin with plasma protein is more complex than salicylic acid. 
This is partly due to the inherent propensity of aspirin to acetylate proteins, which is 
also considered as a major determinant of both the mechanisms of its action and 
toxicity. The acetylation of various proteins, glycoproteins and lipids in stomach, 
kidney, liver and bone marrow by aspirin has been reported (Rainsford et al. 1983).   
 
Based on a lot of studies in human and animal models, the pharmacokinetics of 
aspirin and salicylic acid was found to be unusual. In healthy male volunteers, there is 





















after single oral dose at 80 mg (Benedek et al. 1995). The previous results of the 
disposition kinetics in rats were often apparently contradictory. Baker and Niazi 
(Baker and Niazi 1983a) reported a monoexponential decline of plasma concentration 
vs. time profile following a 10 mg/kg intravenous dose, which conflicted with the 
biexponential decline described by Iwamoto et al. (Iwamoto et al. 1982). 
Pharmacokinetic parameters of aspirin in human and animal models were listed in 
Table 5.1 and 5.2. 
 
In conclusion, aspirin shows clinical importance with special properties, such as 
extensive protein binding of salicylic acid (a key metabolite of aspirin), several 
pathways for metabolism and excretion, variable dose-dependent disposition. It is one 
of the most widely clinically used and self-prescribed drugs for many disorders. 
Hence, there is a high possibility that aspirin may interact with beverages (Odou et al. 
2001), food, prescribed drugs (Miners 1989) or herbal medicines. 
 
Non-steroidal anti-inflammatory drugs (NSAIDs), particularly aspirin, have the 
potential to interact with herbal supplements that are known to possess antipletelet 
activity (such as ginkgo, garlic, ginger, bilberry, dong quai, feverfew, ginseng, 
turmeric, meadowsweet and willow) (Rosenblatt and Mindel 1997), with those 
containing coumarin (such as chamomile, motherworth, horse chestnut, fenugreek and 
red clover) and with tamarind (Mustapha et al. 1996). These herb or food-drug 
interactions may enhance the risk of bleeding. The herb-drug interactions with aspirin 
include spontaneous hyphema when associated with ginkgo and increased 
bioavailability if combined with Tamarindus indica L. fruit extract. It was showed a 
tamarind extract incorporated in a traditional meal increased plasma levels of aspirin 
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Table 5.1  Summary of published pharmacokinetics of aspirin (*) and salicylic acid (SA) in human. 





(min) t1/2,α      t1/2,β 






F (%) References 
1000, i.v. 
     p.o. 
     i.m. 
– 
1420 + 360* 




2.3 + 2.0* 
– 
– 
15.4 + 2.5* 
20.6 + 4.5* 
40.0 + 14.4* 
0.039 + 0.009* 
– 
– 
0.219 + 0.042* 
– 
– 
0.732 + 0.132* 
– 
– 
17.9 + 2.9* 
39.9 + 9.2* 
71 + 2.3* 
– 
770 + 110* 
1290 + 230* 
– 
51.5 + 3.7* 
86.2 + 9.5* 
 bAarons et al.
1989 
9 mg/kg(SA), i.v. 
           p.o. 
– 
58200 + 2300(SA) 
– 
31.5 + 3.1(SA) 
300+ 54 (SA) 
264 + 42(SA) 
– 
270+ 18(SA) 




0.0274 + 0.0019(SA) 
0.0275 + 0.0016(SA) 
– 
– 
333000 + 23500(SA) 
331000 + 18400(SA) 
 
– 
 cMiaskiewicz et 
al. 1982 
650, i.v. 


























10.8 + 0.45 
15.9 + 0.62, 


































15.9 + 0.53* 








    p.o. 
 
6 + 0.4* 
3.94 + 0.3(SA) 
1.3+ 0.3* 
4.35 + 0.21(SA) 
– 
37.2 + 6(SA) 
17.4 + 2.4* 





91.2 + 5.4* 
25.2 + 1.2(SA) 
108.6 + 3* 





0.2 + 0.01* 
0.19 + 0.02(SA) 
– 
– 
0.56 + 0.03* 
0.073 + 0.01(SA) 
– 
– 
21.6 + 0.6* 
151.8 + 9.6(SA) 
34.8 + 1.8* 
158.4 + 8.4(SA) 
1.57 + 0.12* 
12.29 + 1.21(SA) 
0.68 + 0.14* 
10.8 + 0.47(SA) 
– 
– 
42 + 6* 
92 + 9(SA) 
 bBochner et al.
1988 
15mg/kg, Otomies.
p.o.      



































 cLares-Asseff et 
al. 2004 
80, p.o. 0.995 + 0.239* 
4.18 + 0.93(SA) 
30* 
60(SA) 
– 24 + 6* 
126 + 30(SA) 
– – 1.18+ 0.22* – 0.935 + 0.153* 
12.22 + 3.225(SA) 
– 




Table 5.2  Summary of published pharmacokinetics of aspirin (*) and salicylic acid (SA) in animals. 
 












F (%) References 
Rat 
5 mg/kg, i.v. 
10 mg/kg, i.v. 
15 mg/kg, i.v. 













3.5 + 0.35* 
3.5 + 0.92* 
3.6 + 0.39* 
17.25 + 5.76* 
0.67 + 0.12* 
0.69 + 0.26* 
0.70 + 0.01* 
– 
7.82 + 1.01* 
7.64 + 0.93* 
7.60 + 0.62* 
– 
2.99 + 0.32* 
3.2 + 0.33* 
3.47 + 0.75* 
13.2 + 1.7* 
38.8 + 5.0* 
79.3 + 10.3* 
118.9 + 9.8* 




56.6 + 10.4* 
 bFu et al. 1991 
5 mg/kg, i.v 
 
– – – – 
0.176 + 0.022* 0.051 + 0.003* 
– 
101.9 + 6.2* 
– 
 aBakar and Niazi 1983 
40 mg/kg, i.v. 
200 mg/kg 






6.03 + 0.75* 
7.58 + 0.85* 
12.1 + 2.9* 
0.526 + 0.116* 
0.368 + 0.118* 
– 
5.436 + 1.278* 









 cWientjes and Levy 
1988 












   – 



















2 + 0.31* 
1.87 + 0.18* 
0.71 + 0.17* 
1.34 + 0.13* 




 cIwamoto et al. 1982 
100 mg/kg, i.v. 
200 mg/kg, i.v. 
   – 
– 
    – 
– 
  – 
– 
6.5 + 2.5* 
11.1 + 3.3* 
     – 
– 
24.26 + 4.71* 
4 + 0.61* 
     – 
– 
3.9 + 0.53* 
49.92 + 17.1* 
    – 
– 
 aSteele et al. 1991 
New Zealand white rabbit 
2.5 mg/kg, oral 
10 mg/kg, oral 
20 mg/kg, oral 
50 mg/kg, oral 
7.54 + 0.23(SA) 
22.65+ 0.11(SA) 
43.2 + 0.9(SA) 
70 + 18.56(SA) 
97.2 + 39(SA) 
78.6 + 11.4(SA) 
103.2+ 11.4(SA) 
198.6+ 108(SA) 




121.2 + 37.2(SA) 
118.2 + 18(SA) 
168.6 + 49.2(SA) 
223.8 + 63(SA) 




0.08 + 0.45(SA) 
0.103 + 0.02(SA) 
0.082 + 0.03(SA) 
0.081 + 0.02(SA) 




40.28 + 7.37(SA) 
100.6 + 1.7(SA) 
268.8 + 8.1(SA) 
695 + 83(SA) 




 cMarangos et al. 2003 
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—: not reported or not applicable 
a
 one-compartment model 
b
 two-compartmental open system model 
c 
















31.8 + 2.4* 
  – 
      – 
0.36 + 0.02* 
  – 
      – 






42.6 + 1.63* 
7.32 + 1.58* 
2.45 + 0.42* 
– 
0.06 + 0.013* 
0.17 + 0.037* 
 cBroome et al. 2003 
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and salicylic acid (Mustapha et al. 1996). Patients may be at increased risk of 
bleeding if they consume herbal medicines with antiplatelet effect and aspirin 
concomitantly. In addition, the incidence of hepatotoxicity and nephrotoxicity may be 
augmented by coadministration of aspirin. As the active metabolite of aspirin, 
salicylic acid is highly plasma protein-bound, which may further predispose them to 
possible interactions with herbs bearing the same property, although such interactions 
have not yet been documented in the literature. 
 
Ligusticum chuanxiong Hort. shows outstanding hematological effects. It may have 
inhibitory properties on platelet aggregation and plasma coagulation, which has not 
been scientifically studied. Tetramethylpyrazine, one of the reported active 
components isolated from L. chuanxiong, can inhibit the platelet aggregation, causing 
negative chronotropic and inotropic responses on isolated atria and inhibiting 
vasoconstriction in isolated vascular strips. Many studies also indicated that ferulic 
acid can inhibit platelet aggregation, increase coronary blood flow, relax or stimulate 
smooth muscle and possess anti-arrhythmic affects (Fu and He 2004; Zhao et al. 2003; 
Liu et al. 2003; Ou and Kwok 2004). In the abstract of unpublished study (Gam et al. 
2003), aspirin may interact with L. chuanxiong to prolong the clotting and bleeding 
time in experimental mice. Based on these preliminary studies, L. chuanxiong may 




The present study is to characterize the influence of multiple oral doses of Ligusticum 
chuanxiong Hort. extract on pharmacokinetics and pharmacodynamics of aspirin in 
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male Sprague-Dawley rats. In vivo pharmacokinetic studies of aspirin with a single 
intravenous (i.v.) injection or a single intraperitoneal (i.p.) injection at the dosage of  
40 mg·kg-1 were investigated in male Sprague-Dawley rats pretreated or untreated 
with L. chuanxiong extract. The effect of aspirin combined with L. chuanxiong extract 
on the ex vivo inhibition of platelet aggregation in SD rat was also studied.   
 
5.3 Experimental 
5.3.1. Chemical and reagents 
Acetylsalicylic acid (aspirin, USP), salicylic acid, syringic acid, heparin sodium salt 
(180 units·mg-1), formic acid and potassium fluoride were purchased from Sigma (St. 
Louis, MO). LC-grade methanol, acetonitrile, AR grade dichloromethane was 
obtained from Lab-scan Asia Co., Ltd. (Bangkok, Thailand). All other chemicals were 
of analytical-reagent grade or better. Water was purified using the MilliQ-System 
from Millipore Corp (Bedford, MA, USA). 
 
5.3.2. Prepared solutions 
50% (w/v) potassium fluoride was dissolved in MilliQ water. Heparin sodium salt 
was dissolved in sterile normal saline (0.9% sodium chloride, USP) and final 
concentration was 10 U·mL-1. According to a published method (Wientjes and Levy 
1988), aspirin solution was prepared with 200 mg aspirin and equimolar sodium 
bicarbonate dissolved in sterile saline solution and pH value was adjusted to 7.4 with 
sodium hydroxide, so that the final concentration of aspirin in solution was 2 mg·mL-1. 
The resultant solution was passed through a sterile 0.22 µm filter membrane for the 
removal of any particles or microorganism. The aspirin solution was freshly prepared 
due to the instability of aspirin in aqueous solution. Standard stock solutions of aspirin, 
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salicylic acid and syringic acid (internal standard) were prepared by dissolving 
appropriate amount of each compound in methanol to yield the concentration at 5 
mg·mL -1for each analyte. A series of standard solutions of aspirin and salicylic acid 
were prepared by diluting the stock solutions with mobile phase, to give the 
concentration range from 25 µg·mL-1 to 2.5 mg·mL-1, immediately prior to assay. 
Syringic acid solution was diluted to 200 µg·mL-1, which was working as the internal 
standard. Standard and quality control samples were separately prepared by spiking 
the standard solutions into drug-free rat plasma to produce the concentration range of 
0.25-250 µg·mL-1. The dilution solution for platelet aggregation experiment was 
phosphate buffered saline (PBS; 8 g·L-1 NaCl, 0.2 g·L-1 KCl, 1.44 g·L-1 Na2HPO4, 
0.24 g·L-1 KH2PO4 made up to one liter with Milli-Q water). 
 
5.3.3. Preparation of L. chuanxiong Hort. extract and vehicle solution 
Dried roots of Ligusticum chuanxiong Hort. were purchased from Tong-Ren-Tang 
Pharmaceutical Co. Ltd. (Beijing, P. R. China). 350 g of the herbal materials were 
refluxed in 2.1 L of 75% (v/v) ethanol aqueous solution for 15 min and repeated one 
more time. The mixtures were combined together and filtered through a filter paper 
(Whatman International Ltd., Maidstone, UK). The solvent evaporated off using a 
rotary vacuum evaporator (Fisher General Scientific (SEA) Private Ltd). The residue 
was resuspended in 25% (v/v) aqueous propylene glycol to give an oral solution 
concentration of 1 g (calculated at the level of crude L. chuanxiong herbal 
material)·mL-1. A comparable volume of 25% (v/v) aqueous propylene glycol solution 




Forty-eight adult male Sprague-Dawley (SD) rats, weighing over the range of 180 to 
230 g were obtained from Laboratory Animal Center (National University of 
Singapore, Singapore). They were housed in a temperature-controlled room (22±2°C) 
with a light cycle of 12 h. The lights were on from 8:00 am to 8:00 pm, during which 
time all the experiments were conducted. The animals had free access to standard 
laboratory chow and tap water, unless otherwise stated. After acclimatization for one 
week, the rats were divided equally into 9 groups for the following experiments. All 
animal procedures were approved by the Institutional Animal Care and Use 
Committee (National University of Singapore, Singapore). 
 
5.3.5. Ex vivo inhibition of platelet aggregation experiment 
Male SD rats were separately fed with L. chuanxiong extract or the vehicle (25% 
aqueous propylene glycol). Then a single dose of aspirin was intraperitoneally 
administered to these rats, and the ex vivo effects of L. chuanxiong extract on platelet 
aggregation were subsequently explored. Five groups of rats were pretreated 
according to the schedule listed in Table 5.3 (Two groups of rats were treated with L. 
chuanxiong extract and the other two groups of rats were treated with vehicle solution 
for 14 days.). After two weeks of pretreatment, three groups, except the control and L. 
chuanxiong (CX) groups, were separately given a single i.p. dose of aspirin at 40 
mg·kg-1. One hour after the aspirin administration, all of the rats were anaesthesized 
with the mixture of ketamine (Ketapax, ketamine 75 mg·mL-1) and xylazine (Ilium, 
Xylazil-20, 10 mg·mL-1 xylazine hydrochloride) at the dose of 0.1 mL / 100 g body 
weight. Blood samples were collected by cardiac puncture from each rats and 
transferred into a citrated tube (Tapval, 4 mL blood collection tubes, 0.106 M citrate, 
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Deltalab S. A., Barcelona, Spain). Collected blood was pre-warmed to 37 °C in a 
water bath and used within five hours. 
 
Whole blood aggregation was determined by the measurement of impedance using a 
whole blood aggregometer (Chronolog Corporation, Havertown, PA) as described by 
Cardinal and Flower (Cardinal and Flower 1980). 450 µL of pre-warmed blood was 
diluted with pre-warmed 450 µL PBS and allowed to equilibrate for 2~4 min. 2 µL 
collagen (Chronolog, Havertown, PA) was then added to initiate platelet aggregation. 
All tests were performed in triplicates. Percentage inhibition of platelet aggregation 
was calculated as follows: 




where X is the impedance value of the control, and Y is the impedance value of the 
tested samples.  
 
5.3.6. Pharmacokinetic study 
In another in vivo pharmacokinetic study, 24 rats were randomly assigned into four 
groups of six rats per group. Two groups were treated with the extract of L. 
chuanxiong (10 g herbal material·kg-1·d-1) and the other two groups with 25% aqueous 
propylene glycol solution (used as control) for 14 days. On the last day of treatment, 
the rats were implanted with an indwelling catheter in the right jugular vein as 
described in Section 4.3.9. All cannulae were exteriorized dorsally at the neck and 
were filled with sterile saline solution. The rats were housed individually in cages for 
recovery from the surgery for 24-hr with free access to food and water. On day 15, 
aspirin was administrated intravenously (iv) or intraperitoneally (ip) at dose of 40 
mg·kg-1 body weight, respectively.  
 168 
For the pharmacokinetic study of aspirin, 200 µL blood was collected from the jugular 
vein via the cannula with a chilled 1-mL plastic syringe containing 2 U heparin and 
25 mg potassium fluoride. For i.p. aspirin administration at the dose of 40 mg·kg-1 to 
the control and L. chuanxiong pre-treated groups of rats, blood samples of were taken 
immediately at 5, 10, 15, 20, 25, 30, 45, 60, 90 and 120 min after administration. after 
For i.v. aspirin administration at the dose of 40 mg·kg-1 to another control and L. 
chuanxiong pre-treated groups of rats, blood samples were taken immediately at 1.5, 3, 
4.5, 6, 9, 12, 16, 20, 30, 40, 50 and 60 min after administration. Time 0 was recorded 
as the time when half of the dose had been administrated. The collected blood 
samples were mixed gently and immediately placed in an ice bath and centrifuged at 6, 
000 × g for 10 min at 4°C. For each whole blood sample, 0.1 mL plasma was 
harvested and mixed with 0.1 mL syringic acid solution (internal standard, 200 
µg·ml-1, dissolved in mobile phase). 50 µL formic acid and 1.5 mL dichloromethane 
were added into each plasma sample and mixed vigorously. The organic phase was 
transferred into another polypropylene tube and evaporated under vacuum to dryness. 
The residue was kept in -80 °C freezer. Prior to the analysis by LC-MS/MS, the 
residue was dissolved in 200 µL mobile phase and centrifuged at 10,000 g for 10 min. 
The supernatant was transferred into a HPLC sample vial and a 5 µL portion was 
injected for analysis. The concentration of aspirin and salicylic acid were determined 
by use of LC-MS/MS within 4 weeks after sample collection.  
 
5.3.7. LC-MS/MS Analysis of aspirin and salicylic acid 
A Q-TRAPTM LC-MS/MS system was used, which was from Applied BiosystemsTM/ 
MDS SCIEXTM (Foster City, CA USA) and coupled to an Agilent 1200 Series HPLC 
system (Agilent Technologies, Waldbronn, Germany). The chromatographic method 
was developed using an Agilent Zorbax RX-C18 reversed-phase column (150 × 2.1 
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mm I.D., 5 µm). The isocratic elution buffer consisted of water (80%,v/v) and  
acetonitrile (20%, v/v), which was acidified by formic acid (1%, v/v). The flow rate 
was 0.17 mL·min-1 and the injection volume was 5 µL. The Q-TRAPTM LC-MS/MS 
system is a hybrid triple quadrupole/linear ion trap mass spectrometer equipped with a 
Turbo Ionspray ion source. Quantization of acetylsalicylic acid, salicylic acid and 
syringic acid was performed by negative multiple reaction monitoring (MRM) scan 
mode. Both Q1 and Q3 were set at unit mass resolution. The mass spectrometric 
parameters of each compound were optimized using flow injection analysis (FIA). 
The optimized parameters are listed as follows: curtain gas, 15 units; ionspray voltage, 
-4.5 kV; desolvation temperature, 400 °C; collision gas, high; declustering potential, 
-25 V; collision energy, -20 eV; entrance potential, -7.0 V; collision cell exit potential, 
-1.8; nebulizer gas (gas 1), 20 units; heater gas (gas 2), 30 units. Multiple reaction 
monitoring (MRM) was used to quantify aspirin, salicylic acid and syringic acid (I.S.) 
using the transitions: m/z 179 → m/z 137 for aspirin, m/z 137 → m/z 93 for salicylic 
acid and m/z 197 → m/z 182 for I.S., respectively. Data acquisition and processing 
were performed using Analyst 1.4.1 software supplied with the instrument. 
 
Standard curves were prepared by plotting the ratios of peak area analytes to that of 
internal standard versus concentrations of analytes. The concentrations of aspirin and 
salicylic acid were calculated from the relative peak areas using appropriate standard 
curves.  
 
5.3.8. Protein binding 
Binding of aspirin and salicylic acid to blood proteins was determined using the 
reported ultrafiltration method (Herrera et al. 1990) with a slight modification. For the 
binding experiment of aspirin, bovine serum albumin (BSA) at the concentration of 
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40 mg·mL-1 (approximate concentration of albumin in blood) was prepared according 
to a reported reference (Steele et al. 1991) for the purpose of minimizing the 
hydrolysis of aspirin in plasma. The studies on the binding of aspirin and salicylic 
acid were also separately performed with plasma from SD rats pretreated or untreated 
with L. chuanxiong. The hydrolysis degree of aspirin in BSA solution or rat plasma 
was compared. Aspirin or salicylic acid was added to BSA solution or rat plasma to 
get the final concentrations of 1, 5 or 20 µg·mL-1 separately. Salicylic acid samples 
were incubated with constant shaking at 37 °C for 1 h. Aspirin samples were vortexed 
for 1 min for two times. After the incubation, 200 µL sample solution was transferred 
to ultrafiltration device (10000 MWCO PES Vivaspin micropartition system, 
Sartorious, Goettingen, Germany) and centrifuged at 10,000 g for 60 min at 4 °C. The 
residue in each microtube was frozen in -80 °C freezer and then lyophilized using a 
Freeze Dryer (Model: Freezon 2.5; Labconco Corparation, Missouri, U.S.A.). The 
control samples for aspirin or salicylic acid were spiked with 1% aqueous formic acid 
solution and prepared similar as the protein binding samples. All experiments were 
performed in triplicates. Prior to the analysis by LC-MS/MS, the residue was 
dissolved in 200 µL mobile phase and centrifuged at 10,000 g for 5 min. The 
supernatant was transferred into a HPLC sample vial and a 5 µL portion was injected 
for analysis. The percentage of aspirin or salicylic acid bound to plasma proteins 


















Where Atotal and Afree were the total and free amounts of aspirin or salicylic acid at 
equilibrium, and Aabsorption was the amount of them absorbed to the filtration device 
and membrane at each concentration. 
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5.3.9. Pharmacokinetic data analysis and Statistical analysis 
The plasma concentration-time data for each rat were analyzed by two-compartment 
open system model using WinNolin 5.2 software (WinNonlinTM; Pharsight, Mountain 
View, CA). Calculations of pharmacokinetic parameters were performed according to 
the equations described in Section 4.3.9 
 
All pharmacokinetic parameters of aspirin in control and L. chuanxiong pre-treated 
groups were expressed as mean ± S.D. (n=6). For samples comparisons of the 
percentage inhibition of platelet aggregation caused by the combination of aspirin and 
L. chuanxiong, the one-way analysis of variance (ANOVA) with the 
Student-Newman-Keuls post-hoc multiple comparisons test was performed (SPSS, 
Version 11.5, SPSS Inc., Chicargo, Illinois). The statistical significance of difference 
for calculated pharmacokinetic parameters between control and L. chuanxiong 
pre-treated groups was evaluated using two tailed, independent-samples t-test. A 
value of P<0.05 was considered to be statistically significant. 
 
5.4. Results  
5.4.1. Effects of interaction between L. chuanxiong and aspirin on antiplatelet 
activity 
The percentage inhibition (%) of platelet aggregation was determined according to the 
formula in Section 5.3.5. by comparing the impedence values obtained from the 
graphs against that obtained from the control. The results in Table 5.3 and Figure 5.2 
showed the percentages of inhibition of platelet aggregation in rats treated separately 
with control together with aspirin, L. chuanxiong extract together with aspirin, control, 
L. chuanxiong extract or aspirin. A single i.p. administration of aspirin at the dose of 
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40 mg·kg-1 alone significantly suppressed platelet aggregation (Control, 2.3% + 3.2%; 
aspirin, 50.2% ±14.7%, p‹0.05) in SD rats. There was no difference in the platelet 
aggregation between the control and L. chuanxiong pre-treated groups. In this part of 
the study, based on the results from ex vivo platelet aggregation experiments, no 
antiplatelet effect was observed in male SD rats fed with L. chuanxiong extract for 14 
days. In addition, the inhibition effect of aspirin on platelet function, which was 
evaluated by collagen induced platelet aggregation, was unaffected by the combined 
administration of L. chuanxiong extract and aspirin, since there was no difference in 
platelet aggregation between the groups treated by aspirin only and that combinedly 
fed with L. chuanxiong extract and aspirin. There was no synergistic effect on 
antiplatelet aggregation when combining aspirin with L. chuanxiong extract in the 
treated SD rats. 
 
Table 5.3 Effect of combinated treatments of aspirin and L. chuanxiong extract on the 




Treatment  % inhibition of 
platelet aggregation 
Control+Aspirin Control: 25% propylene glycol×14d 
Aspirin: ip 40 mg·kg-1, a single dose on day 15 
40.5 ±13.4* 
CX+Aspirin CX: 10 g herbal material·kg-1·d-1×14d 
Aspirin: ip 40 mg· kg-1, a single dose on day 15 
40.2 ± 16.0* 
Control Control: 25% propylene glycol×14d 2.3 + 3.2 
CX CX: 10 g herbal material·kg-1·d-1×14d 
 
2.8 + 3.2 
Aspirin Aspirin: ip 40 mg· kg-1, a single dose 50.2 ±14.7* 
 
All values are expressed as mean ± S.D. (n=6). 











L. chuanxiong (g·kg-1)    0         10         0         10         0 
Aspirin (mg·kg-1)        0          0        40         40        40 
 
Figure 5.2 Effects of different dose treatments with aspirin combined with L. 
chuanxiong on the percentage inhibition of platelet aggregation in SD rats. The ex 
vivo inhibition effect of platelet aggregation was measured 1 h after the single ip 
administration of aspirin.  
Each column represents the mean + S.D. of 6 rats. 
*Asterisks represent values significantly different from those in control group, p<0.05 
 
 
5.4.2. Pharmacokinetics studies 
Mass spectrometry has demonstrated its great advantages with high sensitivity and 
specificity, etc. The retention times of aspirin (ASA) and salicylic acid (SA) were 2.9 
min and 4.6 min, respectively. With the developed analytical method, the analysis was 
completed within about 8 min, which was fast and selective. Plasma standards were 
prepared by spiking the drug-free plasma with syringic acid (internal standard), as 
well as known amounts of ASA and SA, yielding the concentration range of 0.25-250 
µg·mL-1for both analytes. The standard curve for ASA was y=0.1893x+0.4926 
(R2=0.9986) and that for SA was y=0.6233x+4.0971 (R2=0.9923). The calibration 
lines of aspirin and salicylic acid, with good linearity, were accepted to determine the 
plasma concentrations of analytes. The concentrations of analytes in all plasma 


































aspirin and salicylic acid at 0.25, 5, and 250 µg·mL-1 were listed in Table 5.4. The 
inter-day and intra-day coeffients of variation were less than 3.0% and 4.0, 
respectively (Table 5.5).  
 
Table 5.4 Extraction recoveries of aspirin and salicylic acid in plasma (n=5). 
 
 
Table 5.5 Precision and accuracy for the determination of aspirin and salicylic acid in 







Compound Added (µg·mL-1) Recovery (%) RSD (%) 
Aspirin  0.25 88.4 + 3.61 4.08 
 5 79.8 + 3.70 4.64 
 250 86.2 + 3.23 3.75 
Salicylic acid 0.25 83.5 + 2.20 2.63 
 5 75.5 + 1.13 1.51 
 250 87.4 + 3.72 4.25 
Concentration (µg·mL-1)  RSD (%)  Relative error (%) 
Added Found  Intra-day Inter-day  Intra-day Inter-day 
Aspirin       
0.25 0.25  4.0 4.0  -0.8 1.4 
5 5.07  3.2 2.4  1.5 -1.0 
250 260  4.2 4.7  3.9 2.2 
Salicylic acid       
0.25 0.25  4.0 4.2  1.3 -2.2 
5 4.94  3.6 3.0  -1.1 -1.2 
250 258  3.0 3.9  3.3 1.7 
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Intravenous Administration 
The mean plasma concentration-time profiles of aspirin (ASA) and salicylic acid (SA) 
after a single i.v. injection of aspirin at a dose of 40 mg·kg-1 to the male SD rats 
treated or untreated with L. chuanxiong extract were shown in Figure 5.3. The 
relevant values of pharmacokinetic parameters were presented in Table 5.6. It was 
obvious that the plasma concentrations of aspirin declined biexponentially as a 
function of time after administration, whereas salicylic acid plasma concentrations 
increased rapidly and then remained essentially constant for the duration of the 
experiment. Plasma concentrations of aspirin declined rapidly during the first 20 min 
after a single intravenous dose and to an undetectable level after 40 min. For each 
identical rat, the key metabolite of aspirin, salicylic acid, was detectable in all the 












Figure 5.3 Mean plasma concentrations versus time of aspirin (ASA) and salicylic 
acid (SA) after a single i.v. dose of 40 mg·kg-1 of aspirin to rats treated or untreated 



























Table 5.6 Pharmacokinetic parameters of aspirin and salicylic acid a after a single i.v. 
dose of 40 mg·kg-1 of aspirin to SD rats treated or untreated with L. chuanxiong 
extract. 
 












PK parameters Control L. chuanxiong extract 
pretreatment 
Aspirin   
t1/2,α (min) 2.48 + 0.27 2.6 + 0.47 
t1/2, β (min) 6.89 + 0.8 6.6 + 0.49 
Cl (mL·min-1·kg-1) 27.18 + 2.71 24.56 + 1.9 
AUC0～∞ (µg·min·mL-1) 1484.4 + 150.7 1636.7 + 121.7 
MRT (min) 7.46 + 0.33 7.57 + 0.5 
Vc (mL·kg-1) 31.72 + 1.95 36.99 + 4.54 
Vss (mL·kg-1) 470.7+ 52.2 459.9 + 30.9 
Salicylic acid   
Cmax (µg·mL-1) 90.4 + 6.5 92.9 + 9.2 
Tmax (min)  5.75 + 0.61 5.4 + 1.34 
AUC0～60 (µg·min·mL-1) 4907.5 + 342.3 4595.2 + 412.7 
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Every profile of plasma concentrations of aspirin versus time after a single i.v. dose of 
aspirin at 40 mg·kg-1 for each rat in either L. chuanxiong extract treated or untreated 
groups was biexponential in appearance but statistically inconclusive comparing with 
one-compartmental model according to the AIC test. These conflicts in model 
selection have been reported and discussed in several papers. For example, Baker and 
Niazi (Baker and Niazi 1983a) reported a monoexponential decline of plasma 
concentration versus time profile following a 10 mg·kg-1 intravenous dose, which 
conflicts with the biexponential decline reported by Iwamoto et al. and Fu et al. 
(Iwamoto et al. 1982; Fu et al. 1991) for the same dose. The monoexponential 
disposition in rats may be due to the improper schedule for sampling or inaccurate 
sampling time point in those experiments. In this study, the applied 
two-compartmental open model for disposition kinetics was consistent with the ones 
used by most of the other researchers (Iwamoto et al. 1982; Fu et al. 1991). 
  
All calculated pharmacokinetic parameters of aspirin and salicylic acid presented in 
Table 5.6 were not significantly different (p>0.05) between L. chuanxiong extract 
treated and untreated groups, which indicating no effect on the pharmacokinetics of 
aspirin and salicylic acid after a single intravenous administration of aspirin at 40 









Intraperitoneal administration  
The mean concentration-time profiles of aspirin (ASA) and salicylic acid (SA) in 
plasma after a single intraperitoneal injection of aspirin at a dose of 40mg·kg-1 in both 
L. chuanxiong extract treated and untreated groups were shown in Figure 5.4. Table 
5.7 listed the various pharmacokinetic parameters of ASA and SA obtained after a 
single intraperitoneal administration of aspirin at 40 mg·kg-1 to the two groups of rats. 
It can be observed that the plasma concentrations of aspirin rose up sharply, reached 













Figure 5.4 Mean plasma concentrations versus time of aspirin (ASA) and salicylic 
acid (SA) after a single i.p. dose of 40 mg·kg-1 of aspirin to rats treateded or untreated 


































Table 5.7 Pharmacokinetic parameters of aspirin (40 mg·kg-1, i.p.) after 14-day 
treatment of L. chuanxiong extract in rats.  
 
All values are expressed as mean ± S.D. 
* p<0.05 compared with control 
 
The calculated pharmacokinetic parameters of aspirin and salicylic acid after a single 
i.p. dose of 40 mg·kg-1 of aspirin to SD rats pre-treated or untreated with L. 
chuanxiong extract were presented in Table 5.7. The bioavailability of aspirin 
following a single intraperitoneal injection of aspirin at a dose of 40mg·kg-1 in control 
group was 96.1%, indicating the near complete absorption after i.p. administration in 
SD rats. 
 
Similar values of pharmacokinetic parameters of salicylic acid found between the 
control and L. chuanxiong treatment groups indicate no apparent effect of L. 
chuanxiong pre-treatment on the pharmacokinetics of salicylic acid. There were no 
statistically significant differences in t1/2,α, t1/2, β of aspirin after a single i.p. injection 
between the control and L. chuanxiong treatment groups, indicating no significant 
herb-drug interaction in the disposition and elimination process of aspirin when 
pre-treated with L. chuanxiong. AUC0～∞ in L. chuanxiong pre-treatment group was 
PK parameters Control L. chuanxiong extract 
pretreatment 
Aspirin   
Cl/F (mL·min-1) 16.78 + 1.31 39.11 + 3.56 * 
AUC0～∞ (µg·min·mL-1) 1426.0 + 263.2 647.2 + 247.4* 
F (%) 96.1 + 17.7 43.6+ 16.7* 
Salicylic acid   
Cmax (µg·mL-1) 66.66 + 6.64 77.20 + 7.6 
AUC0～120 (µg·min·mL-1) 6182.5 + 1027.7 7166.6 + 1620 
 180 
significantly reduced by 54.6% (p>0.05) compared to that in the control group when 
two-independent t-test was employed. Other parameters, F (%) and a Cl/F were 
reduced accordingly. This reduced bioavailability of aspirin observed following a 
single i.p. dose of 40 mg·kg-1 of aspirin to SD rats pre-treated with L. chuanxiong 
extract may be attributed to decreased fraction of aspirin available for absorption after 
i.p. administration. Aspirin is easily hydrolyzed to salicylic acid, which can occur in 
many organs in the body. The pre-systemic loss of aspirin is easily affected by many 
factors, which may result in a reduced fraction of aspirin for absorption. The present 
results suggest a potential in vivo pharmacokinetic interaction between L. chuanxiong 


















Protein binding  
Pharmacokinetic interactions caused by displacement from protein binding are often 
important for drugs with extensive protein binding capacity. Aspirin (ASA) and 
salicylic acid (SA) show different extent of protein binding. The changes of protein 
binding capacities of aspirin and salicylic acid may affect their distribution, 
elimination processes, and thus the intensity and duration of their pharmacological 
action in the body. In the following experiment, the protein binding capacity of ASA 
and SA were investigated for their influences on pharmacokinetic results.  
 
Since albumin is generally considered to be the major site of acidic drugs binding in 
blood (McElany and D'Arcy 1983), bovine serum albumin solution (prepared with 1 
M Tris buffer) and rat plasma were to study the protein binding capacity of aspirin. 
By comparing with the results using rat plasma, it was found that degree of aspirin 
hydrolysis in albumin solution was higher than that in rat plasma (data not shown). 
The MS signal of aspirin was very low in albumin solutions, with the intensity around 
e3 ～e4 compared to that of baseline noise (e2 ～e3). To collect the L. chuanxiong 
plasma, rats were fed with a single dose of L. chuanxiong extract (the dosage was 
similar to those in pharmacokinetic studies), whole blood was then collected by 
cardiac puncture 30 min after L. chuanxiong administration and the plasma was 
prepared accordingly. Table 5.8 showed the mean percentages of aspirin and salicylic 
acid bound to plasma protein in the absence and presence of L. chuanxiong. It was 
found that binding percentages for aspirin and salicylic acid in the presence of L. 
chuanxiong plasma tended to be higher than those in blank rat plasma, but the 
changes did not reach a statistical significance.  
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Table 5.8 Mean percentages of protein binding for aspirin and salicylic acid in blank 
and L. chuanxiong plasma (n=3). 
 
Compound   Concentration 
groups 
1 µg·mL-1 5 µg·mL-1 20 µg·mL-1 
Aspirin Blank 51.7 + 7.1 57.9 + 10.5 53.3 + 1.8 
 With L. chuanxiong 62.7 + 13.9 66.5 + 8.3 62.0 + 5.5 
Salicylic acid Blank 48.9 + 13.5 60.3 + 7.6 58.4 + 10.3 
 With L. chuanxiong 66.7 + 6.4 70.6 + 7.2 70.1 + 5.3 
 
Since aspirin is a weak acid, the changes in pH value may have some effects on its 
hydrolysis. Higher pH values may influence the un-ionized/ionized forms of aspirin 
during its absorption process (Cooke and Hunt 1970). The pH values of aspirin 
solution (prepared in 1 M Tris buffer) were determined at three different 
concentrations before and after being mixed with L. chuanxiong extract. The 
corresponding results were shown in Table 5.9. It was shown that there were no 
change of pH values after aspirin was mixed with L. chuanxiong extract (1 g herbal 
material·mL-1) at the ratio of 1: 9.   
Table 5.9 The influence of L. chuanxiong extract on the pH values of aspirin solutions 
(in 1 M Tris buffer).      
 
These results suggest no obvious effect on the ptotein binding of aspirin and salicylic 
acid in the presence of L. chuanxiong, which may indicate no change of the 
disposition of aspirin and salicylic acid in SD rats. It is consistant with the results got 
from Table 5.7. 
Concentration 1 µg·mL-1 5 µg·mL-1 20 µg·mL-1 
Aspirin 7.51 7.48 7.42 
With L. chuanxiong 7.49 7.44 7.38 
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Although ultrafiltration method does not require the long equilibration time, it can be 
complicated by reequilibration as concentrations of the plasma protein and drug may 
change during filtration. So the temperature control during the centrifugation of 
samples is very critical for the ultrafiltration process. Although microdialysis is ideal 
for determination of the in vivo binding efficiency of drug under physiological 
conditions, it needs an equipment to run but was not currently available in the lab. 
 
5.5. Discussion 
The effects of aspirin combined with L. chuanxiong on the percentage inhibition of 
platelet aggregation were investigated ex vivo in Sprague-Dawley rats. It was found 
that after 14-day pre-treatment of L. chuanxiong extract to the SD rats, there were no 
change of the antiplatelet effect of aspirin administrated by a single intraperitoneal 
dose. 
 
In the pharmacokinetic studies, the stability of aspirin posed a problem for its 
quantitative analysis in plasma. Aspirin was reported to be hydrolyzed into salicylic 
acid by enzymes in blood so that simply removing the rat blood from an animal 
cannot stop subsequent hydrolysis in the blood samples. In order to minimize this 
continuous hydrolysis of aspirin in the blood samples from rats, some special 
precautions have been reported, including using ice-cold syringes (Rowland and 
Riegelman 1967), inhibition of esterase activity by physostigmine (Cham et al. 1980; 
Wientjes and Levy 1988) or fluoride (Reidl 1983), immediate precipitation of protein 
followed by liquid-liquid extraction of aspirin and salicylic acid from the collected 
plasma (Bakar and Niazi 1983b; O'Kruk et al. 1984). In this part of our work, blood 
samples in the pharmacokinetic study were collected with chilled 1-mL plastic 
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syringe containing heparin and potassium fluoride (an inhibitor of aspirin hydrolysis). 
The plasma was collected by centrifugation and transferred to a -80 °C freezer 
immediately. 
 
Due to the esterase activity in rats which is subject to circadian variation 
(Bhattacharya and von Mayersbach 1981), the pharmacokinetic experiments were 
performed at the same time every day (in the afternoon) for the duration of 
experiments. The sampling frequency (10 time points for each rat) was limited to 
minimize blood loss. It was worthwhile to note that, in the pharmacokinetic studies, 
simultaneous determination of aspirin and salicylic acid may result in lower resolution 
in the concentration–time curve of salicylic acid, since the elimination half life of 
aspirin was shorter compared to that of salicylic acid was long. As a result, subtle 
changes in the pharmacokinetics of salicylic acid might not be observed due to the 
short sampling time.  
 
The effects of L. chuanxiong extract pre-treatment on the pharmacokinetics of aspirin 
in SD rats were evaluated in this study. After a single intravenous administration of 
aspirin, the pharmacokinetic parameters of aspirin and salicylic acid in the group 
pre-treated with L. chuanxiong were comparable to those in the control group. In a 
following experiment, after 14-day pre-treatment of L. chuanxiong extract in SD rats, 
its pharmacokinetic parameters of aspirin and salicylic acid after a single 
intraperitoneal injection of aspirin at a dose of 40mg·kg-1 were almost similar 
compared with those in the control group, except for AUC0-∞ value of aspirin in the 
group pre-treated by L. chuanxiong extract. It was observed that AUC0-∞ of aspirin 
was decreased by 54.6% in SD rats which were daily fed with L. chuanxiong extract 
for 14 days at the dosages of 10 g herbal material·kg-1·d-1 before the pharmacokinetic 
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experiments, indicating a decreased bioavailability of aspirin in L. chuanxiong extract 
treatment group. The results also showed that the elimination kinetics of aspirin in rats 
was not affected by L. chuanxiong treatment. This reduced bioavailability of aspirin 
observed following a single i.p. dose of 40 mg·kg-1 of aspirin to SD rats pre-treated 
with L. chuanxiong extract may be attributed to decreased fraction of aspirin available 
for absorption after i.p. administration. The present results suggest a potential in vivo 
pharmacokinetic interaction in male SD rats between L. chuanxiong and aspirin. 
 
As explained in Section 5.1, the metabolism of aspirin is relatively complex, since 
salicylic acid, the most important key metabolite of aspirin, can be further 
metabolized in two major pathways, leading to the formation of salicyluric acid and 
salicyl phenolic glucuronide. Nevertheless, plasma concentrations of salicylic acid 
decline slowly because of the limited capacity of the formation of salicyluric acid and 
salicyl phenolic glucuronide. In addition, salicylic acid is partly excreted unchanged 
in urine and salicylate renal clearance is sensitive to changes in urinary pH (Levy 
1979). In this study, after the i.p. administration of aspirin at the dose of 40 
mg·kg-1aspirin, it showed that 14-day pre-treatment of L. chuanxiong extract can 
reduce mean bioavailability of aspirin by 54.6%, but had no obvious effect on the 
pharmacokinetics of salicylic acid. The results of in vitro plasma protein binding 
experiment showed that binding percentages for aspirin and salicylic acid in the 
presence of L. chuanxiong plasma tended to be higher than those in blank rat plasma, 
but changes did not reach a statistical significance, indicating no obvious effect on the 
disposition of asprin and salicylic acid in SD rats. The reduced bioavailability of 
aspirin observed following a single i.p. dose of 40 mg·kg-1 of aspirin to SD rats 
pre-treated with L. chuanxiong extract may be attributed to decreased fraction of 
aspirin available for absorption after i.p. administration. 
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To interpret the salicylic acid plasma concentration resulting from the changes of 
aspirin pharmacokinetics or the formations of salicyluric acid and salicyl phenolic 
glucuronide (key metabolites from salicylic acid), future works should include 
salicylic acid administration to SD rats to study its pharmacokinetics, as well as those 
of salicyluric acid and salicyl phenolic glucuronide in the presence of L. chuanxiong.  
Other in vitro experiments involving P-gp and other drug-metabolizing enzymes, 
aiming to more precisely delineate the mechanisms of interactions between L. 
chuanxiong and aspirin will be carried out. 
 
5.6. Conclusion 
Owing to the complex mechanisms of herb-drug interactions, there often appear some 
contradictions which need to be critically and carefully evaluated, especially with 
regards to the experimental methods and the interpretation of data. In addition, many 
herb-drug interactions may also arise from changes in both pharmacokinetic and 
pharmacodynamic effects, more experimental models should be developed to better 
understand these effects, on the basis of characterizing the locale, extent, pre-systemic 
metabolisms, and the underlying interaction mechanisms. 
 
Interactions between herbal medicines and pharmaceutical drugs may occur and lead 
to serious clinical consequences. Many of the underlying mechanisms for the altered 
drug concentrations and/or effects by concomitant consumption of herbal products are 
yet to be determined or confirmed.  
 
In this study, the combined pharmacodynamic and pharmacokinetic protocols for the 
studies of herb-drug interactions, illustrated by aspirin and L. chuanxiong – a potential 
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interaction pair, may form the basis for general screening to investigate herb-drug 
interactions in rat model. The results serve as a prerequisite for a possible 
























Conclusion and Future work 
The work presented in this thesis aims to develop methods and apply them for the 
assessment of quality and safety of herbal medicines. A successful utilization of 
herbal medicines integrated into modern medical practices depends on the interrelated 
issues of quality, safety and efficacy. Quality is the paramount issue which affects the 
efficacy and safety of herbal medicines. Analytical methods were developed to 
control the quality of herbal medicines and related products, while ex vivo and in vivo 
methods to assess potential herb-drug interactions were explored. 
 
Chapter 1 gives a general overview of the quality issues of herbal medicines. Chemical 
analysis methods and molecular methods for the quality control of herbal medicines are 
reviewed. The popularity of herbal medicines renders a critical assessment of their 
safety an urgent necessity, among which herb-drug interaction is an important safety 
issue which is often neglected and sometimes recognized as adverse drug reaction. The 
mechanisms and approaches employed in the studies of herb-drug interactions are 
summarized. The rationale and objectives of the work are presented. 
 
In Chapter 2, hydroxyacetildenafil, a new analogue of acetildenafil, was isolated and 
purified from a pre-mixed bulk powder, which was destined to be formulated or 
encapsulated and sold as a botanical dietary supplement. Its structure was elucidated 
by the use of UV, IR, high-resolution MS, MSn and NMR spectrum. This is the first 
report of the presence of such as analogue. It is not an approved drug and its safety 
and efficacy are not known. This compound should be included as a target compound 
when screening for PDE-5 inhibitors and their analogues adulterated in dietary 
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supplements and herbal products. Its structural information is helpful for the detection 
of such related analogues in botanical health products. 
 
In Chapter 3, HPLC, LC-DAD-MS/MS and high resolution LC-MS methods were 
developed for the chemical analysis of L. chuanxiong herbal material. The 
concentrations of ferulic acid in different L. chuanxiong extracts were quantified by a 
HPLC method and its content was low in different L. chuanxiong extracts. 
Tetramethylpyrazine, another reported biomarker in L. chuanxiong, however, cannot 
be detected by both HPLC and LC-MS/MS with a low limit of detection (LOD) as 
low as 1.3×10-8 g. An on-line rapid MS analytical method was successfully 
established for screening phthalides and related bioactive components in a L. 
chuanxiong extract. By comparing their retention time (tR), UV, etc with those from 
the literature, a total of 70 compounds were identified or tentatively characterized 
based on a combination of tR, high resolution mass data, and their multistage 
fragmentation behaviors information.  
 
As a result, the majority of the chemical compounds in L. chuanxiong were profiled 
qualitatively. The results of this study suggested that tetramethylpyrazine and ferulic 
acid are not suitable marker compounds to assess the quality of L. chuanxiong. This 
study can lead to the better quality control of L. chuanxiong. The chemical 
information, especially of phthalides, provides a valuable aid for structure-related 
investigation of similar phthalides in other medicinal herbs, complex pharmaceuticals 
or even biosamples. 
 
Modulation of the drug-metabolizing enzymes is one of the main causes of herb-drug 
interaction. In Chapter 4, the potential herb-drug interaction of L. chuanxiong was 
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studied by evaluating the effects of the ethanol extract of L. chuanxiong and its 
reported active components tetramethylpyrazine and ferulic acid on the activities of 
the most important drug-metabolising enzymes, namely cytochrome P450 (CYP) 3A 
and 2D, in Sprague-Dawley rat liver. The results showed that 14-day pre-treatment 
with low (2 g herb·kg-1·d-1) or high dose (10 g herb·kg-1·d-1) of L. chuanxiong extracts 
reduced the body weight in SD rats. The relative liver weights in rats pretreated with a 
high dose of L. chuanxiong extracts were significantly higher than those in the blank 
group rats. However, its reported active components, ferulic acid and 
tetramethylpyrazine, have no effects on these growth characteristics including body 
weight, liver weight and relative liver weight in rats. In addition, the protein 
concentrations of rat hepatic microsomes in tetramethylpyrazine pretreatment group 
were lower than those of the blank group. 14-day pre-treatment with ferulic acid, low 
dose or high dose of L. chuanxiong extracts showed no change in protein 
concentrations and protein contents in the hepatic microsomes of treated rats as 
compared to those in the control group.  
 
The effects of L. chuanxiong extracts pre-treatment on CYP 3A and 2D activities in 
rat hepatic microsomes were further investigated in ex vivo experiments. The results 
showed that activities of CYP 3A and CYP 2D were not affected by treatments with 
low dosages of the extract of L. chuanxiong, ferulic acid or tetramethylpyrazine. The 
CYP 2D activity of rat hepatic microsomes in the group pre-treated with high dose L. 
chuanxiong was significantly higher than that in the control group (p<0.05). For the 
further confirmation of the enzyme induction effect of L. chuanxiong pretreatment on 
CYP 2D, the effect of L. chuanxiong extract on the pharmacokinetics of 
dextromethorphan (a CYP 2D substrate) was investigated in SD rats. It was found that 
L. chuanxiong has no effect on the pharmacokinetics of dextromethorphan and 
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dextrorphan after a single intraperitoneal (i.p.) administration of 30 mg·kg -1 
dextromethorphan in SD rats in vivo, suggesting high doses of L. chuanxiong 
treatment have no effects on CYP 2D in vivo in SD rat. This contradiction between 
the enzyme induction effect seen in the ex vivo experiments and in vivo in SD rat 
suggested the complex mechanisms of herb-drug interactions, which need to be 
critically and carefully evaluated, especially with regard to the experimental methods 
and the interpretation of the data.  
 
Since marked species differences in the activities of cytochrome P450 have been 
reported, the results obtained with treated SD rats could not be directly extrapolated to 
humans. For future work, in vitro models, such as human hepatic cytochromes and 
primary hepatocytes cultures can be selected as other standard models for the 
evaluation of the impact of L. chuanxiong and its active components on human 
drug-metabolizing enzymes. Further studies on the level of the genes coding for CYP 
2D are needed to elucidate the mechanisms and significance of the induction effect on 
CYP 2D in SD rat. In addition, the constituents in the L. chuanxiong extract 
responsible for CYP 2D induction need to be further elucidated in future studies.  
 
In Chapter 5, the pharmacokinetic and pharmacological herb-drug interaction between 
L. chuanxiong and aspirin were investigated in vivo in Sprague-Dawley rats. 14-day 
pre-treatment of L. chuanxiong extract did not affect the antiplatelet effect produced 
by a single intraperitoneal administration of aspirin in rats and the pharmacokinetics 
of aspirin after a single intravenous administration. In a following experiment, after a 
single intraperitoneal administration of aspirin, the mean bioavailability of aspirin was 
reduced by 54.6% without obvious effect on the pharmacokinetics of salicylic acid in 
the L. chuanxiong extract pre-treatment group. The reduced bioavailability of aspirin 
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observed following a single i.p. dose of 40 mg·kg-1 of aspirin to SD rats pre-treated 
with L. chuanxiong extract may be attributed to decreased fraction of aspirin available 
for absorption after i.p. administration. These results indicate a potential 
pharmacokinetic herb-drug interaction between aspirin and L. chuanxiong in SD rats.  
 
Further work to better elucidate the active components in L. chuanxiong responsible 
for the quality, efficacy and safety of L. chuanxiong and related herbal products 
containing L. chuanxiong should be conducted. More active compounds should be 
isolated and purified from L. chuanxiong for a better quality control of L. 
chuanxiong-containing herbal products. Other in vitro or in vivo experimental models 
for characterizing the underlying pharmacokinetic and pharmacodynamic interaction 
mechanisms should be used for the better elucidation of a potential herb-drug 
interaction.  
 
In conclusion, the work presented in this thesis has contributed to the greater 
understanding and appreciation of the challenges involved in herbal medicine research 
and has laid a solid foundation for future work. While the detection and identification 
of adulterants is achievable, more work to decipher the complex mechanisms involved 
in herb-drug interactions is needed. With concerted efforts by researchers, health 
professionals, regulators, industry players and patients, the full benefits of herbal 
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Figure 7. HPLC chromatogram of the bioactive Ligusticum chuanxiong Hort. extract.  
Chromatographic conditions: The binary gradient elution system consisted of (A) 0.5% 
aqueous acetic acid and (B) methanol, and separation was achieved using the following 
gradient: 0–5 min, 32% B; 5–40 min, 32–85% B; 40–50 min, 85–100% B; 50–60 min, 100% 
B. The column temperature was kept at 25◦C. The flow rate was 1 mL·min-1 and the injection 


















 DAD1 B, Sig=280,16 Ref=390,100 (CHX\CHX00076.D)
 
1.
72
6
 
10
.
94
2
 
13
.
90
9
 
16
.
36
5
 
32
.
04
1
 
33
.
14
7
 
36
.
56
5
 
36
.
84
5
 
37
.
84
1
 
39
.
02
8
 
47
.
23
2
 
48
.
37
8
